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Abstract 
Frataxin deficiency coordinates iron-sulfur-dependent metabolic and genomic stress to 
promote endothelial senescence in pulmonary hypertension 
 
Miranda Kay Culley, Ph.D.  
 
University of Pittsburgh, 2020 
 
 
Pulmonary hypertension (PH) is a heterogeneous, fatal disease of the lung vasculature with 
incompletely defined molecular underpinnings. Specifically, the pathological contributions of 
endothelial cells to this panvasculopathy remain controversial and unresolved. Endothelial 
mitochondrial dysfunction and DNA damage have been separately linked to PH, but any shared 
mechanistic regulation, joint contribution to shifting endothelial phenotypes, and relevance across 
PH subtypes are unknown. Mutations in the iron-sulfur (Fe-S) biogenesis gene frataxin (FXN) 
disrupt metabolism and genomic integrity, causing Friedreich’s ataxia (FRDA). This multisystem 
disease is defined by neurodegeneration and hypertrophic cardiomyopathy (HCM) with the latter 
driving patient mortality. HCM is often complicated by PH but few studies have interrogated 
pulmonary vascular phenotypes in FRDA. Separately, deficiencies of other Fe-S cluster assembly 
genes induced endothelial mitochondrial dysfunction and PH development in vivo. Therefore, we 
hypothesized that endothelial FXN deficiency and its metabolic and genomic consequences may 
predispose to PH. Here, we demonstrated acute FXN knockdown abrogated Fe-S biogenesis to 
attenuate mitochondrial respiration and induce replication stress and growth arrest. Sustained FXN 
deficiency led to inhibition of Fe-S-containing nuclear proteins, persistent DNA damage response, 
and apoptosis resistance, culminating in increased vasomotor tone and senescence. Consequently, 
endothelial FXN deficiency in hypoxic mice increased senescence and worsened PH, which could 
be prevented with senolytic treatment. Supporting this mechanism, reduced FXN expression 
alongside elevated senescence markers were observed in animal and patient lung tissues 
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representing multiple PH etiologies. Specifically, we defined HIF--dependent epigenetic 
reduction of FXN, illustrating the relevance of acquired FXN deficiency in the pulmonary 
endothelium. Notably, FXN-dependent endothelial senescence was also demonstrated in inducible 
pluripotent stem cells-derived endothelial cells from patients with FRDA, offering a plausible 
explanation for a predisposition to PH, independent of or additive to left ventricular dysfunction. 
Altogether, these data demonstrate that epigenetic or genetic FXN deficiency orchestrates Fe-S-
dependent metabolic and replication stress which converge on irreversible senescence, signifying 
a novel endothelial-specific mechanism across PH subtypes, including PH due to left heart disease. 
In doing so, this work offers foundational evidence for the identification of a cohort of FRDA 
patients at risk for PH and endorse several Fe-S-related treatment options including senotherapies. 
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1.0 Introduction 
1.1 Pulmonary hypertension 
Pulmonary hypertension (PH) is a progressive, enigmatic disease marked by pathological 
narrowing and occlusion of the distal arterioles and small vessels of the lung. In turn, this panvascular 
remodeling causes elevated pulmonary vascular resistance (PVR >3 Wood units) and mean pulmonary 
arterial pressure (mPAP >20mmHg), resulting in right ventricular failure and thus significant morbidity and 
mortality in this patient population (2, 3). 
1.1.1 Cellular pathology  
Addressing the primary pathology, histologic imaging of lungs from patients with the particularly 
severe PH subtype, pulmonary arterial hypertension (PAH), illustrates medial layer hypertrophy and 
hyperplasia, proliferation and fibrosis of the intimal and adventitial layers, perivascular inflammation, in 
situ thrombosis, and the distinctive, end-stage plexiform lesions (4). The pathological vessel architecture 
provides some insight into the fundamental cell-specific dysfunction present. For example, the hypertrophy 
and hyperplasia of the medial and adventitial layers reflects an apoptosis-resistant, pro-proliferative 
phenotype in pulmonary artery smooth muscle cells (PASMCs) (a synthetic phenotype as compared to a 
contractile phenotype) (5) and adventitial fibroblasts (PAAFs) (6). Accumulation of these cells results in 
enhanced vasoconstriction (7), vessel stiffening due to fibrotic matrix deposition (8, 9), and perivascular 
inflammation (10, 11), altogether contributing to the structural remodeling that precipitates disease.  
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1.1.1.1 Controversial endothelial phenotypes 
Pulmonary endothelial dysfunction is another defining feature of panvascular remodeling 
in PAH but remains incompletely understood. Histologic evaluation provides evidence of 
significant microvascular loss (vessel rarefaction) (12, 13) as well as neointimal proliferation and 
“angio-obliterative” lesions in lungs from patients with end-stage PAH (4). Therefore, unlike the 
unilateral hyperproliferation observed in other vascular types, both apoptosis and proliferation 
have been ascribed to pulmonary endothelial dysfunction. Controversy exists over the timing and 
relative pathogenicity of these cell fates in pulmonary vessel remodeling and disease development 
(14-16). Specifically, induction of endothelial apoptosis in different animal models resulted in 
pulmonary vessel rarefaction prior to disease development and endothelial proliferation (17, 18); 
these time-dependent studies highlight endothelial apoptosis as a trigger of PAH and suggest 
proliferation could be an epiphenomenon later in disease. 
Separately, other in vivo models have established a causative role for endothelial 
proliferation in neointimal formation and PAH development (19, 20). Altogether, the major 
hypothesis in the field postulates that the endothelium is the site of inciting injury and apoptosis 
followed by hyperproliferation (21-24); however, dynamic control and the causative importance 
of these divergent cell fates remains unclear. Furthermore, how these changes in endothelial cell 
survival impact the other aspects of endothelial cell function important in PH, such as permeability, 
vasomotor tone, inflammatory and thrombolytic signaling, as well as cell-to-cell communication 
with circulating immune cells and smooth muscle cells (25), is not well-defined. 
This observed shift in endothelial cell phenotype may also support the notion of 
heterogenous endothelial populations in the pulmonary vascular tree with the added possibility of 
other cell fates (e.g., endothelial-to-mesenchymal transition (EndoMT) (26-28)) beyond the 
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accepted apoptosis versus proliferation binary. Senescence, defined by irreversible growth arrest 
and a pro-inflammatory senescence-associated secretory phenotype (SASP) (29, 30), represents 
one alternative endothelial outcome important in the pathology of extrapulmonary vascular beds 
(31, 32) that has been linked but not yet described in depth in PAH (33, 34). In aging and age-
associated diseases, multiple aberrant processes converge to drive senescence, including 
attenuated mitochondrial (35-37) and genomic integrity (29, 30). However, the complex regulatory 
events that control putative endothelial senescence and how such events fit into the evolution of 
pulmonary endothelial cell function are not known.  
1.1.2 Molecular pathology 
1.1.2.1 Mitochondrial dysfunction 
Extensive basic, translational, and clinical analyses spanning over two decades support a 
causative link between metabolic reprogramming and PAH (5). Parallel to Warburg’s observations 
that proliferating tumor cells display mitochondrial respiratory repression followed by increased 
glucose uptake and glycolysis (38, 39), foundational studies demonstrated a mechanism for 
diminished glucose oxidation and increased glycolysis in PASMCs. Specifically, in PH, hypoxia-
inducible factor alpha (HIF-α)-dependent upregulation of pyruvate dehydrogenase kinases 1 and 
2 (PDK1/2) inhibits pyruvate dehydrogenase (PDH)-mediated conversion of pyruvate to acetyl-
CoA (40, 41). Notably, the master transcription factors HIF-1 and HIF-2α are critical effectors in 
this metabolic shift and are stabilized by hypoxic, inflammatory, and metabolic stress – known 
pathologic triggers of PH (42-44). Coupled with metabolically-driven hyperpolarization of the 
mitochondria membrane (40, 41, 45, 46), “aerobic glycolysis” results in less efficient energy 
production but more biomass for cell division, giving rise to the anti-apoptotic and pro-
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proliferative PASMC phenotype observed in disease. While prior studies initially focused on 
tissues with high bioenergetic requirement and high mitochondrial content, like PASMCs, this 
metabolic shift has since been observed in other pulmonary vascular cell types (10, 11, 47-50), the 
right ventricle (51), and even cells outside the RV-PA circuit (52-55) in animal models and patients 
with PH. 
In addition, while the Warburg effect has served as a conceptual anchor, additional data 
has expanded the focus to include other forms of metabolic rewiring (e.g., glutaminolysis (56, 57), 
fatty acid oxidation (58, 59), pentose phosphate pathway (60-62)) as well as changes in 
mitochondrial structure and function including altered ROS signaling (63) and iron handling (64), 
increased fission (65-67), and decreased mitochondrial mass due to an imbalance in mitochondrial 
biogenesis (53, 68) and clearance (mitophagy) across multiple cell types (1). For endothelial cells 
specifically, an understanding of metabolic reprogramming and mitochondrial dysfunction is still 
developing. Studies have characterized attenuated oxidative phosphorylation with elevated 
compensatory glycolysis (49, 50, 69-72), altered fatty acid handling (73), and increased 
glutaminolysis (74, 75); in turn this metabolic rewiring has been linked to decreased mitochondrial 
biogenesis (76, 77) and increased mitophagy (78). Interestingly, these data attribute mitochondrial 
dysfunction as drivers of both apoptosis and proliferation. Despite the fact that PH pathogenesis 
seems to converge at the mitochondria, fundamental questions still remain, including the causal 
mechanism(s) of mitochondrial dysfunction and how the dysregulated metabolic programs 
promote cell specific-dysfunction, particularly in the endothelium, during different disease stages. 
Further interrogation of endothelial mitochondrial function could be instrumental in characterizing 
the maladaptive shift between early-stage apoptosis and late-stage hyperproliferation (21, 23) or 
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in explaining alternative cell fates already associated with mitochondrial dysfunction in PH (79) 
or in other vascular diseases (80). 
In sum, more work is required to define spatio-temporal phenotypes and their functional 
consequences in the pulmonary endothelium of patients with PAH as well as other, lesser 
characterized forms of PH. Ultimately, an understanding of the dynamic phenotypic landscape 
could have significant translational implications, potentially facilitating diagnostic determination 
of disease stage and therapy options. 
1.1.2.2 DNA damage 
DNA damage represents a less defined molecular driver recently been linked to PH 
pathogenesis (81-83). Broadly, DNA lesions represent a diverse number of chemical modifications 
to the genome, including but not limited to single- and double-stranded DNA breaks, that can 
inhibit normal replication and transcription, result in mutations (i.e., genomic instability), alter cell 
viability, and ultimately influence human disease. There are several endogenous drivers of DNA 
damage, including products of metabolism, like oxidative stress, and replication stress (84). 
Addressing the latter, replication stress disrupts genomic integrity by compromising efficient, 
error-free replication fork progression and resulting in pathological DNA breaks (84). In turn, 
replication stress (or another endogenous drivers) results in the DNA damage response (DDR), a 
multi-step process that detects damage and signals for DNA repair (85); measurement of enhanced 
signaling within this network of proteins of  is often used as a surrogate for the underlying DNA 
damage. If repair is fundamentally impaired or overwhelmed by an increase in the causative agents 
of endogenous DNA damage, cell-fate outcomes vary between apoptosis and senescence 
depending upon length and severity of stressor and cell type (86, 87). 
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Both pulmonary smooth muscle cells (88) and endothelial cells exhibit markers of DNA 
damage. Speaking to the latter, initial studies highlighted the presence of microsatellite and 
chromosomal instability in the clonal endothelial population of neointimal lesions in PAH (82, 89-
91). Additional data demonstrated elevated baseline as well as oxidative stress-induced DNA 
damage in cultured pulmonary artery endothelial cells (PAECs) from these patients (82) with both 
studies attributing endothelial survival and proliferation to the underlying genomic instability. 
Conversely, other studies have shown that decreased expression of DDR markers associated with 
an increased sensitivity to apoptosis in PAH (92, 93). Therefore, to date there is no consensus or 
definitive mechanism by which DNA damage promotes proliferation versus apoptosis (versus 
senescence) in endothelial cells. Moreover, there is little data describing the driver(s) of this 
genomic damage. Whether DNA damage promotes disease outside of PAH is not yet defined; 
however, given that DNA damage accumulates as we age, DNA damage-associated outcomes 
could be particularly important in PH subtypes due to age-associated comorbidities.   
In summary, the underlying endothelial dysfunction in PAH is controversial and 
incompletely defined. Endothelial mitochondrial dysfunction and DNA damage have been 
separately linked to PAH, but any shared mechanistic regulation of dynamic endothelial 
phenotypes and relevance across PH subtypes other than PAH are unknown. 
1.1.3 Epidemiology and classification 
PH is a heterogenous disease driven by multiple disparate triggers. The term PH 
encompasses several groups of patients categorized based upon clinical criteria and etiology. These 
distinctions reflect patient prognosis and therapeutic options as our understanding of disease 
pathophysiology (1.1 and 1.2) as well as existing treatments are largely exclusive to Group 1 PAH 
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which is the result of idiopathic or heritable causes or associated with conditions such as 
connective tissue disease, infection, toxin exposure, and congenital heart disease. Separately, PH 
in groups 2-5 occurs secondary to a myriad of comorbidities: left heart disease (Group 2), hypoxic 
lung diseases (Group 3), chronic thromboembolic disease (CTEPH, Group 4), as well as other 
multifactorial, ill-defined conditions such as hematologic and metabolic disorders (Group 5) (3).  
According to the Registry to Evaluate Early and Long-term PAH Disease Management 
(REVEAL registry) (94), there is an estimated incidence and prevalence are 2.3 and 12.4 cases of 
PAH per million adults, respectively (95). Within this population, there is female: male 
predominance (~4:1) and paradoxically a female survival benefit (96) that remains incompletely 
defined. Although characterized as a disease of previously healthy, young-to-middle-aged adults 
in the past, recent data suggests the PAH population has an increased proportion of older adults 
with the average age of enrollment in the REVEAL registry being 53+15 years (97). Moreover, 
these older patients are more likely to present with more advanced disease, decreased exercise 
capacity, and multiple co-morbidities, making management more complicated (97-99).  
As the population ages, the number of patients with chronic illnesses rises with 
cardiovascular disease (30.3%) and chronic respiratory illnesses (9.5%) among the leading 
contributors in patients >60 years old (100). Therefore, Group 2 PH due to left heart disease (101, 
102) and Group 3 PH due to hypoxic lung disease (103, 104) represent an emerging majority of 
PH patients. The prevalence of the most common Group 2 PH is dependent upon the specific type 
of left ventricular dysfunction. For example, specific studies have shown that PH was present in 
51% of patients with obstructive hypertrophic cardiomyopathy (HCM) and advanced heart failure 
(105) and 83% of patients with heart failure with preserved ejection fraction (HFpEF) (106). 
Similarly, Group 3 PH resulting from chronic lung diseases is also relatively common, especially 
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in with more severe disease (103); for patients with advanced or severe disease, up to 90% of those 
with chronic obstructive pulmonary disease (COPD) (107, 108), up to 50% with emphysema (109), 
and between 30-60% with idiopathic pulmonary fibrosis (IPF) exhibited PH (110, 111). In sum, 
PH represents a significant disease burden in patients with left heart disease or chronic lung 
disease; however, there are no treatment strategies available. 
The clinical distinction between Group 2 PH and the other PH groups is made using right 
heart catheterization, which directly measures mPAP, cardiac output (CO), and pulmonary artery 
wedge pressure (PAWP) with the latter achieved by occluding a smaller branch of the pulmonary 
artery with the balloon catheter tip (‘wedging’) and allowing for evaluation of the pressure beyond 
the balloon tip – a reflection of pulmonary venous and left heart hemodynamics. From these values, 
pulmonary vascular resistance can be calculated using the principles of Ohm’s law and the 
following equation: PVR=(mPAP–PAWP)/CO. A mPAP >20mmHg coupled with varying PAWP 
and PVR measurements delineates between pre-capillary PH, post-capillary, or combined pre- and 
post-capillary PH. Pre-capillary hemodynamic values (PAWP <15mmHg, PVR >3WU) reflect 
intrinsic pulmonary vasculopathy often observed in Groups 1, 3, 4, and 5 PH while post-capillary 
values (PAWP >15mmHg, PVR <3WU) reflect backward transmission of elevated left-sided 
filling pressures into the pulmonary circulation in Group 2 PH (3).  Importantly, many patients 
meet the criteria for multiple PH categories, especially as the PH population ages, often reflected 
as combined pre- and post-capillary PH pressures (PAWP >15mmHg, >3WU). Specifically, there 
is emerging evidence that “Group 1-like” primary vascular pathophenotypes contribute to Group 
2 PH (112), and are not solely due to vascular reactions to increased left heart afterload (105, 113). 
Consequently, Group 1 versus Group 2 PH can be difficult to diagnose and treat and often portends 
increased morbidity and mortality (114).  
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As our understanding of this enigmatic disease develops, this classification schema and its 
defining clinical features are modified by the by the World Symposium on Pulmonary 
Hypertension (WSPH) Task Force every five years. Specifically, the hemodynamic features of 
disease were recently updated to reflect a mean pulmonary artery pressure (mPAP) above 20 
mmHg instead of the previously arbitrary 25 mmHg threshold (3). It should be noted that some 
data included in this dissertation will be based upon prior hemodynamic guidelines. While these 
WSPH groups provide necessary guidelines for diagnosis and treatment, the distinctions between 
these clinical phenotypes are not always clear, especially with co-morbidities in patients of 
advanced age. Furthermore, these classifications do not yet adequately incorporate emerging 
molecular drivers of this disease. Thus whether there is overlap in the mechanisms that underlie 
PAH and other PH groups, in particular Group 2 and 3 PH, remains incompletely defined. The 
molecular classification of PH will require a better understanding of the shared pulmonary vascular 
pathophysiology but has the potential for improved management and prognosis in lesser 
characterized subtypes as well as those patients with a mixed clinical picture. 
1.1.4 Prognosis and therapies 
According to the REVEAL registry, 1-, 3-, 5-, and 7-year survival rates in PAH patients 
from the time of diagnosis were 85%, 68%, 57%, and 49%, respectively (95). More specifically, 
five-year survival of newly diagnosed patients as stratified modified New York Hear Association 
(NYHA)/World Health Organization (WHO) functional class (I, II, III, IV) remains poor at 72.2%, 
71.7%, 60.0%, and 43.8% (115). Routine evaluation of the patient’s exercise and functional 
capacity (as measured by the 6-minute walk distance (6MWD) and NYHA/WHO functional class), 
hemodynamic instability (e.g., right atrial pressure, cardiac index), and limited biomarkers (e.g., 
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the N-terminal fragment of brain natriuretic peptide (NT-proBNP)) allows for the assessment of 
response to treatment and well as risk of mortality (116).  
PH-specific treatments are only effective for patients with Group 1 PAH and target three 
primary mechanisms involved in vasomotor tone regulation: endothelin-1 (ET-1), nitric oxide 
(NO), and prostacyclin signaling pathways (117). To start, endothelin-1 (ET-1) acts at G-protein 
coupled receptors ETA and ETB: ETA exists predominately on pulmonary smooth muscles cells 
and controls vasoconstriction as well as cellular proliferation, hypertrophy, and fibrosis while ETB 
is expressed on both endothelial and smooth muscle cells, inducing vasodilatory and anti-
proliferative signaling and vasoconstrictive signaling in these respective cell types (118). There is 
simultaneous elevation of ET-1 in the plasma (119) and lungs (120) and receptor expression in 
smooth muscle cells of patients with PH (118). Consequently, endothelin receptor antagonists that 
target ETA (ambrisentan) or both ETA and ETB (bosentan, macitentan) each improved functional 
outcomes (121, 122) or prevented morbidity and mortality (123). 
Separately, nitric oxide (NO) is produced by endothelial nitric oxide synthase (eNOS) and 
promotes vasodilation by binding soluble guanylyl cyclase (sGC), which in turn, converts 
guanosine triphosphate (GTP) to the secondary messenger cGMP to activate cGMP-dependent 
protein kinase (PKG) and relax smooth muscle cell contractile filaments. In multiple forms of PH, 
NO bioavailability is diminished due to reduced expression of eNOS (124) or inadequate levels of 
enzymatic cofactors required for NO biosynthesis (uncoupling) (125, 126). While NO reduction 
contributes to the vasoconstrictive pathophenotype of this disease, data also suggest the NO-sGC-
cGMP pathway alters platelet aggregation, leukocyte recruitment, inflammation, fibrosis, smooth 
muscle proliferation, and pulmonary vascular remodeling. Currently two drug classes work to 
improve NO signaling: sGC stimulators and PDE5 inhibitors. First, the sGC stimulator riociguat 
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binds the prosthetic heme group of sGC to enhance cGMP production either independent of or in 
tandem with available NO (127) and represents the first in its drug class approved for treatment of 
different subtypes of Group 1 PAH (128-130) and refractory Group 4 CTEPH (131) with 
significant improvements in 6MWD and WHO functional class. Notably, emerging data in pre-
clinical models suggests the use of riociguat may be beneficial for other PH groups (132). 
Downstream of sGC, the secondary messenger cGMP is degraded by the enzyme 
phosphodiesterase 5 (PDE5), which is highly expressed in vascular smooth muscle cells (133). 
PDE5 inhibitors, like sildenafil and tadalafil, interfere with the catalytic domain to prevent 
hydrolysis and thus enhance cGMP activity in PAH (134-136). 
Lastly, prostacyclin is an endothelial prostanoid and also acts as a vasodilator by binding 
its prostaglandin I2 (PGI2) receptor on smooth muscle cells. From there, activation of adenylyl 
cyclase (AC) leads to the conversion of adenine triphosphate (ATP) to cAMP and subsequent 
activation of protein kinase A (PKA), exerting anti-platelet, anti-thrombotic, and anti-proliferative 
effects in addition to vasodilation of the vasculature (137). Patients with Group 1 PAH exhibit 
decreased prostacyclin levels (138) as well as reduced synthase (139) and receptor expression 
(140). Continuous infusion of the prostanoid analogue, epoprostenol, improves exercise capacity, 
hemodynamic instability, and overall survival, and remains a foundational therapy in patients with 
severe PAH. Newer formulations that are longer-lasting and do not require continuous 
administration, like treprostinil, are approved for treatment-naïve patients (141) or in combination 
with other vasodilatory therapies (142). In addition to these analogues, selexipag (hydrolyzed by 
the liver to the active metabolite ACT-333679) acts as a selective agonist for the prostacyclin IP 
receptor and reduces worsening of PH (e.g. diminished 6MWD or worsened WHO functional 
class) or complications related to PH (e.g., hospitalizations, listing for transplantation) (143).  
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While these therapies, particularly in combination (144), may improve clinical measures 
of disease, there is still no cure for PAH and patients remain functionally impaired despite these 
drugs with extreme interventions such as the creation of a right to left shunt (a bridge to transplant) 
or bilateral lung transplant required for refractory patients (145). Moreover, these vasodilatory 
therapies have been clinically tested in patients with Group 2 and 3 PH with mixed outcomes that 
do not comprehensively support their use in these patient populations (103, 146), leaving a 
majority of PH patients without available treatments. Therefore, the search for diagnostic and 
therapeutic tools that target the causative mechanisms of disease continues. In response, there are 
several emerging therapies aimed at targeting inflammation and immune modulation (e.g., 
rituximab NCT01086540, tocilizumab IL6 receptor antagonist NCT02676947), metabolic 
dysfunction (e.g., metformin NCT03349775, ranolazine NCT02829034, dichloroacetate 
NCT01083524 (147)), iron deficiency (148), DNA damage (e.g., olapirib, NCT03782818), and 
epigenetic modulation (e.g., apabetalone, NCT03655704 (149)) with a particular emphasis on drug 
repurposing to ensure an expedited drug to treatment pipeline (150, 151). However, whether these 
drugs will be effective in not only PAH but across diverse etiologies is unknown, providing the 
impetus to better understand any shared cellular and molecular mechanisms across multiple PH 
classifications to treat these increasingly prevalent subtypes.  
1.2 Iron-sulfur clusters 
Separately, iron-sulfur (Fe-S) clusters are evolutionarily conserved bioinorganic cofactors 
essential for a diverse number of processes (152), including those involved in mitochondrial 
respiration (153) as well as DNA replication and repair (154, 155). First, these clusters have potent 
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reduction-oxidation (redox) potential with the iron able to reversibly switch between oxidative 
states (Fe2+ or Fe3+) and serve as a competent electron donor and acceptor (152). This function is 
particularly important for electron transfer between mitochondrial complexes (I-IV) during 
oxidative phosphorylation and the TCA cycle (succinate dehydrogenase in complex II) (153). 
Others studies have expanded the roles of Fe-S centers to include enzymatic catalysis (e.g.,  lipoate 
synthase (156)), environmental sensing and transcription activation (e.g., IRP1 (157), and even 
structural integrity (e.g., XPD, FANJ (158)).  
Notably, Fe-S centers have more recently been identified in nuclear proteins. In particular, 
helicase (e.g., DNA2), primase, and B-family DNA polymerase proteins operate at the level of the 
replication fork; these as well as glycosylases (e.g., MUTYH involved in base excision repair 
(BER)) and specialized helicases, like XPD in nucleotide excision repair (NER) or RTEL1 in 
homologous recombination and telomere maintenance, participate in multiple DNA repair 
pathways to maintain overall genomic stability (154, 155). Human disease, particularly cancers 
and progeroid syndromes, associated with loss-of-function mutations in these Fe-S-containing 
nuclear proteins confirm their importance in DNA synthesis and repair (159-162). Although some 
data supports contributions to stability of tertiary and quaternary protein structure (158, 163), the 
study of these proteins is difficult and the exact function(s) of these cofactors within their 
respective nuclear apoproteins are still incompletely defined. 
1.2.1 Iron-sulfur biogenesis 
The synthesis, trafficking, and integration of Fe-S cofactors into their respective 
apoproteins depends upon a group of mitochondrial and cytosolic Fe-S assembly (CIA)  proteins 
with the former ensuring the integrity of the latter (155, 164). Conserved across bacteria (E. coli) 
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and eukaryotic cells, de novo cluster formation beings via a complex of the cysteine desulfurase 
NFS1-ISD11 (sulfur donor) , frataxin (FXN, iron donor), and the iron sulfur assembly protein 1 
and 2 (ISCU1/2, scaffold that contains cysteine residues for labile Fe-S binding) (165-169). From 
there, several chaperones and assembly proteins complete mitochondrial Fe-S maturation. The 
connection between mitochondrial Fe-S biogenesis exports and CIA is still incompletely defined 
but additional scaffolding proteins (e.g., CFD1-NBP35, DRE2, MMS19) continue the Fe-S cluster 
maturation process in the cytoplasm ensuring appropriate transfer to cytosolic and nuclear 
apoproteins (155, 170).  
1.2.2 Pulmonary hypertension in diseases due to Fe-S biogenesis gene deficiency 
The essential nature of these ubiquitous clusters is further supported by several 
mitochondrial diseases linked to mutations in Fe-S biogenesis genes (152). For example, a splicing 
defect in the ISCU gene results in decreased expression iron sulfur assembly protein 1 and 2 
(ISCU1/2) and myopathy characterized by decreased succinate dehydrogenase, aconitase, and 
IRP1 alongside intracellular iron overload (171, 172). In addition, patients with multiple 
mitochondrial dysfunctions syndrome 1 (MMDS1) and 2 (MMDS2), due to mutations in Fe-S 
assembly genes NFU1 (173-175) and BOLA3 (174, 176) respectively, present with similar 
metabolic reprogramming in the form of attenuated pyruvate dehydrogenase, respiratory complex 
I and II, and glycine cleavage system function. Notably, patients with MMDS exhibit a PH 
phenotype (173, 175). While the origins of PH in these populations had previously been ill-defined, 
recent work has causatively linked genetic deficiencies of Fe-S cluster assembly genes to 
pulmonary vascular disease (71, 72, 177). 
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Specifically, our laboratory’s data demonstrated ISCU1/2 deficiency attenuated Fe-S 
cluster formation and subsequent mitochondrial respiration to increase endothelial apoptosis and 
promote PH development in vivo (70, 71). Importantly, these findings were confirmed via 
cardiopulmonary exercise testing of a woman with homozygous ISCU mutations, revealing the 
first known observation of pulmonary vascular dysfunction in an ISCU-deficient patient and 
expanding upon the list of genetic Fe-S biogenesis gene deficiencies that drive PH (71).  
Additionally, deficiency of BOLA3 resulted in similar Fe-S-dependent metabolic rewiring in the 
form of the Warburg effect (i.e., decreased mitochondrial respiration coupled with increased 
glycolytic capacity (178)) as well as hyperglycinemia, which ultimately promoted endothelial 
dysfunction in the form of imbalanced vasomotor tone, reduced angiogenesis, and enhanced 
proliferation as well as PH in vivo (72). Importantly, beyond genetic mutations, multiple PH animal 
models and patient tissues showed decreased ISCU1/2 and BOLA3 levels in the pulmonary 
endothelium. Specifically, HIF-, a well-characterized transcription factor involved in metabolic 
reprogramming in PH (42, 179), acted as a master regulator of endothelial ISCU1/2 (via 
microRNA-210) and BOLA3 expression (via histone deacetylase 1) in chronic hypoxia (70, 72). 
Together, our studies illustrated that not only genetic but acquired Fe-S assembly gene deficiency 
in the endothelium promoted PH development. Whether additional Fe-S cluster biogenesis 
proteins contribute to not only the endothelial metabolic but also genomic dysfunction that 
underlies PH has not yet been investigated. 
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1.3 Friedreich’s ataxia 
1.3.1 Trinucleotide repeat mutations in frataxin 
Frataxin (FXN) is another highly conserved mitochondrial protein involved in the early 
steps of Fe-S cluster biogenesis via its interaction with ISCU1/2 as well as other assembly proteins, 
NFS1 and ISD11  (167-169). Although its exact function(s) are controversial, FXN is thought to 
act as an iron chaperone (180) and support NFS1 cysteine desulfurase activity (and thus provision 
of sulfur) (181) when bound to the aforementioned initiation complex during Fe-S cluster 
formation. FXN has also been characterized as an iron chaperone during heme synthesis (182) and 
an iron storage protein (180), contributing to mitochondrial as well as global iron balance.  
Genetic FXN deficiency causes the autosomal recessive neurodegenerative disease, 
Friedreich’s ataxia (FRDA). For this nuclear-encoded gene, homozygous trinucleotide repeat 
expansions in intron 1 represent the predominating mutation type compared to compound 
heterozygotes carrying a GAA expansion on one allele and a point mutation on the other (183-
185). Full penetrance, disease-causing GAA repeats ranging from 66-1300 triplicates (as compared 
to between 5 and 35 in healthy individuals) alter genomic and heterochromatin structure with the 
formation of triplex, or ‘sticky’, DNA (186) and hypoacetylation of histone H3 and H4 combined 
with hypermethylation of H3 at Lys9 (187, 188), respectively. The resulting transcriptional 
silencing yields 5-35% of normal FXN levels in FRDA patients with the length of the expansion 
mutations inversely related to the amount of FXN produced (183). Interestingly, heterozygous 
carriers are asymptomatic, suggesting a FXN expression greater than 50% do not produce tissue 
dysfunction (189). 
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1.3.2 Epidemiology and clinical presentation 
FRDA is the most common inherited ataxia in patients of European, Middle Eastern, and 
North African descent (190) with a prevalence of 3-4 in 100,000 and a carrier frequency of 1:60-
1:100 (191, 192). A multisystem disease, the neurodegenerative and cardiovascular symptom 
profile represent the dominant and most debilitating phenotypes. Speaking to the former, 
progressive degeneration of large sensory neurons in the dorsal root ganglia (DRG), the 
spinocerebellar and corticospinal tracts of the spinal cord, and the dentate nucleus of the 
cerebellum result in a myriad of neurologic symptoms including limb ataxia, sensory neuropathy, 
loss of deep tendon reflexes, lower limb spasticity, dysarthria, and motor weakness (191, 193, 
194). Limb ataxia and gait instability typically represent the initial sign and symptom and almost 
all patients will eventually require a wheel chair following loss of ambulation (193). Other non-
neurologic symptoms include skeletal abnormalities like kyphoscoliosis and pes cavus, diabetes 
mellitus and glucose intolerance, and hypertrophic cardiomyopathy (HCM) (193). The length of 
the intronic expansion on the shorter allele dictates severity of symptoms and age of onset ; 
specifically, neurologic signs like ataxia, visual and auditory loss, dysarthria, and scoliosis as well 
as cardiomyopathy correlate with GAA repeat length (183, 195, 196). Age of onset typically occurs 
around puberty (10-15) and is often before age 25 and life expectancy is typically between 30 and 
40 years old (197). Variability in these parameters is again related to length and/or interruption of 
trinucleotide repeats.   
1.3.2.1 Hypertrophic cardiomyopathy 
Cardiac dysfunction in FRDA is defined by concentric hypertrophy, fibrosis, and myocyte 
necrosis and causing severe left ventricular dysfunction and less often dilated cardiomyopathy and 
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arrhythmia (198). HCM occurs in approximately 60% of FRDA patients, driving mortality in this 
population (188, 197). In the broader context of Group 2 PH due to left heart disease, HCM is 
accompanied by PH in up to 40% of patients and the combination is associated with increased 
mortality (105, 199). Case reports have described pulmonary arteriolar vasculopathy in this 
population (200); however, PH and cardiopulmonary complications as a whole in FRDA have 
been underreported (201, 202), in part due to the lack of hemodynamic outcomes and lung 
specimens available for study. Of the FRDA heart failure reports that are available, focus has been 
given to the diastolic dysfunction and markedly elevated left ventricular filling pressures rather 
than the PH that, by definition, is present (202). Further studies are required to confirm the 
presence of PH in FRDA independent of or additive to HCM. 
1.3.3 Cellular and molecular pathology 
Underlying the severe neurologic and cardiovascular clinical presentation, there is 
significant tissue-specific dysfunction within the. Data have largely focused on the Fe-S cluster-
dependent changes in these post-mitotic cell types like neurons of the spinocerebellar tracts (e.g., 
dorsal root ganglia) and cardiomyocytes. Consistent with the roles of Fe-S centers in cytosolic iron 
sensing (IRP1/aconitase) and mitochondrial electron transport (153, 157), FXN deficiency 
decreased the activity of complexes I-III and aconitase in multiple tissue types (203, 204). This 
metabolic reprogramming is accompanied by tissue evidence of mitochondrial iron loading (205-
207) and elevated oxidative stress (208, 209) due increased production and sensitivity to reactive 
oxygen species (ROS) (210, 211). Some controversy exists over the causative importance of iron 
accumulation; some data suggests iron overload enhances iron-dependent ROS (i.e., hydroxyl 
radicals) via the Fenton reaction while others suggest it is a late-stage byproduct in FRDA (212, 
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213). Notably, both mitochondrial and nuclear DNA damage has been observed in FRDA and 
largely attributed to oxidative stress (214-217). Given the reliance of non-mitochondrial Fe-S-
containing proteins on FXN-dependent mitochondrial Fe-S cluster formation (218), specific 
disruption of DNA replication and repair proteins with Fe-S centers may also result in DNA 
damage (219) but has not been investigated in the context of FXN deficiency and FRDA. 
In addition, the pathological changes in metabolism and ROS handling have been 
associated with variable or incompletely defined cellular outcomes; most often, FXN deficiency 
seems to increase susceptibility to apoptosis (220-223) while more recent studies highlight FXN-
driven cellular senescence (224, 225). The phenotypes of FXN-deficient pulmonary vascular cells, 
namely endothelial cells, have not been studied in FRDA; but the essential nature of FXN, Fe-S 
biology, and the potential pathobiological consequences of their deficiency could have a profound 
effects on pulmonary endothelial cell health.  
1.3.4 Emerging therapies 
With no available cure for FRDA, proposed therapies are primarily focused on either 
enhancing FXN expression or curbing downstream metabolic stress. First, given that GAA 
expansion mutations occur in a non-coding region, improving the transcription of FXN with 
epigenetic pharmacotherapies is a promising option. To this end, histone deacetylase inhibitors 
have been shown to relieve FXN repression in FRDA in both preclinical (187, 226) and early 
clinical studies (227). However, despite achieving the primary endpoint of up-regulated FXN 
expression, the nicotinamide treatment did not alter clinical parameters related to neurological 
deficits while cardiopulmonary dysfunction was not assessed. Future long-term studies of 
epigenetic pharmacotherapies may yield increased FXN alongside improved clinical outcomes, 
 20 
specifically for HCM. With similar intentions, both interferon gamma (IFN) (228) and resveratrol 
(229) increased FXN in vitro; preliminary clinical trials did not restore FXN expression but did 
improve physical clinical parameters (230-232), suggesting an alternative mechanism of action.  
Treatment targeting the downstream mitochondrial oxidative stress or iron accumulation 
have also been pursued in this population. Specifically, idebenone (a CoQ10 analog) initially 
appeared to improve disease by altering cardiac outcomes (233-235); however this drug failed to 
improve neurologic and cardiovascular disease parameters in in recent advanced-stage clinical 
trials (236, 237). Similarly, reduced antioxidant function of NRF2 in FRDA patient cells (238) 
encouraged the development of NRF2 activators (NCT02255435) (239). Mitochondrial-specific 
iron chelators, like deferiprone, yielded inconclusive clinical results (240). Another trial 
demonstrated the combination of idebenone and deferiprone did not alter neurologic parameters 
but did reduce intraventricular septum thickness as well as left ventricular mass index (241). On 
the whole, therapies combating the FXN-dependent oxidative stress and iron dysregulation have 
not been reliably effective in preventing disease progression to date; however, combination therapy 
may provide a way forward. 
Current strategies for patient care are limited to symptom management and include 
comprehensive physical and occupational therapy as well as antispasmodics, hypoglycemic agents 
and insulin for diabetes mellitus, and traditional drug and device implantation to manage 
arrhythmia and heart failure (242). In summary, the diagnosis of FRDA and HCM represents 
tremendous morbidity and mortality for patients. A better understanding of the underlying 
pathophysiology of genetic FXN deficiency in the pulmonary vasculature may identify a group of 
FRDA patients at risk for PH. 
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1.4 Rationale  
PH is an enigmatic, heterogeneous disease with increasing prevalence of Group 2 PH due 
to left heart disease (101, 102) and Group 3 PH due to hypoxic lung disease (103, 104) as the 
population ages. With no curative therapies for any WSPH group, a diagnosis of PH represents 
significant morbidity and mortality to patients (95, 115). Whether there is any molecular 
connection between PAH and the other PH groups is still under investigation. Endothelial cell 
dysfunction represents a defining feature of PH panvascular remodeling yet its molecular 
mechanisms remain poorly defined as compared to other cell types such as smooth muscle cells. 
Notably both endothelial mitochondrial dysfunction (1) and DNA damage (81, 93) have been 
independently associated with PH. However, whether they share mechanistic regulation, how they 
converge on resultant endothelial phenotypes, and their relevance across PH subtypes are still 
undefined. 
Fe-S clusters are evolutionarily conserved, essential cofactors for multiple cellular 
processes, namely redox-dependent mitochondrial respiration (153) and genomic replication and 
maintenance (154), and provide a model to study the combined effect of endothelial metabolic 
reprogramming and DNA damage in PH. In particular, patients with genetic deficiencies of Fe-S 
biogenesis genes (ISCU-myopathy, MMDS) exhibit PH (71, 173, 175); moreover, HIF--
mediated acquired reduction of ISCU1/2 and BOLA3 each drive metabolic rewiring, endothelial-
specific dysfunction, and PH in vivo (70-72). Whether this causative link between endothelial Fe-
S cluster deficiency and PH depends upon genotoxic as well as metabolic stress and extends to 
acquired or genetic deficiencies of other Fe-S assembly proteins has not been investigated.  
Trinucleotide repeat mutations in the Fe-S biogenesis gene FXN cause FRDA (183). 
Mortality in this patient population is driven largely by hypertrophic cardiomyopathy (HCM) 
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(197). Case reports have described pulmonary arteriolar vasculopathy in this population (200), 
consistent with the fact that ~50% of patients with hypertrophic cardiomyopathy (HCM) in general 
suffer from PH due to left heart disease (105). However, little attention has been paid to the 
pulmonary vascular phenotypes in FRDA. Apart from the clinical potential for a PH phenotype 
concurrent with FRDA-dependent HCM, several studies have demonstrated mitochondrial 
dysfunction (184), oxidative stress, and DNA damage in FRDA tissues (208, 209, 214-217). 
Coupled with our laboratory’s data on endothelial Fe-S deficiency promoting PH (70-72), there 
may be a role for coordination of Fe-S-driven metabolic and genomic integrity by FXN in the 
pulmonary endothelium. 
Therefore, we hypothesized that genetic or acquired FXN deficiency disrupts Fe-S-
dependent endothelial function to promote PH. Herein I will 1) interrogate whether FXN 
deficiency disrupts metabolic and genomic integrity and how these FXN-dependent stressors 
coordinate endothelial phenotypes, 2) determine how acquired drivers of PH alter endothelial FXN 
expression, and 3) establish pulmonary endothelial FXN deficiency predisposes to PH in multiple 
PH subtypes. The identification of FXN as a lynchpin in PH pathogenesis will improve our 
understanding of Fe-S biology, the shifting pathophenotypes of endothelial cells, and the 
development of PH. Furthermore, this study may provide mechanistic insight and thus new 
diagnostic and therapeutic targets for pulmonary vascular disease in FRDA as well as multiple PH 
groups, including Group 2 PH.  
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2.0 Frataxin deficiency disrupts pulmonary endothelial metabolism 
            This work was adapted from a published review (1) and a manuscript in preparation. 
Culley MK, and Chan SY. Mitochondrial metabolism in pulmonary hypertension: beyond 
mountains there are mountains. J Clin Invest. 2018;128(9):3704-15.  
 
Culley MK, Zhao J, Tang Y, Negi V, Yu Q, Perk D, Reynolds M, Pilli J, Shiva S, Chan SY. 
Frataxin deficiency disrupts iron-sulfur-dependent mitochondrial reprogramming in the 
pulmonary endothelium. In preparation. 
 
Notably, iron-sulfur fluorescent sensor experimental design and imaging by Ying Tang and 
quantification by Jingsi Zhao (Figure 1A-B). Seahorse assay performed with the help of by 
Michael Reynolds and Dr. Sruti Shiva (Figure 2). Total nitrite and nitrate (Figure 3F) and 
contraction assay (Figure 5E) performed by Jingsi Zhao. 
2.1 Introduction 
Pulmonary hypertension (PH) is a progressive and fatal disease of the lung vasculature in 
which metabolic and mitochondrial dysfunction contribute to pathogenesis (1). A hallmark of the 
metabolic reprogramming in PH is the shift from mitochondrial oxidation to glycolysis, similar to 
the Warburg effect in cancer (38, 178), that has been observed in both pulmonary (10, 11, 47-50) 
and extrapulmonary tissues  (51-55). Specifically, emerging data causatively links rewiring of 
 24 
endothelial metabolic pathways in the pulmonary circuit (49, 50, 69-72); however the 
identification of any upstream driver as well as the downstream consequences for the dynamic 
endothelial cell fates observed in PH require further study. 
Our laboratory identified iron-sulfur (Fe-S) cluster deficiency as a driver of disruption of 
endothelial cell metabolism and PH in vivo (70-72). Fe-S clusters are essential, redox-capable 
cofactors incorporated into different apoproteins across cellular compartments (152); for example, 
Fe-S centers facilitate electron transfer between mitochondrial complexes allowing for effective 
oxidative phosphorylation (153). Biogenesis of these bioinorganic clusters requires a number of 
evolutionarily conserved mitochondrial and cytoplasmic assembly proteins (152), the importance 
of which is underscored by rare, often fatal mitochondrial diseases driven by mutations in specific 
assembly genes, like ISCU (which encodes iron sulfur cluster assembly proteins 1 and 2)  (171, 
172), BOLA3 (BolA 3 family member) (174, 176), and NFU1 (173-175). While case reports have 
previously catalogued PH as an associated phenotype in these disorders (173, 175), new data 
supports a causative role for Fe-S biogenesis gene deficiency in this disease (70-72) with the most 
recent study demonstrating pulmonary vascular disease development in a rat model with the human 
NFU1 mutation (Multiple mitochondrial dysfunctions syndrome 1, MMDS1)(177). 
In addition to genetic deficiencies, our previous data established hypoxia-inducible factor 
alpha (HIF-) as a shared regulator of microRNA-210-mediated ISCU1/2 reduction (70, 71) and 
histone deacetylase 1 (HDAC1)-mediated BOLA3 reduction (72) in cultured pulmonary artery 
endothelial cells (PAECs) exposed to chronic hypoxia, a widely recognized trigger relevant to both 
Group 1 and Group 3 PH (243). Both acquired and genetic deficiencies resulted in metabolic 
reprogramming in the form of the Warburg shift (i.e., decreased respiration and compensatory 
glycolysis) (70-72) as well as altered glycine homeostasis (72). Given that BOLA3 provide the Fe-
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S cluster required for lipoic acid synthesis (156), reduced expression of the lipoate-dependent 
enzyme, glycine cleavage system H (GCSH), led to increased glycine levels (72), consistent with 
the hyperglycinemia in MMSD2 patients (174, 176). These Fe-S-specific metabolic changes 
promoted shared endothelial-specific phenotypes relevant to PH including increased 
vasoconstrictive signaling and dysregulated angiogenesis. Despite differences in endothelial cell 
survival, with ISCU1/2 causing endothelial apoptosis and BOLA3, proliferation, both resulted in 
pulmonary vascular disease in vivo (70-72). Whether alternative Fe-S biogenesis gene deficiencies 
contribute to metabolic reprogramming and its dynamic consequences for endothelial cell 
phenotypes has not been studied. 
The nuclear-encoded mitochondrial protein frataxin (FXN) acts as an iron chaperone and 
binding partner of ISCU1/2 during the initiation of Fe-S cluster assembly (169, 180, 181). This 
gene has been predominantly studied in the context of genetic deficiency: homozygous GAA 
repeat expansion mutations result in decreased functional FXN and the neurodegenerative disease 
Friedreich’s ataxia (FRDA) (244). Much attention has been given to diseased tissues with high 
bioenergetic capacity such as the nervous system, myocardium, and endocrine pancreas; to date, 
there are no studies on genetic FXN deficiency in the endothelium. However, data in non-vascular 
cell types whereby FRDA-dependent FXN deficiency drives mitochondrial dysfunction (203), 
oxidative stress and DNA damage (214, 215), arrested growth and apoptosis (220), and more 
recently senescence (224, 225), suggest that these same phenotypes in endothelial cells could have 
profound pathobiological consequences. Furthermore, recent findings reported that exposing 
FXN-depleted models to anaerobic conditions may rescue Fe-S biogenesis, reverse the FRDA-
specific ataxia phenotype, and improve viability (245). The consequences of the interaction 
between FXN deficiency and hypoxia have not been investigated in pulmonary endothelial cells. 
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Therefore, we investigated whether FXN deficiency controls Fe-S mediated metabolic 
reprogramming and endothelial dysfunction relevant to PH pathogenesis, similar to other 
biogenesis genes.  
 
2.2 Materials & Methods 
Cell culture  
            Primary human pulmonary artery endothelial cells (PAECs) (PromoCell) were plated in 
collagen-coated plastic and cultured in cell-specific basal media supplemented with a growth 
media kit (PromoCell; Lonza) and 5% fetal bovine serum (FBS) without antibiotics or antifungals 
added. Experiments were performed between passages 4 to 9. Serum-starved primary cells were 
exposed to hypoxia (0.2% O2, 5% CO2, with N2 balance at 37
 degrees C) using a modular hypoxia 
chamber or standard non-hypoxic conditions (20% O2, 5% CO2, with N2 balance at 37
 degrees C) 
or recombinant IL-1 (R&D Systems, 10ng/ml). 
 
Transfection  
Transfection was performed in PAECs at 70-80% confluency using 40nM of FXN siRNA 
(Santa Cruz Biotechnology, sc-40580) or pooled negative control siRNA (Santa Cruz 
Biotechnology, sc-44236) and Lipofectamine 2000 reagent (Life Technologies) in one-part 
OptiMEM (ThermoFisher) and three-parts serum-starved cell-specific media (Lonza). Following 
6-8 hours incubation, transfection media was removed and replaced with full-serum cell-specific 
growth media. Experiments were performed 48 hours post-transfection unless otherwise specified.  
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RNA extraction and quantitative  
RT-PCR Cells were lysed in Qiazol (Qiagen) and RNA extracted using Rneasy Mini Kit 
(Qiagen). Complementary DNA (cDNA) was synthesized via reverse transcription 
(ThermoFisher) on an Applied Biosystems Real Time PCR instrument (ThermoFisher). 
Quantitative RT-PCR (RT-qPCR) was performed on an Applied Biosystems QuantStudio 6 Flex 
Fast Real Time PCR device, and fold-change of RNA species was calculated using the formula (2-
∆∆Ct) normalized to -actin or SIN3A expression. TaqMan primers were purchased from 
ThermoFisher and are listed in Appendix A Table 1. 
 
Immunoblotting  
Cells were lysed in RIPA buffer (ThermoFisher) with added protease inhibitor 
(Thermofisher) and phosphatase inhibitor (PhosSTOP, Roche), and the concentration of the 
soluble protein fraction was estimated using a Pierce BCA protein assay kit (ThermoFisher). 
Protein lysates (15-20g) were separated by a 4-15% gradient SDS-PAGE gel system (Biorad) 
and transferred onto a PVDF membrane (ThermoFisher). Membranes were blocked in 5% non-fat 
milk in Phosphate-Buffered Saline (PBST) or BSA in Tris-buffered Saline with 0.1% Tween20 
(TBST) for 1 hour at room temperature and incubated with primary antibodies at 4 degrees C 
overnight. A complete summary of primary antibodies is listed in Appendix A Table 2. After 
washing with PBST or TBST (>10 minutes, three times), membranes were exposed to appropriate 
secondary antibodies (anti-rabbit, anti-mouse, and anti-rat) coupled to HRP (Dako) for 1 hour at 
room temperature.  After another set of washes, immunoreactive bands were visualized with the 
Pierce ECL reagents (ThermoFisher) and Biorad ChemiDoc XRS+ and ImageLab 6.0.1 software. 
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Fe-S fluorescent sensor  
Expression plasmids for GRX2 and GCN4 transgenes fused to the N-terminal or C-
terminal portions of the Venus fluorescent protein were generously provided by Dr. J. Silberg 
(Rice University) (72, 246). Transgenes were subcloned into the pCDH-MCS-EF1-PURO 
lentiviral parent vector (System Biosciences) via BamHI and NotI sites. Cultured PAECs were 
incubated with Fe-S fluorescent sensor lentiviruses in the presence of 8g/ml polybrene (Santa 
Cruz Biotechnology) for 24 hours. Virus-transduced human PAECs were transfected with FXN or 
control siRNAs as described above. Seventy-two hours post-transduction, fluorescence was 
imaged by EVOS FL microscope (Life Technologies), and Fe-S content was presented as 
percentage of PAECs with positive fluorescence. Manual quantification was performed blinded. 
Experiments were performed with the help of Ying Tang, M.S. and Jingsi Zhao, M.S. 
 
Seahorse assay  
In transfected PAECs (20,000 cells/well), oxygen consumption rate and extracellular 
acidification rate were measured on an XFe96 Extracellular Flux Analyzer (Agilent) following 
exposure to oligomycin (1M), the uncoupler FCCP (0.5M), and the Complex I and Complex III 
inhibitors rotenone (2M), and antimycin (0.5M). Basal DMEM contained either high (25mM) 
or low (1g/L) glucose. Etomoxir (40 µM), a CPT1a (carnitine palmitoyl transferase 1a) inhibitor, 
was added 15 minutes prior to the assay in a separate experiment to block fatty acid uptake by the 
mitochondria. Measurements were normalized to protein concentration. Experiments were 
performed with the help of Michael Reynolds, Jyotsna Pilli, and Sruti Shiva, Ph.D. 
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H2O2 assays  
At 48 hours, transfected PAECs were counted and re-distributed in a 96-well plate (100,000 
cells/well). Intracellular H2O2 was assessed by Amplex Red Hydrogen Peroxide/Peroxidase Assay 
kit (Invitrogen). Absorbance (560nm) and/or fluorescence (530nm/590nm) were measured by 
spectrophotometer (Synergy HTX multimode reader, Biotek). Alternatively, at 48 hours post-
transfection, cultured PAECs were incubated with 2’,7’ –dichlorofluorescin diacetate (DCFDA; 
1M) for 10 minutes at 37 degrees C and then assessed by flow cytometry (BD LSRFortessa). 
 
Endothelin-1 ELISA  
Level of secreted endothelin in concentrated serum-free endothelial cell culture media was 
assessed by endothelin-1 ELISA kit (Enzo Life Sciences) while colorimetric change was measured 
by spectrophotometer (Biotek).  
 
Contraction assay  
Pulmonary artery smooth muscle cells (PASMCs) (50,000/well) were embedded in 100μl 
of matrix gel and plated into a 96-well plate as described previously (247). Briefly, to make the 
collagen matrix gel, collagen I solution (Corning 354249) was mixed on ice with a 1/8 volume of 
0.1M NaOH and a 1/8 volume of 10X PBS followed by pH adjustment to 7.5 using 0.1M HCL. 
Matrigel (Corning, 356231) to make 3mg/ml collagen I. PASMCs were trypsinized, counted, and 
resuspended in growth medium; then 1 volume of cells was mixed with 1 volume of the collagen 
matrix gel. After 1 h at 37 °C, these matrices were overlaid with 100μl of conditioned PAEC 
serum-free medium (transfected with siRNA). The endothelin receptor antagonist, ambrisentan 
(10M) was supplemented in conditioned media. Media for all groups were changed every 12 
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hours, and pictures were taken after 2 days. Image J software (NIH) was used to analyze percentage 
contraction (well diameter – gel diameter)/well diameter. Experiments were performed with the 
help of Jingsi Zhao, M.S. 
 
Scratch assay  
Confluent PAECs were scratched using sterile pipet tips and brightfield images of scratch 
closures were taken at 0, 8, and 12 hours using an EVOS XL CORE imaging system (Life 
Technologies). Scratch areas were quantified using NIH ImageJ software 
(http://rsb.info.nih.gov/ij/) while blinded. 
 
In vitro tube formation assay  
Capillary tube formation was assessed using an in vitro angiogenesis assay kit (Cultrex). 
Briefly, Matrigel with reduced growth factors was plated into 96-well plate (50 µl Matrigel per 
well) and allowed to solidify for 30 minutes at 37 degrees C. Transfected PAECs (30,000 
cells/well) were resuspended in 100 µl of basal media and plated in the Matrigel-coated 96-well 
plate. After 6 hours, tubular structures were photographed using EVOS XL CORE imaging system 
(Life Technologies) with a 10× magnification. The number of branch points and total tube length 
were automatically quantified using NIH ImageJ software with Angiogenesis Analyzer plugin 
(http://rsb.info.nih.gov/ij/). 
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2.3 Primary Data 
2.3.1 FXN knockdown attenuated mitochondrial respiration and elevated reactive oxygen 
species 
To confirm FXN-mediated disruption of Fe-S integrity in pulmonary artery endothelial 
cells (PAECs), Fe-S clusters were first assessed using a fluorescent glutaredoxin 2 (GRX2) sensor, 
which homodimerizes and fluoresces in proportion to the level of intact Fe-S clusters (71, 72). 
Following transduction with GRX2 versus GCN4 (a homodimer sensor with Fe-S-independent 
fluorescence), siRNA knockdown of FXN (Supplemental Data Figure 4A) drove decreased 
GRX2-specific but not GCN4-specific fluorescence in normoxic (Figure 1A-B) and hypoxic 
conditions (Supplemental Data Figure 5A), reflecting a failure of low oxygen conditions to rescue 
Fe-S biogenesis in the presence of FXN knockdown.  
 
Figure 1. FXN knockdown attenuates Fe-S cluster integrity in pulmonary artery endothelial cells. (A and B) 
Representative images (scale bar indicates 400m) and quantification of Fe-S cluster formation by fluorescent cell 
percentage in PAECs transduced with glutaredoxin (GRX2) or GCN4 control constructs and transfected with FXN 
siRNA or negative control (n=3). 
 
Next, to directly assess mitochondrial respiration, extracellular acidification rate (ECAR), 
a surrogate for glycolysis, and oxygen consumption rate (OCR), a surrogate for oxidative 
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phosphorylation, were measured by Seahorse extracellular flux analysis in FXN-deficient PAECs.  
At baseline and following termination of oxidative phosphorylation by the ATP synthase inhibitor 
oligomycin (indicative of glycolytic capacity), FXN knockdown increased ECAR (Figure 2A-C) 
but did not alter OCR (Figure 2D-E, Supplemental Data Figure 4B). Unlike endothelial 
deficiencies of other Fe-S biogenesis genes such as BOLA3 (72), sustained OCR was not 
dependent upon fatty acid oxidation, as evidenced by a negligible change in baseline OCR with 
CPT1 inhibition by etomoxir (Supplemental Data Figure 4C). Instead, by reducing the available 
glucose, and thus flux through the mitochondria, we found that FXN deficiency decreased baseline 
and ATP-linked respiration (Figure 2F-H), consistent with the notion that oxidative 
phosphorylation is attenuated due to loss of Fe-S centers in the mitochondrial ETC. Measures of 
maximal respiratory capacity, proton leak, and non-mitochondrial O2 consumption were not 
significantly different between groups (Supplemental Data Figure 4D). Separately, expression 
analysis demonstrated FXN-dependent up-regulation of glycolytic genes, hexokinase 2 (HK2), 
pyruvate dehydrogenase kinase 1 (PDK1), and lactate dehydrogenase A (LDHA) (Supplemental 
Data Figure 4E); however, FXN knockdown did not alter GCSH expression (Supplemental Data 
Figure 4F), suggesting limited involvement in glycine homeostasis compared to BOLA3 (72). 
Corresponding with this metabolic rewiring, FXN deficiency in PAECs increased reactive oxygen 
species (ROS), as measured by intracellular hydrogen peroxide levels (Figure 2I) with hypoxic 
enhancing ROS production (Supplemental Data Figure 5B). Thus, knockdown of FXN promotes 
metabolic rewiring and an imbalance in ROS in PAECs. 
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Figure 2. FXN deficiency abrogates mitochondrial respiration and increases oxidative stress.  (A-H) Seahorse 
extracellular flux analysis measurements of PAECs transfected with FXN siRNA (red) or negative control (blue) 
(n=12) in response to media control (DMEM), the ATP synthase inhibitor oligomycin (1M), the uncoupler FCCP 
(0.5M), and the Complex I and Complex III inhibitors rotenone (2M), and antimycin (0.5M). Error bars reflect 
mean +/- SEM. (A) Extracellular acidification rate (ECAR; mpH/min/g protein) of PAECs cultured in high glucose 
(25mM). (B) Measurement of basal glycolysis (post DMEM). (C) Measurement of glycolytic capacity (post 
oligomycin). (D) Oxygen consumption rate (OCR; pmol/min/g protein) of PAECs in high glucose. Error bars reflect 
mean +/- SEM. (E) Measurement of basal respiration (post DMEM). (F) OCR of PAECs in low glucose (1g/L). (G) 
Measurement of basal respiration (post DMEM). (H) Measure of ATP-linked respiration (post oligomycin). (I) 
Amplex red colorimetric assay measuring intracellular hydrogen peroxide (H2O2) in PAECs transfected with FXN 
siRNA compared to control (n=6). Two-tailed Student’s t-test with error bars that reflect mean +/- SD unless otherwise 
specified. Experiments performed at least three separate times.  
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2.3.2 FXN-dependent metabolic reprogramming contributes to endothelial dysfunction 
consistent with PH 
Accompanying alterations in mitochondrial metabolism, we found that FXN deficiency 
promotes a number of endothelial-specific pathophenotypes also present in PH. Namely, in PAECs 
the vasoconstrictive mediator, endothelin-1 (EDN1/ET-1), was increased with FXN knockdown 
(Figure 3A-B), phenocopying chronic hypoxia. Moreover, the combination of hypoxia and FXN 
knockdown further elevated this pathologic response (Supplemental Figure 5C-D). Signifying the 
importance of oxidative stress in this response, EDN1 up-regulation was abrogated by a cell-
permeable mimetic of superoxide dismutase and peroxynitrite scavenger and antioxidant, 
MnTBAP (Figure 3C). When cultured in matrigel, primary PASMCs exposed to media from FXN-
deficient hypoxic PAECs exhibited increased contraction, which could be reversed with the EDN1 
receptor antagonist ambrisentan, consistent with FXN-dependent elevation of EDN1 
(Supplemental Data Figure 5E).  
At the same time, FXN knockdown reduced nitric oxide synthase 3 (NOS3) (Figure 3D-
E), the enzyme required for production of the vasodilator nitric oxide (NO); like ET-1 levels, 
NOS3 down-regulation was more pronounced during FXN knockdown in combination with 
chronic hypoxia (Supplemental Data Figure 5F-G). Importantly, quantification of total nitrite and 
nitrate levels, a surrogate measurement for NO, were diminished (Figure 3F), indicating a decrease 
of NO production by FXN-deficient PAECs and thus enhancing the vasoconstrictive phenotype. 
Furthermore, in hypoxia, NOS3 was increased with forced expression of FXN (Figure 3G), 
demonstrating that FXN is both necessary and sufficient for NOS3 expression.  
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Figure 3. FXN-deficient pulmonary endothelial cells exhibit an imbalance in vasomotor tone effectors and 
reduced angiogenesis.  
(A and B) Relative endothelin-1 (EDN1/ET-1) expression by RT-qPCR and ELISA in PAECs transfected with FXN 
siRNA or negative control and exposed to hypoxia or normoxia (n=3). (C) RT-qPCR of EDN1 in transfected PAECs 
treated with MnTBAP (50M) or vehicle (>24 hours) (n=3). (D and E) Relative nitric oxide synthase (NOS3) 
expression by RT-qPCR and immunoblot in PAECs with and without FXN knockdown and/or hypoxic exposure 
(n=3). (F) Total nitrate and nitrite levels (ng/ng) as measured by Griess reagent colorimetric assay in FXN-deficient 
PAECs compared to control (n=4).  (G) NOS3 fold change by RT-qPCR after overexpression of FXN using a lentiviral 
vector(s) in hypoxic PAECs (n=3). (H) Scratch assay measured at baseline and 12 hours in PAECs with or without 
FXN knockdown and hypoxic exposure (n=3). (I-K) Tube formation assay measuring number of branch points and 
relative tube length (arbitrary units) in PAECs transfected with FXN siRNA or negative control and exposed to 
hypoxia or normoxia (n=4-5). Two-tailed Student’s t-test with error bars that reflect mean +/- SD. Experiments were 
repeated three times. 
 
 
Finally, FXN knockdown in normoxic and hypoxic PAECs decreased migration assessed 
by scratch assay (Figure 3H, Supplemental Figure 5H) as well as decreased branch points (Figure 
3J, Supplemental Figure 5J) and total tube length (Figure 3K, Supplemental Figure 5K) in a tube 
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formation assay (Figure 3I, Supplemental Data Figure 5I). In sum, similar to our previous data in 
ISCU1/2- or BOLA3-deficient endothelial cells (22-24), FXN deficiency in PAECs disrupts Fe-S 
cluster biogenesis, ultimately leading to a dysfunctional endothelium characterized by 
mitochondrial dysfunction, an imbalance in vasomotor tone mediators, and diminished angiogenic 
potential. Moreover, the combination of FXN and hypoxia exacerbated these phenotypes. 
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2.4 Supplemental Data 
 
Figure 4. Effects of FXN deficiency on endothelial metabolism. 
(A) 48-hour transfection control for FXN transcript expression by RT-qPCR following siRNA knockdown in PAECs. 
(B) PAEC oxygen consumption rate (OCR; pmol/min/g protein) measurements of maximal respiratory capacity, 
reserve capacity, proton leak, and non-mitochondrial O2 consumption by Seahorse assay in high glucose media 
(25mM) (n=12). Error bars reflect +/- SEM. (C) Basal respiration following treatment with etomoxir (40M) in high 
glucose media (n=12). Error bars reflect +/- SEM. (D) PAEC OCR measurements of maximal respiratory capacity, 
proton leak, and non-mitochondrial O2 consumption by Seahorse assay in low glucose media (1g/L) (n=12). Error 
bars reflect +/- SEM. (E) RT-qPCR expression analysis of glycolytic markers: hexokinase 2 (HK2), pyruvate 
dehydrogenase kinase 1 (PDK1), and lactate dehydrogenase A (LDHA) (n=3). (F) GCSH mRNA levels in FXN-
deficient PAECs compared to negative control (n=3). Two-tailed Student’s t-tests were performed and error bars 
reflect +/- SD unless otherwise specified.  
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Figure 5. Chronic hypoxia worsens Fe-S-dependent endothelial dysfunction.  
(A-K) Experiments reflect PAECs transfected with FXN siRNA (si-FXN) or negative control (si-NC) and exposed to 
hypoxia (<1% O2, > 24 hours) unless otherwise specified. The dotted line provides comparison relative to normoxic 
controls. (A) Fe-S cluster formation measured by GRX2-specific fluorescence compared to GCN4 constitutive 
fluorescence (n=3). (B) Flow cytometry of hypoxic PAECs pulsed with DCFDA (1M) measuring intracellular H2O2 
(n=3).  (C and D) RT-qPCR and ELISA depict relative endothelin-1 (EDN1) expression (n=3). (E) Human PASMCs 
seeded in a collagen matrigel treated with conditioned media from FXN-deficient compared to control PAECs, 
exposed to hypoxic or normoxic conditions, and treated with ambrisentan (> 48 hours, 10M). Contraction measured 
as a percentage of PASMC well area compared to baseline area. (n=3). (F and G) RT-qPCR and immunoblot of 
relative nitric oxide synthase (NOS3) expression (n=3). (H) Rate of scratch closure (m/h) after measurements at 
baseline (n=3-4).  (I-K) Representative light microscopic imaging and quantification of PAEC tube formation 
measuring number of branch points and relative tube length (n=4). Two-tailed Student’s t-test or one-way ANOVA 
(Tukey’s post hoc analysis) with error bars that reflect mean +/- SD. Experiments repeated three times. 
A B C D
E F
H I J K
NOS3
b-actin
140 kDa
42 kDa
s
i-
N
C
s
i-
F
X
N
Hypoxia
Hypoxia
si-NC si-FXN
G
 39 
2.5 Discussion 
In summary, these data represent the first step in understanding the effects of FXN deficiency on 
pulmonary endothelial cells. Taking cues from FRDA (203, 204) as well as recent data linking Fe-S 
biogenesis gene deficiencies with PH (70-72), we have confirmed similar metabolic dysfunction (Figure 
2) and illustrated a pathological imbalance in vasomotor signaling and diminished capacity for angiogenesis 
(Figure 3). Both of these endothelial phenotypes are important in the pathophysiology of PH, suggesting a 
role for FXN in this disease. At the same time, while there has been little focus on the pulmonary 
endothelium or associated vascular diseases in FRDA (200), these findings support the potential for 
underlying, vascular dysfunction due to FXN mutations. 
Whether additional metabolic pathways (e.g., fatty acid synthesis versus oxidation (FAO), 
glutaminolysis, or the pentose phosphate pathway (PPP)) are dysregulated in FXN-deficient endothelial 
cells is not yet known. While these pathways do not include Fe-S-containing proteins, loss of appropriate 
Fe-S-dependent glucose oxidation alone can lead to compensatory alterations in bioenergetic production. 
For example, while the Warburg effect focuses on glycolysis, the PPP, which yields reductive NADPH and 
ribose-5-phosphate for nucleotide synthesis, is often augmented in parallel with glycolysis. PPP flux is 
upregulated in pulmonary vascular cells in multiple PH models (50, 60-62). Moreover, despite our focus 
on metabolic rewiring, it is also possible that endothelial deficiency of FXN may have additional effects on 
mitochondrial dynamics such as attenuated mitochondrial biogenesis. Distinct from but relevant to 
metabolic dysfunction, a disruption in mitochondrial biogenesis has been previously observed in non-
vascular FRDA tissues (248) as well as pulmonary vascular cells in PH  (53, 68).  
Oxidative stress is a well-accepted yet incompletely understood driver of tissue dysfunction in 
FRDA (208, 214-217) and PH (63), separately. While our data are consistent with enhanced mitochondrial 
ROS observed in genetic FXN deficiency, a more detailed understanding of species production and 
signaling is possible. Supported by the potential accumulation of mitochondrial iron (205, 206) observed 
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in FRDA, future studies may identify other pertinent ROS products, such hydroxyl radicals via the Fenton 
reaction. These data will help inform the ROS-mediated effects on endothelial cell dysfunction in FXN-
deficient conditions. While our data link mitochondrial ROS and EDN1 transcript expression (Figure 3C), 
connecting oxidative stress and vasomotor tone, further experimentation is required to uncover additional 
oxidative stress-driven pathophenotypes (e.g., mtDNA or nuclear DNA damage) relevant to PH. 
Furthermore, oxidative stress may not account for all of the Fe-S-dependent phenotypes presented 
here; the precise mechanisms that result in changes in vasomotor tone and angiogenesis remain 
incompletely defined. In the context of FXN-dependent down-regulation of NOS3 expression (Figure 3D-
E), a possible explanation could center on FXN-specific inhibition of ferrochelatase activity (182), the Fe-
S-dependent, rate-limiting enzyme in heme synthesis; thus FXN deficiency may impair heme production 
and ultimately reduce the expression and activity of NOS3, a heme-containing enzyme (249). resulting in 
diminished NO production. Separately, because nitric oxide can directly bind and damage Fe-S clusters, 
endothelial cell NOS3/NO may be inhibited by some unknown feedback mechanism in conditions of FXN 
deficiency and reduced Fe-S biogenesis (250). Regardless, Fe-S-mediated changes in effectors of 
vasomotor tone suggest current PAH-specific vasodilatory therapies that inhibit ET-1 and enhance NO 
signaling may be effective in circumstances of endothelial FXN deficiency.  
Lastly, in response to recent data that suggested hypoxic exposure may be a useful therapy for 
FRDA patients (245), we interrogated the interaction of pulmonary endothelial FXN deficiency and chronic 
hypoxia. In contrast, our work demonstrated showed a hypoxia-dependent reduction in Fe-S cluster 
formation that worsened with FXN knockdown (Supplemental Data Figure 5A), indicating that anaerobic 
conditions do not rescue pulmonary endothelial Fe-S cluster formation. PH-relevant phenotypes worsened 
with a ‘two-hit’ model of endothelial FXN knockdown and chronic hypoxia including oxidative stress 
(Supplemental Data Figure 5B), vasoconstriction (Supplemental Data Figure 5C-G), and angiogenesis 
(Supplemental Data Figures 5H-K). Thus, our data caution against the systemic use of hypoxia treatment 
in FRDA which would not account for differences in cell-specific responses to hypoxia and instead could 
accelerate a patient’s predisposition to PH. 
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These findings support FXN as a lynchpin connecting Fe-S-dependent oxidative respiration with 
endothelial metabolic reprogramming critical to PH development, reinforcing the importance of Fe-S 
biology in endothelial cell function (see working model below). Following these initial data, further 
experimentation is required to fully characterize the Fe-S-dependent endothelial phenotypes coordinated 
by FXN and to causatively link FXN deficiency to the development of disease in vivo. 
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3.0 FXN deficiency promotes pulmonary endothelial evolution from acute replication stress 
to cellular senescence  
            This work was adapted from a manuscript in revision: 
Culley MK, Zhao J, Tai YY, Tang Y, Perk D, Negi V, Yu Q, Handen A, Speyer G, Kim S, Lai Y-
C, Satoh T, Watson A, Al Aaraj Y, Sembrat J, Rojas M, Khan OF, Anderson DG, Dahlman JE, 
Norris KE, Gurkar A, Rabinovitch M, Gu M, Bertero T, Chan SY. Endothelial frataxin deficiency 
induces replication stress to promote senescence in pulmonary hypertension. In revision. 
 
Notably, long RNA sequencing performed by the UPMC Children’s Hospital Health Sciences 
Research Core and GO enrichment analysis performed by Adam Handen with technical support 
by Drs. Gil Speyer and Seungchan Kim (Figure 6). Senescence-associated -galactosidase staining 
quantified by Dror Perk (Figure 8D). Lentiviral vectors prepared by Ying Tang (Figure 12). Mouse 
hemodynamic assessments performed by Jingsi Zhao and Yi Yin Tai (Figure 9B, H-I, and L, 
Figure 13B-C and G-H). 7C1 nanoparticles prepared by Drs. Omar Khan, Dan Anderson, and 
James Dahlman (Figure 10A). Pharmacologic mouse data produced with the help of Yu Lu and 
Sophia Annis (BWH) (Figure 10, Figure 13J-M). Echocardiography performed and analyzed by 
Dr. Taijyu Satoh and Brenda McMahon (Figure 13D-F). 
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3.1 Introduction 
Definitive endothelial phenotypes and their consequences for pulmonary vascular 
remodeling remain elusive in PAH and other WSPH groups. While many postulate the 
endothelium as the site of inciting injury and apoptosis followed by hyperproliferation (251), 
endothelial cells likely exhibit dynamic, spatio-temporal phenotypes that are incompletely defined. 
DNA damage represents a disease modifier recently linked to PAH (81) with several potential cell 
outcomes, namely apoptosis or senescence (86, 87). The latter describes a cellular phenotype of 
apoptosis resistance and irreversible growth arrest assessed by distinct set of markers including 
p16INK4 and -galactosidase and a potentially pathogenic senescence-associated secretory 
phenotype (SASP) (29). Although senescence represents an emerging phenotype in PAH (34) and 
other WSPH groups (252, 253), the role of senescence in the pulmonary endothelium has not been 
defined. Instead, studies have demonstrated DNA damage-induced apoptosis resulting from 
reduced expression of specific DNA damage response (DDR) markers in the pulmonary 
endothelium (92, 93). The complex regulatory events that control endothelial apoptosis versus 
senescence and how such events fit into the evolution of endothelial cell function in PH are not 
known. Any mechanistic insight into the coordination of endogenous mediators of DNA damage, 
such as oxidative stress or replication stress (defined as compromised fork progression) (84), have 
also not been characterized.  
Fe-S clusters are required for metabolic (153) and genomic integrity (155). Specifically, 
evidence suggests FXN deficiency disrupts genomic integrity via oxidative damage (214-217).  
Given that mitochondrial Fe-S biogenesis influences cytoplasmic Fe-S assembly (CIA) and non-
mitochondrial Fe-S protein maturation (154, 155), FXN deficiency may drive oxidative stress as 
well as insufficiency of nuclear Fe-S-containing proteins, compromising genomic replication and 
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repair and contributing to DNA damage. Therefore, these studies aim to causatively link FXN-
dependent Fe-S deficiency and DNA damage and characterize the resultant endothelial phenotypes 
that may predispose to PH development, expanding upon the importance of Fe-S biology in 
pulmonary vascular disease.  
3.2 Materials & Methods 
            Shared methods were referenced in a previous Materials & Methods section (2.2) while 
new materials and procedures have been described below. 
Plasmids construction and lentivirus production  
The coding sequence of FXN transcript 1 (mitochondrial isoform; Dharmacon, clone ID 
4829356) and ISCU1 (cytosolic isoform; clone ID: 23479) and 2 (mitochondrial isoform; clone 
ID 66383) were purchased and sub-cloned in the pCDH-CMV-MCS-EF1-copGFP (System 
Biosciences #CD511B-1) using EcoRI and NotI restriction sites, respectively. All cloned plasmids 
were confirmed by DNA sequencing. HEK293T cells (American Type Culture Collection) were 
grown in DMEM containing 10% FBS and transfected using Lipofectamine 2000 (Life 
Technologies) with lentiviral plasmids along with a packaging plasmid system (pPACK, System 
Biosciences), according to the manufacturer’s instructions. Viral particles were harvested 48 hours 
after transfection, concentrated, and sterile filtered (0.45 µm). Transduction was performed in 
cultured PAECs (70-80% confluence) by incubating lentiviral vectors compared to a parent vector 
expressing GFP and polybrene (8 µg/ml) in serum-free cell-specific media for 24 hours. 
Experiments were performed 72 hours after infection. Transduction efficiency was assessed in 
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each experiment by observing the GFP expression under a fluorescence microscope and assessing 
expression of lentiviral targets by RT-qPCR. Lentiviral vectors were prepared by Ying Tang, M.S. 
 
RNA sequencing and gene set enrichment analysis  
Following total RNA extraction from transfected PAECs and Broad Range RNA Qubit 
quality control, long RNA sequencing (Paired-end read 75 cycles, 40-50M reads/sample) was run 
by the Health Sciences Sequencing Core (UPMC Children’s Hospital of Pittsburgh). Transcript 
quantification was performed using Salmon and differential expression using DESEQ (254, 255). 
Pathway enrichment of direct Gene Ontology biological processes was performed using DAVID 
version 6.8 (256-259) on genes with an absolute log fold change > and FDR corrected p-value < 
0.05. Quality control and long RNA sequencing was performed with the help of William Horne 
and the Health Sciences Sequencing Core. Analysis was performed by Adam Handen, M.S. with 
the help of Gil Speyer, and Seungchan Kim, Ph.D. 
 
Cell cycle analysis 
Cell cycle phase was determined using the BD Pharmingen BrdU Flow Kit. To summarize, 
transfected PAECs were serum-starved overnight and then pulsed with BrdU (10M) in serum 
replete endothelial cell media for 4 hours at 37 degrees C. Cells were washed with PBS three times, 
trypsinized, and fixed for 30 minutes on ice. Following fixation, samples were washed, spun down, 
and the supernatant discarded before permeabilization for 10 minutes on ice. Following another 
wash step, PAECs were re-fixed for 5 minutes on ice before incubation with Dnase (300g/ml) 
for 1 hour at 37 degrees C. After an additional wash step, cells were incubated with anti-BrdU 
antibody (1:50) for 20 minutes at room temperature, washed again, and ultimately stained with 7-
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amino-actinomycin D (7-AAD). Stained cells were gated based upon BrdU (FITC) and 7-AAD 
(PE-Texas Red-A, linear) following flow cytometry analysis (BD LSRFortessa and FlowJo). 
 
Replication assays  
Endothelial cells were plated in a 96-well plate (5000 cells/well) with overnight serum-
starvation to sync cell cycle prior to BrdU pulse in full serum for 2 hours. BrdU Cell Proliferation 
Assay Kit (Cell Signaling Technology) was performed and colorimetric change (absorbance 
450nm) was assessed by spectrophotometer (Biotek). Separately, transfected PAECs were also 
manually counted using a haemocytometer. 
 
DNA fiber staining  
DNA preparation, staining, and imaging was performed per the described protocol (260). 
Briefly, transfected PAECs were serum-starved overnight and then exposed to CldU (50M) 
followed by IdU (250M) with hydroxyurea (HU, 2mM) for 10 minutes each in serum-replete 
media; plated cells were washed with PBS three times after each pulse. On a glass slide, PAECs 
resuspended in PBS (1200 cells/l) were lysed with 0.5% SDS, 200mM Tris HCl, 50mM EDTA, 
pH 7.4 for 5 minutes at room temperature before allowing the mixed solution to spread across the 
slide surface by tilting the slide to a 15 degree angle. After drying, DNA was fixed with 3:1 
Methanol: Acetic acid for 5 minutes and denatured with 2.5M HCl for 30 minutes at room 
temperature. After washing, samples were blocked with 0.1% Triton X-100 and 10% goat serum 
in PBS for 1 hour at 37 degrees C and incubated with primary antibodies (rat anti-BrdU, mouse 
anti-BrdU) overnight at 4 degrees C. After washing, slides were incubated for 1 hour at 37 degrees 
C with secondary antibodies (488-conjugated anti-rat, Cy3-conjugated anti-mouse) and mounted 
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using gelvatol. Imaging was performed using a Nikon A1 confocal microscope and 60x oil 
immersion lens with 1.75x zoom. Quantification was blinded and performed on >100 
fibers/samples using NIH ImageJ software (http://rsb.info.nih.gov/ij/).  
 
Apoptosis assays 
The Caspase-Glo 3/7 Assay (Promega) substrate was applied in equal volume to 
endothelial cells (5000 cells/well) in serum-depleted media and chemiluminescence was measured 
by spectrophotometer (Biotek).  Results were normalized to protein concentration determined 
using the Pierce BCA protein assay kit. 
 
Senescence-associated -galactosidase staining  
Endothelial cells at <80% confluency were washed with PBS twice and then PFA-fixed for 
10 minutes at room temperature before staining with the Senescence -galactosidase Staining Kit 
(Cell Signaling Technology) overnight at 37 degrees C in a dry incubator. After 12-18 hours 
incubation, images were taken using EVOS XL CORE imaging system (Life Technologies) with 
a 10x magnification. Blinded image analysis of the percentage of SA--gal positive cells per total 
cell number was performed by Dror Perk using NIH ImageJ software (http://rsb.info.nih.gov/ij/).  
 
Immunofluorescent staining and confocal microscopy  
Cryostat sections (5-7m) from OCT-embedded lung tissues were mounted on gelatin-
coated histological slides (Fisherbrand). Following rehydration with PBS for 5 minutes, sections 
were fixed (2% PFA, 30 minutes, room temperature), permeabilized (0.1% Triton X-100, 15 
minutes, room temperature), and blocked (5% donkey serum and 2% BSA in PBS, 1 hour, room 
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temperature). Primary antibodies were diluted in 2% BSA and incubated at 4 degrees C overnight. 
A complete antibody summary is included in Appendix A Table 2. Alexa 488, 568 or 647-
conjugated secondary antibodies (ThermoFisher Scientific) were applied at a 1:1000 dilution in 
2% BSA for 1 hour at room temperature. Following counterstaining with Hoechst for 1 minute at 
room temperature, slides were mounted with gelvatol. Images were taken using a Nikon A1 
confocal microscope and 40x oil immersion lens. Small pulmonary vessels (30-100m diameter) 
present in a given tissue section (>10 vessels/section) that were not associated with bronchial 
airways were selected for analysis. Intensity (integrated density) of staining was quantified using 
ImageJ software (NIH). Degree of pulmonary arteriolar muscularization was assessed in OCT lung 
sections stained for SMA by calculation of the proportion of fully and partially muscularized 
peripheral pulmonary arterioles to total number. Analyses were performed blinded to condition. 
 
Animal studies 
All animal experiments were approved by the University of Pittsburgh (DLAR) and the 
Harvard Center for Comparative Medicine. Animal husbandry was managed with the help of Jingsi 
Zhao, M.S., Ying Tang, M.S., and Dror Perk.  
 
Genetic models: Animal studies to assess the effects of cell-specific FXN deficiency included male 
EC Fxn-/- mice expressing Cdh5(PAC)-ERT2+-Cre (261) or male SMC Fxn-/- mice expressing 
Myh11-ERT2+-Cre recombinase (Jackson Laboratories, Catalog 019079) (262)  compared to Fxn 
flox/flox controls (212). These conditional knockout mice received intraperitoneal injections of 
tamoxifen for 5 consecutive days at 10 weeks of age, exposed to hypoxia at 12 weeks of age, and 
subjected to hemodynamic analysis and tissue harvest at 15 weeks of age. For chronic hypoxia 
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exposure, 12 week-old mice were subjected to 3 weeks of normobaric hypoxia in a temperature-
humidity controlled chamber (10% O2, OxyCycler chamber, Biospherix Ltd.) compared with 
normoxia (21% O2). The lyophilized senolytic ABT-263 (Selleckchem) was suspended in DMSO 
(0.25mg/ml) and diluted in corn oil for oral gavage.  Mice were weighed at the beginning of week 
2 and 3 of hypoxia and received 25mg/kg ABT-263 daily versus 2% DMSO in corn oil as a vehicle 
control. Additional experiments assessing the efficacy of a senolytic were performed with the same 
dosing and timeline in male C57BL/6 wild type mice or female IL-6 transgenic mice (19) 
(Taconic). 
 
Pharmacologic model: The polymeric nanoparticle 7C1, composed of low molecular weight 
polyamines and lipids, was utilized for endothelial-specific delivery of FXN siRNA 
oligonucleotides in male C57Bl6 mice (71, 72, 263). Male mice received tail-vein intravenous 
doses 7C1 nanoparticles containing FXN siRNA (si-FXN:7C1) (Stealth siRNA, Life 
Technologies, 1mg/kg) or scramble control siRNA (si-NC:7C1) (Stealth siRNA, Life 
Technologies, 1mg/kg) in 5-day intervals before and during (day minus 5, day 0, day 5, day 10) 
the 2 weeks of hypoxic exposure (10% O2).  
 
Hemodynamic assessment: In 15 week-old mice, echocardiography was performed using a 15-
45MHz transthoracic transducer and a VisualSonics Vevo770 system (Fujifilm). Inhaled 
isoflurane anesthesia was used at 2% in 100% O2 during positioning and hair removal and then 
decreased to isoflurane 0.8% during imaging. Digital echocardiograms were analyzed by Taijyu 
Satoh in a blinded manner (264). Non-invasive tail plethysmography of systemic blood 
pressure was performed using the CODA system (Kent Scientific). Mice were either given 
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Ketamine/xylazine (9:1 ratio, Henry Schein) or subjected to isoflurane (Henry Schein) prior to the 
catheterization procedure. Isoflurane vaporizer was maintained at 1.5-2% with oxygen gas flow 
rate at 1L/min. To assess right ventricular systolic pressure, a surrogate for mPAP, Close-chest 
right ventricular systolic pressure was measured using Millar catheters (SPR-671, SPR-513). 
Catheters are inserted into jugular vein and guided through the right atrium into the right ventricle. 
Steady RVSP waveforms were measured for 2 minutes. Blood pressure measurements and 
catheterization were performed and analyzed in a blinded fashion by Yi Yin Tai, M.S. and Jingsi 
Zhao M.S. 
 
Tissue processing: After hemodynamic measurements, terminal cardiac puncture blood collection 
is performed using an EDTA-coated syringe. Plasma is extracted following centrifugation at 
3500rpm for 10 minutes at 4 degrees C. Whole-heart as well as separate right (RV) and left 
ventricle (LV) weights are recorded to assess cardiac hypertrophy. A portion of the lung, RV, LV, 
liver, kidney, and spleen are flash-frozen in liquid nitrogen while addition sections of lung are 
OCT-embedded or saved for CD31+ MACS separation. To isolate endothelial cells, mouse lungs 
were cut into small pieces and dissociated in HBSS containing collagenase IV (2.5mg/ml, 
Worthington Biochemical) and DNase (10ng/ml, Sigma) using a stir bar (1000rpm) at 37 degrees 
C for 40 minutes. Following filtration (45m) and removal of red blood cells using ACK lysis 
buffer (Thermofisher Scientific), the cell pellet is resuspended in 80l MACS separation buffer 
(0.5% bovine serum albumin and 2mM EDTA in PBS) and 20l CD31 Mouse microbeads 
(Miltenyi) and incubated for 15 minutes on ice. After washing the MACS LS column mounted on 
a magnetic plate (Miltenyi) with separation buffer, 500l of separation buffer is added to 
dissociated lung cells and the entire suspension is filtered through a washed; filtrate is discarded. 
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Placing the tip of the column in an Eppendorf tube, the plunger is used to collect CD31+ beads left 
on the column. From there, the cell pellet is prepared for RNA extraction and RT-qPCR analysis. 
3.3 Primary Data 
3.3.1 Acute replication stress and cell cycle arrest in FXN-deficient endothelial cells  
To determine the predominate effects of FXN deficiency endothelial metabolic 
reprogramming, an unbiased high-throughput screening by RNA sequencing was performed in 
PAECs after transfection with FXN siRNA or control. Analysis of differentially expressed genes 
(498 total genes) was followed by Gene Ontology (GO) enrichment by DAVID. Of the top 30 
most significant direct GO biological processes (FDR < 0.05, 66 total), a majority were associated 
with cell cycle (blue), DNA replication (green), and cellular response to DNA damage stimulus 
(orange) (Figure 6A and Appendix Table 3). No pathways pertained to mitochondrial metabolism. 
Using these GO terms as a guide, a hypergraph, which characterizes differentially expressed genes 
(nodes) by log fold change and the potential relationships between those nodes via edges (256, 
257), highlighted pertinent genes within each selected GO pathway that were significantly 
upregulated by FXN knockdown (Figure 6B). These data propose FXN deficiency coordinates 
significant nuclear dysfunction with implications for cell cycle progression. Whether these 
transcriptional changes are reflective of the metabolic consequences of deficient mitochondrial Fe-
S integrity or support a more direct insufficiency of nuclear Fe-S-containing proteins is yet-to-be 
defined.  
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Figure 6. RNA sequencing of FXN-deficient pulmonary artery endothelial cells. 
(A) Long RNA sequencing in PAECs transfected with FXN siRNA versus negative control following by Gene 
Ontology (GO) enrichment (n=3). Histogram of top 30 most significant direct GO terms (FDR < 0.05) representing 
the percentage of differentially expressed genes in the RNAseq data set within each pathway. GO terms related to cell 
cycle (blue), DNA replication (green), and cellular response to DNA damage stimulus (orange). (B) Hypergraph 
differentially expressed genes (FDR < 0.05) depicting log-fold change via a color scale within GO pathways pertaining 
to cell cycle (blue), DNA replication (green), and cellular response to DNA damage stimulus (orange). 
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To first assess the functional consequences of these gene changes, replication was 
measured by bromodeoxyuridine (BrdU) incorporation in PAECs. Despite the increase in 
nucleotide incorporation with FXN inhibition (Figure 7A), there was no increase in cell number 
(Figure 7B). Instead, BrdU pulse labeling combined with the fluorescent DNA intercalator 7-AAD 
revealed an increase of FXN-deficient PAECs in S phase with a corresponding decrease in G0/G1 
or G2 (Figure 7C), signifying cell cycle arrest. These data were supported by an increase in 
replication fork markers (MCM2, RPA70) and the cyclin-dependent kinase inhibitor p21Cip1 
associated with DNA damage-dependent cell cycle arrest (Supplemental Data Figure 11A).  
To characterize this S-phase arrest, we assessed the replication stress marker 
phosphorylated RPA32 (84), observing elevated protein levels in FXN-deficient PAECs (Figure 
7D). To specifically assess replication fork dynamics, chloro-deoxyuridine (CldU) and iodo-
deoxyuridine (IdU) pulse labeling and DNA fiber staining of PAECs with FXN inhibition 
demonstrated a modest increase in CldU nucleotide incorporation; this FXN-dependent effect was 
robustly increased with hydroxyurea, a ribonucleotide reductase inhibitor that depletes nucleotide 
pools to induce fork stalling (Figure 7E). This aberrant increase in replication rate correlated with 
the up-regulation of the transcript of the M2 subunit of ribonucleotide reductase (RRM2), which 
was significantly up-regulated with FXN knockdown in the RNA sequencing data set (Figure 6B 
and Table 3) and confirmed by RT-qPCR (Supplemental Data Figure XB), potentially signaling 
elevated nucleotide synthesis by ribonucleotide reductase (265). In response to this replication 
stress, DDR markers (e.g. phosphorylated ATR, CHK1, and ubiquitinated H2AX) assessed by 
immunoblot (Figure 7F) as well as 53BP1 foci by immunofluorescent staining and confocal 
microscopy (Figure 7G), were all up-regulated. To determine whether mitochondrial ROS 
accounts for this nuclear phenotype, these same markers were evaluated in PAECs with or with 
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FXN knockdown and in the presence of the antioxidant MnTBAP compared to control 
(Supplemental Data Figure 11C). MnTBAP treatment did not prevent replication stress or DNA 
damage-associated cell cycle arrest (Supplemental Data Figure 11D), suggesting DNA damage 
and replication stress are not dependent upon oxidative damage.  
To determine whether FXN is both necessary and sufficient, phenotypic reversal in PAECs 
exposed to known triggers of PH, such as chronic hypoxia (243) or inflammation (266), was 
evaluated. First, lentiviral transduction of FXN in combination with its binding partner ISCU1/2 
(Supplemental Data Figure 12A-B) reduced BrdU incorporation (Supplemental Data Figure 12C-
D) Forced expression of FXN or ISCU1/2 alone slightly reduced certain replication stress (p-
RPA32, H2AX) and cell cycle arrest markers; additionally, overexpression of FXN in 
combination with ISCU1/2 most effectively reduced protein levels of all of these targets under 
conditions of chronic hypoxia (Supplemental Data Figure 12E), consistent with reversibility of 
replication above. The same reduction in BrdU incorporation (Supplemental Data Figure 12F-G) 
as well as in replication stress response and cell cycle arrest markers (Supplemental Data Figure 
12H) was achieved by the combined overexpression of FXN and ISCU1/2 following IL-1 
treatment. Taken together, these data reveal that acute replication stress and cell cycle arrest in 
endothelial cells are reversible processes. In summary, these data support a oxidative stress-
independent, reversible mechanism by which acute FXN deficiency drives replication stress, 
resulting in genomic damage, early activation of the DDR, and endothelial cell cycle arrest. 
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Figure 7. Acute FXN knockdown promotes replication stress and S-phase arrest.  
(A-G) All experiments were performed 48 hours after transfection in PAECs with or without FXN inhibition by 
siRNA. (A) Colorimetric BrdU incorporation (n=6). (B) Manual cell count (n=3). (C) Flow cytometric analysis of 
FXN-deficient or control PAECs pulsed with BrdU and the DNA marker 7-AAD (n=6). (D) Immunoblot and 
quantification of the replication stress marker, phosphorylated RPA (p-RPA32) (n=3/group). (E) Representative 
confocal imaging and quantification of replication rate (kb/min) in FXN-deficient or control PAECs pulsed with CldU 
(20 minutes, 50M; green) followed by IdU (20 minutes, 250M; red) with hydroxyurea (2mM; HU). Scale bars 
represent 10m. (F) Immunoblot and quantification of DNA damage response markers (p-ATR, CHK1, Ub-H2AX). 
(G) Immunofluorescent staining and confocal microscopy of nuclear 53BP1 foci (red) in PAECs DAPI-stained nuclei 
(blue). Two-tailed Student’s t-test with error bars that reflect mean +/- SD. Experiments were performed at least three 
separate times.  
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an extended time course (Supplemental Data Figure 11E-F). Interestingly, the initial burst of BrdU 
incorporation in FXN-deficient PAECs was blunted between 3 and 8 days after transfection 
(Figure 8A). At the same time, chronic FXN knockdown resulted in increasing apoptosis resistance 
in PAECs (starting at 3 days post-transfection) (Figure 8B). In contrast to other studies in which 
DNA damage resulted in pulmonary endothelial apoptosis (92, 93), sustained FXN knockdown 
led to up-regulation of markers of senescence: p16INK4  protein (Figure 8C) and senescence-
associated--galactosidase (SA--gal) staining (Figure 8D).  
To characterize a mechanism for the convergence of FXN deficiency on irreversible 
senescence, replication stress and DNA damage response pathways were reassessed. While 
replication and cell cycle protein (Supplemental Data Figure 11G) as well as RRM2 transcript 
(Supplemental Data Figure 11H) peaked and were eventually reduced at day 8 post-transfection, 
FXN-deficient PAECs exhibited chronic and more comprehensive DDR signaling including p-
ATR, p-CHK1, p-CHK2, and p53 alongside H2AX (Figure 8E). In sum, epigenetic FXN 
deficiency promotes an Fe-S dependent evolution in nuclear function starting with replication 
stress and reversible growth arrest and progressing to irreversible DDR-dependent senescence.  
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Figure 8. Endothelial evolution toward cellular senescence due to chronic FXN deficiency. 
(A) Colorimetric BrdU incorporation in FXN-deficient PAECs compared to negative control at 3, 5, and 8 days after 
transfection (n=6). (B) Chemiluminescent measurement of caspase-3/7 activity in FXN-deficient PAECs compared to 
controls at 2, 3, and 4 days post-transfection (n=6). (C-E) Experiments reflect PAECs 8 days after transfection with 
FXN siRNA or negative control (C) Immunoblot of p16INKA protein expression (n=3). (D) Light microscopic images 
of senescence-associated (SA)--galactosidase staining (blue). Scale bar indicates 200m. Quantification reflects 
average percentage of SA--gal stained PAECs out of total cell number (n=3). (E) Quantification of DNA damage 
response markers (p-ATR, p-CHK1, p-CHK2, p53, Ub-H2AX) by immunoblot (n=3). Two-tailed Student’s t-test 
with error bars that reflect mean +/- SD. Experiments were performed at least three separate times. 
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pulmonary endothelial cells from the lungs of EC Fxn-/- mice exhibited appropriate knockout 
(Supplemental Figure 13A) and decreased Fxn transcript (Figure 9B). Consistent with our findings 
of FXN-driven genotoxicity (Figures 7F and 8E), confocal imaging revealed that EC Fxn-/- mice 
displayed increased H2AX in the pulmonary endothelium (Figure 9C-D), in line with chronic up-
regulation of the DDR. At the same time, RT-qPCR analysis of CD31+ endothelial cells isolated 
from FXN-deficient mice showed an increase in p16INK4 (Figure 9E). Expression analysis of the 
pathogenic senescence-associated secretory phenotype (SASP) markers Tnf by RT-qPCR (Figure 
9F) and IL-6 by ELISA in plasma (Figure 9G) reflected the underlying endothelial irreversible 
growth arrest in EC Fxn-/- mice. Correspondingly, right heart catheterization revealed 
hemodynamic manifestations of worsened PH in hypoxic mice, including increased right 
ventricular systolic pressure (RVSP; a surrogate for the clinical measurement of mean pulmonary 
arterial pressure (mPAP)) (Figure 9H) and increased Fulton index (a measurement of RV 
hypertrophy that indirectly reflects increased pulmonary vascular resistance) (Figure 9I) but not in 
normoxic EC Fxn-/- mice (Supplemental Data Figure 13B-C). To rule out any off-target effects 
relevant to the left ventricle or systemic hypertension, echocardiographic imaging prior to 
hemodynamic measurements demonstrated no alterations in left ventricular function 
(Supplemental Data Figure 13D-F). Additionally, alterations in mean arterial pressure 
(Supplemental Data Figure 13G) and heart rate (Supplemental Figure 13H) were not observed. To 
explore the contribution of FXN-dependent endothelial senescence to PH development in vivo, 
hypoxic EC Fxn-/- mice were treated with the senolytic ABT-263, a BCL2 inhibitor that 
successfully kills senescent cells (267), or vehicle control (Figure 9J). ABT-263 treatment 
prevented pulmonary vascular muscularization (Figure 9K) and reduced RVSP (Figure 9L), 
confirming endothelial senescence as a driver in FXN-dependent PH.  
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Figure 9. Genetic FXN deficiency promotes endothelial senescence and worsens PH. 
(A) Diagram of conditional endothelial-specific Fxn knockout mouse model. Experiments compare male Fxn flox/flox 
(Fxn f/f) control mice to mice expressing a tamoxifen-dependent Cdh5(PAC)-ERT2+-Cre recombinase (EC Fxn-/-) 
following chronic hypoxia exposure (3 weeks, 10% O2). (B) RT-qPCR of Fxn expression in CD31+ cells isolated 
from lungs (n=6-7). (C and D) Confocal microscopic imaging (50m scale bar) and quantification of endothelial 
H2AX (red signal represented by white arrows), SMA (green), and DAPI (blue) in lung tissue (n=3). (E and F) 
Relative p16INK4 and Tnf mRNA by RT-qPCR in CD31+ cells isolated from mouse lungs (n=6-7). (G) Plasma IL-6 
protein expression measured via ELISA (n=9 v. n=7). (H)  Right ventricular systolic pressure (RVSP, mmHg) 
measured by right heart catheterization (n=11 v. n=7). (I) Fulton index (RV/LV+S, %) (n=11 v. n = 7). (J) Diagram 
for senolytic treatment in female and male hypoxic EC Fxn-/- mice. Mice were given ABT-263 (25mg/kg) or vehicle 
control via daily oral gavage in weeks 2 and 3 of hypoxic exposure. (K) Representative confocal microscopic images 
and quantification of pulmonary vessel muscularization by immunofluorescent staining of vWF (green) and SMA 
(red) (n=5). Scale bar represents 50m. (L) RVSP following senolytic treatment (n=5). Two-tailed Student’s t-test 
was performed, with error bars that reflect mean +/- SD. 
 
Next, the effect of endothelial FXN deficiency was also assessed in a pharmacologic 
model. Polymeric nanoparticle 7C1, composed of low molecular weight polyamines and lipids 
encapsulating FXN siRNA oligonucleotides or negative control, were delivered to the endothelium 
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via tail-vein injection every five days in wildtype C57BL/6 mice briefly before and throughout 
chronic hypoxia exposure (Figure 10A) (71, 72, 263). In mice receiving siRNA against FXN, FXN 
was down-regulated in CD31+ cells isolated from normoxic (Supplemental Data Figure 13I) and 
hypoxic lungs (Figure 10B) as assessed by RT-qPCR. This knockdown of endothelial FXN 
increased pulmonary vascular muscularization, as measured by immunofluorescent staining of 
SMA (Figure 10C). Moreover, pharmacologic FXN silencing increased Fulton index and RVSP 
in normoxic (Supplemental Data Figure 13J-K) and hypoxic conditions (Figure 10D-E). Notably, 
these FXN-deficient mice also did not exhibit altered mean arterial pressure (Supplemental Figure 
13L) and pulse (Supplemental Figure 13M). Importantly, both genetic and pharmacologic models 
of Fxn deficiency highlight worsened PH in conditions with FXN knockdown and chronic hypoxic 
exposure. In sum, these data provide a unifying, endothelial-specific mechanism that connects 
FXN deficiency, DDR-dependent senescence, and PH development in vivo. 
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Figure 10. Mice with pharmacologic FXN knockdown develop PH. 
(A) Experimental mouse model for pharmacologic Fxn knockdown. Endothelial delivery in male C57Bl6 using serial 
tail-vein injections of 7C1 nanoparticle containing Fxn (si-FXN:7C1) or negative control siRNA (si-NC:7C1) in 
hypoxic conditions (2 weeks, 10% O2). (B) RT-qPCR of Fxn mRNA expression in CD31+ cells isolated from lungs 
(n=4). (C) Vessel remodeling measured by immunofluorescent staining and confocal microscopic imaging of SMA 
(red) and DAPI (blue) in hypoxic mouse lungs (n=6). Scale bars represent 50m. (D) Right heart catheterization 
measuring right ventricular systolic pressure (RVSP, mmHg) (n=7 v. n=10). (E) RV hypertrophy measured by Fulton 
index (RV/LV+S, %) (n=7 v. n= 10). Two-tailed Student’s t-test was performed, with error bars that reflect mean +/- 
SD. 
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3.4 Supplemental Data 
 
Figure 11. FXN deficient-endothelial cells shift from acute cell cycle arrest to DNA damage response-
dependent senescence. 
(A) Immunoblot of replication fork (MCM2, RPA70) and cell cycle (p21) markers measured in PAECs 2 days after 
transfection with FXN siRNA or negative control (NC). (B) RRM2 transcript levels in PAECs 2 days after transfection 
(n=6). (C) Amplex red hydrogen peroxide (H2O2) assay in PAECs treated with FXN siRNA compared to negative 
control (si-NC) and MnTBAP (50M) compared to vehicle control (n=3). (D) Immunoblot of replication stress, DNA 
damage response, and growth arrest markers in FXN-deficient PAECs in response MnTBAP (n=3). (E and F) After 
transfection with FXN siRNA versus negative control, RT-qPCR (n=3) and representative immunoblot of FXN 
transcript and protein levels in PAECs over a time course (Days 3, 5, and 8). (G) Immunoblot of replication fork 
(MCM2, RPA70) and cell cycle (p21) markers measured in transfected PAECs over a time course (day 3, 5, 8) (n=3). 
(H) RRM2 mRNA expression at 3, 5, and 8 days post-transfection (n=3). (I) Quantification of SA--galactosidase 
staining in PAECs with FXN siRNA or negative control 8 days after transfection and treated with ABT-263 (>24 
hours, 0.25M) or vehicle (n=3). 
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Figure 12. Forced expression of FXN and ISCU1/2 reversed acute replication stress and cell cycle arrest. 
(A and B) Transduction efficiency of forced overexpression with FXN, ISCU1, ISCU2, and combined lentiviruses compared to 
GFP control (n=3). (C and D) Colorimetric BrdU incorporation following lentiviral transduction of FXN and/or ISCU1 and 2 in 
hypoxic PAECs (n=6). (E) Representative immunoblot of cell cycle (p21) and replication stress (p-RPA32, H2AX) markers in 
hypoxic PAECs with forced overexpression of FXN alone and in combination with ISCU1/2. (F and G) Colorimetric BrdU 
incorporation in IL-1-treated PAECs with forced expression of FXN, ISCU1 and 2, or a combination (n=6). (H) Representative 
immunoblot of DNA damage response and growth arrest in PAECs treated with IL-1. One-way ANOVA with Tukey’s post hoc 
analysis. 
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Figure 13. The effects of genetic and pharmacologic FXN deficiency. 
(A-H) Experiments compare conditional EC Fxn-/- mice compared to Fxn f/f controls in normoxic or hypoxic 
conditions.  (A) DNA gel of CD31+ and CD31- cells isolated from lungs of normoxic mice. (B) Fulton index 
(RV/LV+S, %) in normoxic mice (n=8 v. n=4). (C) Right ventricular systolic pressure (RVSP, mmHg) (n=8 v. n=4) 
in normoxic mice. (D-F) Echocardiography of hypoxic mice measuring ejection fraction (%), fractional shortening 
(%), and interventricular septal end diastole (IVSd) width (mm) (n=4 v. n=5). (G) Tail cuff measurement of mean 
arterial pressure (mmHg) in hypoxic mice (n=11 v. n=5). (H) Heart rate (beats/minute) (n=11 v. n=5). (I) In C57Bl6 
mice treated with 7C1 nanoparticles containing Fxn (si-FXN:7C1) or negative control siRNA (si-NC:7C1) in 
normoxic conditions, RT-qPCR of Fxn mRNA expression in CD31+ cells isolated from lungs (n=4). (J) Fulton index 
(%) in normoxic mice (n=7 v. n= 10). (K) RVSP (mmHg) in normoxic mice (n=7 v. n=10). (L) Tail cuff measuring 
mean arterial pressure in normoxic or hypoxic mice treated with negative control (n=4) or FXN siRNA (n=6). (M) 
Heart rate (beats/minute) (n=4 v. n=6). Two-tailed Student’s t-test with error bars that reflect mean +/- SD. 
3.5 Discussion 
In summary, we have demonstrated that FXN knockdown attenuated Fe-S cluster integrity 
(Figure 1), subsequently promoting nuclear replication stress and acute cell cycle arrest (Figure 
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7); chronic FXN knockdown ultimately induced DNA damage response-associated endothelial 
senescence (Figure 8). Correspondingly, senescence in mice with endothelial-specific FXN 
deficiency propelled PH development while treatment with a senolytic prevented it (Figures 9 and 
10). In contrast to previous studies, our findings define FXN as an upstream mediator of 
endothelial DNA damage in PH, illustrate the DNA damage-dependent evolution of endothelial 
cell phenotype toward irreversible growth arrest, and causatively link PH development to FXN-
driven senescence.  
These results join our previous data on FXN deficiency and metabolic reprogramming. 
Importantly, DNA damage has been observed in FRDA patient tissues previously, presumed to 
result from incompletely defined oxidative processes (214, 215). While our work does not preclude 
the possibility that FXN-dependent mitochondrial dysfunction and oxidative DNA damage 
contribute to or enhance irreversible senescence (35, 268), acute FXN knockdown induced nuclear 
replication stress independent of mitochondrial ROS (Supplemental Data Figure 11D), consistent 
with the pleiotropic mitochondrial and nuclear activities of Fe-S clusters. Establishment of FXN 
as a lynchpin of both mitochondrial and nuclear dysfunction expands on the importance of Fe-S 
biology in the endothelium beyond those identified with other Fe-S biogenesis gene deficiencies. 
Investigation of the precise Fe-S-dependent nuclear processes that promote replication 
stress and cell cycle arrest is still ongoing. First, by demonstrating an increased replication rate 
with FXN knockdown (Figure 7E), we highlight a lesser-known form of replication stress that has 
only recently been shown to promote DDR and ultimately genomic instability (269). With 
increased ribonucleotide reductase subunit RRM2 transcript expression (Figure 6B and 
Supplemental Data Figure 11B), up-regulation in replication fork elongation may be driven at least 
in part by altered ribonucleotide reductase (RNR) activity and a consequent imbalance in the 
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nucleotide pools, both of which have been shown to impact DNA integrity (270, 271). 
Interestingly, RNR contains an essential di-ferric tyrosyl radical cofactor donated by cytoplasmic 
Fe-S machinery (265), and its activity is preferentially preserved in the early stages of iron 
deficiency in yeast (272). This same acute sequestration of iron cofactors and conserved function 
may be characteristic of other critical DNA replication and repair machinery in conditions of acute 
FXN deficiency. In our work, RRM2 expression (Supplemental Data Figure 11H) also follows the 
simultaneous arc of nucleotide incorporation (Figure 8A) and replication fork markers 
(Supplemental Data Figure 11G) from acute replication stress to eventual senescence. Potentially 
similar to RRM2-deficient cancer cells exhibiting senescence-associated growth arrest (273), our 
data may reflect diminished RNR activity that leads to replication collapse and irreversible growth 
arrest. 
In addition to an inappropriately elevated replication rate, decreased FXN-dependent 
activity of Fe-S containing polymerases and helicases required for efficient, error-free replication 
may result in decreased proof-reading and increased genomic damage during S-phase (154). It is 
also possible that a combination of these pathogenic processes -- for example, oxidative stress and 
failure of Fe-S-dependent error-prone replication -- represents a “double-hit” to genomic integrity.  
By defining an evolution of endothelial cell behavior over time, our data also add detail 
and offer novel conceptual links to the hypotheses on dynamic endothelial dysfunction in PH. 
Although studies have characterized DNA damage (82, 92, 93) as promoting endothelial apoptosis 
in PH (274), genotoxic stress can result in either apoptosis or senescence (87), and our data provide 
mechanistic detail to support latter as a driver of PH. While our results emphasize DDR-driven 
senescence, there are alternative mitochondrial and nuclear mechanisms by which the endothelium 
may reach irreversible growth arrest that have yet to be explored.  
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Taking cues from aging and age-related diseases, senescent cells are inherently 
dysfunctional preventing tissue repair and propagating cell-autonomous damage via its 
inflammatory secretome. More specifically, senescent endothelial cells exhibit reduced NO 
signaling (275) and an increased susceptibility to apoptosis in comparison to other senescent cell 
types (276). Speaking to the latter, the mechanism by which pulmonary endothelial cells become 
apoptotic versus senescent is not fully defined but depends upon cell type as well as the severity 
and length of exposure to the genotoxic insult (29). Whether apoptosis and senescence co-exist on 
the same cellular continuum or represent two separate cell fates that differ based upon PH etiology 
requires further study (87). Our findings provide some insight into the pathobiological 
consequences of senescent endothelial cells, such as the release of senescence-associated secretory 
phase (SASP) mediators (such as IL-6 and TNF- in Figure 9F-G). While both have been 
causatively linked to the immune-mediate pathogenesis of pulmonary vascular disease (277) and 
elevated plasma levels in PAH patients prognosticate mortality (44, 278-280),  more work is 
required to fully characterize the FXN-specific endothelial SASP profile given its dependence 
upon cell type, inciting stressors, and stage of senescence (281). Moreover, how the FXN-
dependent SASP signature contributes to pulmonary vascular inflammation and immune cell 
recruitment as well as vascular remodelling and fibrosis (29, 32) requires further study.  
In total, this work offers a pivotal endothelial-specific mechanism converging on 
senescence, solidifying the regulatory actions of FXN across Fe-S biology, metabolism, and 
genomic integrity and offering compelling targets for more effective diagnostics and therapeutics 
in this deadly disease (see working model below). The relative importance of this novel endothelial 
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phenotype of irreversible senescence in the context of genetic FXN deficiency in FRDA  or 
acquired FXN deficiency across WSPH PH groups is not yet known.  
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4.0 HIF-dependent epigenetic modulation drives acquired FXN deficiency and endothelial 
senescence in multiple PH subtypes 
            This work was adapted from a manuscript in revision: 
Culley MK, Zhao J, Tai YY, Tang Y, Perk D, Negi V, Yu Q, Handen A, Speyer G, Kim S, Lai Y-
C, Satoh T, Watson A, Al Aaraj Y, Sembrat J, Rojas M, Khan OF, Anderson DG, Dahlman JE, 
Norris KE, Gurkar A, Rabinovitch M, Gu M, Bertero T, Chan SY. Endothelial frataxin deficiency 
induces replication stress to promote senescence in pulmonary hypertension. In revision. 
 
Notably, immunofluorescent staining and quantification in animal and human lung tissues 
performed in part by Dr. Thomas Bertero (Figure 14A and I, Figure 20A-B, D-E, and J, Figure 
21C). Pulmonary microvascular endothelial cells from healthy versus Group 1 PAH patients 
provided by Drs. Dmitry and Elena Goncharova (Figure 14G-H, Figure 20I, Figure 21A-B). 
Hemodynamic assessments performed by Jingsi Zhao and Yi Yin Tai (Figure 15C-D and F, Figure 
19F-G). Assistance with immunoblots provided by Jingsi Zhao (Figure 18E and G). 
4.1 Introduction 
PH is a heterogeneous disease caused by multiple disparate triggers. WSPH classifications 
seek to group patients based upon clinical parameters and etiology. These groupings ultimately 
inform prognosis and therapeutic choice as the available treatments are reserved for the particularly 
severe subtype, Group 1 PAH, which arises from idiopathic, hereditary causes, toxin exposure, 
and secondary disease associations. Separately, PH in groups 2–5 is associated with myriad 
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comorbidities (3). Notably, as the population ages and the number of patients with chronic diseases 
rises (100), PH due to left heart disease (Group 2), particularly PH associated with heart failure 
with preserved ejection fraction (HFpEF) (101) and metabolic syndrome (102), and PH due to 
hypoxic lung disease (Group 3) (103) represent a majority of PH patients. There is very little 
understanding of the pathological underpinnings in these subtypes and thus no PH-specific 
treatment options. How the molecular mechanisms that underlie PAH and other PH groups are 
connected is still under investigation. 
Thus far, we have described a mechanism by which FXN deficiency coordinated both Fe-
S-dependent metabolic and replication stress and have causatively linked the ensuing irreversible 
endothelial senescence to the development of PH in vivo. However, whether FXN expression is 
dynamically regulated in PH, independent of FRDA mutations, has not been investigated. Diverse 
triggers including acquired inflammation (266) and hypoxia (243) have been attributed to Group 
1 PAH and Group 3 PH with triggers for other PH subtypes incompletely defined. Both elevated 
(282, 283) and reduced (284) FXN levels have been reported in non-vascular hypoxic cell types; 
specific studies attribute this transcriptional control to the HIF-responsive element in the FXN 
promoter (282). However, the impact of hypoxia, as well as other acquired PH triggers, on FXN 
levels in pulmonary vascular cells is undefined. Our prior work demonstrating how HIF-, a well-
characterized transcription factor involved in metabolic rewiring in PH (42, 179), acts as a master 
regulator of endothelial ISCU1/2 and BOLA3 expression in hypoxia (70, 72), Therefore, hypoxia 
might drive HIF--dependent acquired FXN deficiency, similar to other Fe-S biogenesis genes. 
As previously mentioned, both endothelial apoptosis and proliferation contribute to the 
progressive pulmonary vasculopathy in this disease . By defining endothelial evolution toward 
irreversible senescence in vitro, we introduced a new phenotype to the “endothelial dysfunction”  
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that drives PH. Whether FXN deficiency and endothelial senescence are important in PAH or the 
lesser characterized Group 2 and 3 PH is not yet know. Therefore, we aimed to both characterize 
our endothelial-specific mechanism of FXN-dependent senescence and more specifically, define 
the dynamic control of FXN in response to known PH triggers. 
4.2 Materials & Methods 
            Shared methods were referenced in previous Materials & Methods sections (2.2, 3.2) while 
new materials and procedures have been described below. 
Transfection  
Transfection was performed in both pulmonary artery endothelial cells (PAECs) and 
smooth muscle cells (PASMCs) using pre-determined concentrations of siRNA. Silencer Select 
siRNAs for BMPR2 (s2044, 40nM), ENG (s4678, 40nM), CAV1 (s2447, 40nM), ACRVL1 
(s502493, 40nM), EIF2AK4 (s532694, 40nM), HIF1- (s6541, 6.25nM), HIF2- (s4699, 
6.25nM), CTCF (s20967, 20nM), BRD2 (s12070, 6.25nM), BRD4 (s23901, 6.25nM), and 
negative control #1 and #2 were purchased from Life Technologies. FXN (sc-40580) as well as 
negative control (sc-44236) pooled siRNAs were purchased from Santa Cruz. Experiments were 
completed 48 hours after transfection. 
 
Immunofluorescent staining and confocal microscopy  
De-paraffinization using xylenes (30 minutes at room temperature) was followed by step-
wise rehydration and high-temperature antigen retrieval. Samples were then permeabilized with 
0.1% Triton X-100 (15 minutes) and blocked with 5% donkey serum and 2% BSA in PBS (1 hour 
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at room temperature). After primary antibodies were incubated overnight at 4 degrees C (Appendix 
A Table 2), Alexa 488, 568 and 647-conjugated secondary antibodies (ThermoFisher Scientific) 
for immunofluorescence (1 hour at room temperature) and Hoechst counterstain (~1 minute) were 
applied sequentially prior to mounting. Pictures were obtained using Nikon A1 confocal 
microscope and 40x oil immersion lens. Small pulmonary vessels (30-100m diameter) present in 
a given tissue section (>10 vessels/section) that were not associated with bronchial airways were 
selected for analysis. Intensity (integrated density) of staining was quantified using ImageJ 
software (NIH). Degree of pulmonary arteriolar muscularization was assessed in OCT lung 
sections stained for SMA by calculation of the proportion of fully and partially muscularized 
peripheral pulmonary arterioles to total number. Relative vessel remodeling was quantified by 
measuring vessel wall thickness (i.e., SMA) compared to vessel diameter. Analyses were 
performed blinded to condition. Experiments were performed with the help of Ying Tang, M.S. 
and Thomas Bertero, Ph.D. 
 
Animal studies 
All animal experiments were approved by the University of Pittsburgh (DLAR) and the 
Harvard Center for Comparative Medicine. Animal husbandry was managed with the help of Jingsi 
Zhao, M.S., Ying Tang, M.S., and Dror Perk. 
 
Group 1 PAH models:  
Lung tissues from male Sprague-Dawley rats (10-14 weeks old) injected with 60 mg/kg 
monocrotaline were flash-frozen or paraffin-embedded via an ethanol-xylene dehydration series 
before downstream processing (285).  
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Male IL-6 transgenic (Tg) mice (12 weeks old) were exposed to  3 weeks of normobaric hypoxia 
in a temperature-humidity controlled chamber (10% O2, OxyCycler chamber, Biospherix Ltd.) and 
compared to age-matched wild type kept in normoxic conditions (21% O2) (19) (Taconic). 
Additional experiments assessing the efficacy of the senolytic ABT-263 (Selleckchem) were 
performed in female IL-6 Tg mice by administering the drug (25mg/kg/day) compared to vehicle 
control (2% DMSO in corn oil) via oral gavage during weeks 2 and 3 of hypoxic exposure.  
 
In simian immunodeficiency virus (SIV)-infected rhesus macaques (aged 6-10 years), 
hemodynamic instability (No PH versus PAH) was measured prior to intravenous inoculation with 
SIV ΔB670, at 6 months, and then at 10-12 months after infection. Lung tissue was embedded in 
paraffin for downstream processing obtained as previously described (286). 
 
Group 2 PH-HFpEF models: Sample were generously shared with us by Yen-Chun Lai. 
Flash-frozen and OCT-embedded lung tissue from male AKR/J mice (aged 6-12 weeks) fed a high-
fat diet (60% lipids/kcal) for 16-20 weeks compared to normal chow diet were analyzed (Table 4) 
(287). 
 
In a two-hit model of metabolic syndrome, double-leptin receptor defect (obese) ZSF1 male rats 
were treated with a subcutaneous injection of Sugen (SU4516, 100mg/kg) at 8-10 weeks-old 
compared to lean littermate controls. Hemodynamic assessment and tissue procurement were 
performed 14 weeks after injection (Table 5) (288). 
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Group 3 PH model:  
10-12 week-old C57BL/6 wild type were subjected to 3 weeks of normobaric hypoxia in a 
temperature-humidity controlled chamber (10% O2, OxyCycler chamber, Biospherix Ltd.) 
compared with normoxia (21% O2). Male hypoxic wild type mice were also received oral 
administration of the senolytic ABT-263 (25mg/kg/day) or vehicle control during the final 2 weeks 
of hypoxic treatment. 
 
Human samples 
PH was defined by elevated mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg. For 
paraffin-embedded lung samples, human PH specimens were collected from discarded surgical 
samples or rapid autopsy samples from subjects diagnosed with PH (Tables 6 and 7), some of 
which have been described previously (72).  Non-diseased human lung specimens were from the 
Center for Organ Recovery & Education (CORE). Informed consent was obtained for patient right 
heart catheterization and tissue sampling. All experimental procedures involving the use of human 
tissue and plasma and the study of invasive and non-invasive hemodynamics were approved by 
the institutional review board at the University of Pittsburgh. Ethical approval for this study and 
informed consent conformed to the standards of the Declaration of Helsinki. 
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4.3 Primary Data 
4.3.1 Acquired FXN deficiency and endothelial cellular senescence in Group 1, 2, and 3 PH 
animal and patient lungs 
To determine whether FXN is dynamically regulated in PH beyond FRDA mutations, we 
evaluated FXN levels in multiple in vivo models of PH representing diverse clinical subtypes. At 
the same time, we performed expression analysis of the p16INK4 transcript to begin to characterize 
potential FXN-dependent endothelial senescence in PH. Immunofluorescent staining of the 
pulmonary vasculature followed by confocal microscopy (Figure 14A) revealed a marked 
reduction in FXN in the CD31+ endothelium (Figure 14B), SMA+ smooth muscle layer 
(Supplemental Data Figure 20A), and entire pulmonary vessel (Supplemental Data Figure 20B) in 
a monocrotaline rat model of Group 1 PAH (285). Correspondingly, expression analysis of p16INK4 
mRNA in whole rat lung homogenates revealed significant up-regulation of senescence (Figure 
14C). In another model of Group 1 PAH (19), isolated lung CD31+ endothelial cells and whole-
lung tissue  in transgenic mice expressing the inflammatory cytokine interleukin-6 (IL-6) and 
exposed to chronic hypoxia displayed significantly reduced FXN (Figure 14D, Supplemental Data 
Figure 20C) and increased p16INK4 transcript levels (Figure 14E) when compared to normoxic 
wild-type controls. In simian immunodeficiency virus (SIV)-infected rhesus macaques modeling 
HIV-induced Group 1 PAH (286), FXN expression was also decreased (Supplemental Data Figure 
20D) by immunofluorescent staining and co-localized quantification with the CD31+ endothelium.  
Apart from Group 1 PAH, we performed immunofluorescent staining and expression 
analysis in two rodent models that develop Group 2 PH due to heart failure with preserved ejection 
fraction (PH-HFpEF): AKR/J mice fed a high-fat diet versus a regular diet (287) (Table 4) and 
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obese ZSF1 rats treated with VEGF receptor antagonist SU-5416 (Ob-Su) compared to lean 
controls  (288) (Tables 5). First, immunofluorescent staining and confocal microscopy reveals 
FXN levels (gray) were decreased in the pulmonary arteries of high-fat diet-fed AKR/J mice 
(Supplemental Data Figure 14E). Similarly, FXN transcript (Supplemental Data Figure 20F) and 
protein levels (Figure 14E) were reduced in lungs from obese, SU5416-treated ZSF1 rats compared 
to lean controls. Alongside FXN down-regulation, lungs from rats with PH-HFpEF exhibited 
elevated p16INK4 expression (Figure 14F). Lastly, isolated lung CD31+ endothelial cells 
(Supplemental Data Figure 20G) and whole-lung tissue (Supplemental Data Figure 20H) from 
chronically hypoxic mice, modeling Group 3 PH, demonstrated decreased FXN expression. 
Supporting data observed in multiple PH animal models, expression analysis in isolated 
pulmonary microvascular endothelial cells (PMVECs) from a Group 1 PAH patient and a healthy 
patient that were gender- and age-matched revealed decreased FXN mRNA (Supplemental Data 
Figure 20I) and protein expression (Figure 14G). Group 1 PAH PMVECs also showed an increase 
in p16INK4 levels (Figure 14H) and in the percentage of -galactosidase positive cells 
(Supplemental Data Figure 21A), both signaling irreversible senescence. Forced expression of 
FXN and its binding partner marginally decreased p16INK4 protein expression (Supplemental Data 
Figure 22B), consistent with heterogeneity within the PMVECs population. Separately, FXN 
levels were reduced in CD31+ endothelium (Figure 14I) and SMA+ smooth muscle layer 
(Supplemental Data Figure 23J) in patients with Group 1 PAH (Table 6) as well as interstitial 
pulmonary fibrosis (IPF)-associated PH (Group 3 PH) (Table 7) compared with non-diseased 
controls. Lungs from Group 1 PAH and Group 3 PH patients exhibit increased p16INK4 transcript 
(Figure 14J) and immunofluorescent staining by confocal microscopy (Supplemental Data Figure 
 77 
24C). Taken together, diverse PH triggers in rodent, non-human primate, and human models across 
various WSPH PH groups exhibited decreased endothelial FXN and increased p16INK4 expression. 
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Figure 14. Reduced FXN and elevated p16INK4 expression in Group 1, 2, and 3 PH lungs. 
(A) Representative images of lungs stained with immunofluorescent probes for Fxn (gray), CD31 (green), SMA 
(red), counterstained with DAPI (blue), and imaged by confocal microscopy. Scale bars indicate 50m. Quantification 
of Fxn co-localized within the CD31+ endothelium in rats treated with monocrotaline (MCT) (n=6) or vehicle (n=5). 
(B) Relative p16INK4 expression by RT-qPCR in lung tissue from monocrotaline-treated rats compared to control 
(n=5/group). (C) Fxn mRNA expression in isolated CD31+ lung cells and (D) whole-lung p16INKA mRNA levels in 
hypoxic IL6-Tg (n=3) versus normoxic WT mice (n=5). (E) Fxn protein and (F) p16INKA transcript expression in lung 
tissue from ZSF1 obese rats treated with Sugen (SU5416) (Ob-Su) (n=9) versus lean controls (n=8). (G and H) 
Immunoblot of FXN and p16INKA protein in pulmonary microvascular endothelial cells (PMVECs) from a healthy 
versus Group 1 PAH patient (n=3/group). (I) Representative confocal images probing for FXN (gray), CD31 (green), 
SMA (red) and counterstained with DAPI (blue). Scale bars represent 50m.  Quantification of FXN in the CD31+ 
endothelium of Group 1 PAH (n=8) or Group 3 PH (n=8) patient lungs compared to controls (No PH) (n=6). (J) RT-
qPCR of p16INK4 mRNA levels in lung tissue of patient without PH, Group 1, or Group 3 PH. Two-tailed Student’s t-
test with error bars that reflect mean +/- SD. 
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To provide a causal link between FXN deficiency and elevated p16INKA across different 
PH classifications, Group 1 (Figure 15A) and Group 3 PH (Figure 15E) murine models were 
treated with senolytic ABT-263, which selectively removes BCL2-positive, apoptosis resistant 
cells (267), compared to vehicle control as disease developed. Following removal of senescent 
cells, ABT-263-treatment hypoxic IL-6 Tg mice exhibited a decrease in the percentage of 
muscularized vessels measured by immunofluorescent co-staining endothelial vWF and smooth 
muscle cell SMA in mouse lung tissue (Figure 15B). Correspondingly, the senotherapy also 
reduced Fulton index (Figure 15C), measuring RV hypertrophy, and RVSP (Figure 15D). 
Similarly, the senolytic therapy also decreased RVSP (Figure 15F), suggesting removal of 
senescence can prevent PH development in vivo. In summary, these findings support the notion 
that acquired FXN deficiency and ensuing senescence represents a common and causative 
molecular feature among seemingly diverse clinical subtypes.  
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Figure 15. Senolytic therapy prevents Group 1 and 3 PH development. 
(A) Diagram depicting senolytic treatment (25mg/kg/day via oral gavage) in female IL-6 Tg mice during weeks 2 and 
3 of hypoxic exposure (3 weeks, 10% O2). (B) Representative images and quantified percentage of muscularized 
pulmonary vessels measured by immunofluorescent staining of vWF (green) and SMA (red) (n=3). (C) Fulton index 
(RV/LV+S, %) (n=4 v. n=3). (D) Right ventricular systolic pressure (RVSP, mmHg) (n=4 v. n=3). (E) Diagram of 
male wild type mice treated with ABT-263 (25mg/kg/day via oral gavage) in weeks 2 and 3 of hypoxia exposure. (F) 
RVSP (n=5). Two-tailed Student’s t-test was performed with error bars that reflect mean +/- SD. 
4.3.2 Acquired FXN down-regulation by known PH triggers 
Given that animal and patient PH lung tissues exhibit acquired FXN reduction, primary 
pulmonary artery endothelial cells (PAECs) and smooth muscle cells (PASMCs) were exposed to 
known PH triggers. Exposure to hypoxia, a trigger associated with Group 1 PAH and Group 3 PH 
(243), robustly down-regulated FXN transcript and protein levels in cultured PAECs (Figure 16A-
B). Similarly, exposure to the inflammatory cytokine interleukin-1 beta (IL-1), which is elevated 
(44) and promotes vascular remodeling in Group 1 PAH (289), decreased FXN in PAECs (Figure 
16C-D). Knockdown of genes associated with heritable PAH or exposure to increased matrix 
stiffness did not alter FXN expression in PAECs (Supplemental Data Figure 22A). Thus, both 
 81 
hypoxic and inflammatory stimuli associated with Groups 1 and 3 PH down-regulated FXN in 
pulmonary endothelial cells. 
 
Figure 16. Chronic hypoxia and inflammation down-regulate FXN expression in pulmonary artery 
endothelial cells. 
(A-D) FXN expression analysis in cultured human pulmonary artery endothelial cells (PAECs). (A and B) RT-qPCR 
analysis (n=6) and immunoblot with densitometry (n=3) after exposure to hypoxia (≥ 24 hours, <1% O2). (C and D) 
RT-qPCR and immunoblot following IL-1 treatment (≥ 24 hours, 10 ng/ml) (n=3). Experiments performed at least 
three separate times. Two-tailed Student’s t-test with error bars that reflect mean +/- SD. 
4.3.3 HIF- independently controls CTCF and BRD4 to down-regulate endothelial FXN  
Given the importance of HIF- activity in Fe-S biogenesis (70-72) and the link between 
hypoxia and FXN in PAECs, we aimed to determine whether hypoxic down-regulation of FXN 
was dependent upon HIF-. PAECs were treated with siRNA specific for the HIF- isoforms, 
HIF-1 and HIF-2, alone and in combination, followed by exposure to chronic hypoxia 
(Supplemental Data Figure 22B-C). HIF-1 and HIF-2 knockdown together most effectively 
increased FXN mRNA (Figure 17A) and protein levels (Figure 17B) under hypoxic stimulus. 
Bolstering these results, HIF-1 activation by cobalt(II) chloride (290) robustly decreased FXN 
(Figure 17C-D), similar to hypoxia and inflammation, while HIF-1-specific inhibition by siRNA 
reversed this effect (Figure 17E). Thus, despite the HIF-responsive element in the FXN promoter 
reported in other cell types (282, 283), the repressive activity of HIF- on FXN in PAECs 
suggested a more complex, tissue-specific regulatory landscape. 
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Figure 17. FXN is decreased by HIF. 
(A and B) RT-qPCR and immunoblot of relative FXN transcript and protein expression in hypoxic PAECs transfected 
with HIF-1, HIF-2, or combined isoform-specific siRNAs compared to negative control (NC). (C and D) FXN 
expression analysis in PAECs treated with cobalt(II) chloride (≥ 24 hours, 750M CoCl2). (E) Immunoblot of FXN 
in PAECs treated with CoCl2 and transfected with HIF-1, HIF-2, or both siRNAs compared to negative control. 
Two-tailed Student’s t-test and one-way ANOVA (Tukey’s post hoc analysis) with error bars that reflect mean +/- 
SD. Experiments were performed at least three separate times in triplicate. 
 
 
Consistent with prior description of the chromatin insulator protein CCCTC-binding factor 
(CTCF) binding the FXN 5’UTR (291, 292), we showed that CTCF inhibition by siRNA 
(Supplemental Data Figure XD) markedly reduced FXN transcript (Figure 18A) and protein levels 
(Figure 18B) in PAECs. We observed reduced CTCF protein following chronic hypoxic exposure 
(Supplemental Data Figure 22E) and cobalt(II) chloride treatment (Supplemental Data Figure 
22F), consistent with FXN knockdown under these conditions (Figure 16A-B). Moreover, 
knockdown of the HIF-1 and HIF-2 isoforms together rescued CTCF (Figure 18C), 
corresponding with rescue of FXN levels (Figure 17A-B). In sum, HIF- controls CTCF-
dependent modulation of FXN expression in PAECs.  
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Given the importance of heterochromatin silencing of FXN in FRDA (187, 293) and recent 
data that epigenetic pharmacotherapies reversed experimental PH (149, 294), we investigated 
whether other chromatin modulators, namely bromodomain and extra-terminal (BET) motif 
proteins (295), regulate FXN in PAECs in hypoxic and inflammatory conditions. First, PAECs 
were exposed to chronic PH triggers and simultaneously treated with vehicle control or I-BET151 
– a selective inhibitor of BET family proteins BRD2, 3, and 4 (296). I-BET151 rescued FXN 
expression under hypoxia (Figure 18D-E) and IL-1 stimulation (Supplemental Data Figure 22G). 
Similarly, BRD4 inhibition (Supplemental Data Figure 22H) reversed the hypoxic reduction of 
FXN (Figure 18F-G), and BRD2 inhibition (Supplemental Data Figure 22I) reversed the IL-1-
mediated reduction (Supplemental Data Figure 22J). Furthermore, while cobalt(II) chloride 
treatment increased BRD2 and 4 expression (Supplemental Data Figure 22K) and decreased FXN 
(Figure 17C-D), BRD4 knockdown partially reversed the reduction of FXN mediated by cobalt(II) 
chloride (Supplemental Data Figure 22L). Moreover, siRNA knockdown of HIF-1 during 
cobalt(II) chloride exposure decreased BRD4 (Figure 18H), demonstrating that HIF-1-dependent 
BRD4 expression may be responsible, at least in part, for modulation of FXN. In summary, these 
data highlight the complex HIF--driven epigenetic silencing of FXN following exposure to 
hypoxia or inflammation with rescue by epigenetic inhibitory therapies, similar to cases of genetic 
deficiency (187, 293). 
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Figure 18. HIF independently coordinates both CTCF and BRD4 to down-regulate FXN. 
(A and B) RT-qPCR and immunoblot of FXN in PAECs transfected with siRNA against CTCF or negative control. 
(C) Immunoblot of CTCF in hypoxic PAECs transfected with HIF-1, HIF-2, or both siRNAs compared to control. 
(D and E) FXN transcript and protein expression in PAECs treated with I-BET151 (500nM) or vehicle control 
(DMSO) and exposed to hypoxia or normoxia (>24 hours). (F and G) RT-qPCR and immunoblot of FXN expression 
in PAECs treated with siRNA against bromodomain-containing protein 4 (BRD4) or negative control and with or 
without hypoxic exposure. (H) Immunoblot of BRD4 in PAECs transfected with HIF-1 compared to negative control 
and treated with CoCl2. Two-tailed Student’s t-test and one- or two-way ANOVA (Tukey’s post hoc analysis) with 
error bars that reflect mean +/- SD. Experiments were performed at least three separate times in triplicate. 
 
4.3.4 Smooth muscle FXN deficiency does not promote PH 
Given that FXN was decreased in the SMA+ medial layer of several PH models (Figure 14 
and Supplemental Data Figure 20), we sought to determine if the same acquired triggers might 
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control FXN expression in smooth muscle cells. Chronic hypoxic exposure down-regulated FXN 
transcript expression in cultured PASMCs (Figure 19A) while treatment with IL-1 did not (Figure 
19B), suggesting tissue-specific responses to different triggers of PH. 
Next, we aimed to establish whether acquired FXN deficiency exerts the same coordinated 
effect on replication stress-dependent senescence in smooth muscle cells. Unlike PAECs, 
transfected PASMCs with FXN siRNA knockdown did not exhibit changes in replication stress 
(p-RPA32) or cell cycle arrest (p21) compared to cells treated with negative control siRNA (Figure 
19C). This acute FXN deficiency did not result in up-regulation of DDR markers, suggesting no 
underlying genomic damage (Figure 19D). Consistent with this lack of nuclear stress, conditional, 
smooth muscle-specific FXN knockout mice (SMC Fxn-/-) (Figure 19E) exposed to hypoxia did 
not develop PH as demonstrated by unchanging RVSP and Fulton index when compared to Fxn 
f/f controls (Figure 19F-G), altogether reinforcing the specificity of endothelial FXN deficiency in 
promoting pulmonary vascular disease. 
In sum, these data define a mechanism of HIF--driven epigenetic FXN reduction in 
response to known PH triggers, illustrate the specific importance of FXN deficiency in pulmonary 
endothelium versus other vascular cell types, and support the relevance of FXN-dependent 
senescence in Group 1, 2, and 3 PH. 
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Figure 19. FXN deficiency in pulmonary smooth muscle cells does not promote PH. 
(A) RT-qPCR analysis of FXN transcript levels in PASMCs after exposure to normoxia or hypoxia (≥ 24 hours, <1% 
O2) (n=6). (B) Relative FXN expression by in PASMCs treated with IL-1 (≥ 24 hours, 10 ng/ml) compared to control 
(n=3). (C and D) Immunoblot evaluation of cell cycle arrest (p21), replication stress (p-RPA32), DDR markers (p-
ATR, CHK1, H2AX) in PASMCs transfected with FXN siRNA compared to negative control (n=3). (E) Diagram of 
conditional smooth muscle cell (SMC) Fxn-/- (Myh11-ERT2+-Cre+) mice compared to Fxn f/f control exposed to 
chronic hypoxia (3 weeks, 10% hypoxia). (F) Right heart catheterization measuring right ventricular systolic pressure 
(RVSP, mmHg) in Fxn f/f (n=11) and SMC Fxn-/- (n=16) hypoxic mice. (G) Fulton index (RV/LV+S) (n=11 versus 
16). Two-tailed Student’s t-test with error bars that reflect mean +/- SD. Experiments performed in primary cultured 
cells performed at least three separate times. 
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4.4 Supplemental Data 
 
Figure 20. FXN expression in the pulmonary vasculature of Group 1, 2, and 3 PH models. 
(A and B) Fxn co-localized with pulmonary medial layer (SMA+) for Group 1 PAH monocrotaline-treated rats (n=6) 
versus vehicle control (n=5). (C) RT-qPCR of Fxn transcript expression in whole-lung tissue from hypoxic IL-6 Tg 
mice (n=3) versus normoxic wild type control (n=5). (D) Immunofluorescent staining of SMA (red), CD31 (green), 
FXN (gray), and counterstaining nuclei with DAPI (blue) followed by confocal microscopy. Quantification of FXN 
levels colocalized in CD31+ cells in the pulmonary vessels of SIV-infected nonhuman primates (NHP) with and 
without PAH (n=6). (E) Representative immunofluorescent images and quantification of Fxn (gray) in pulmonary 
vessels from AKR/J mice fed a high-fat or regular diet (n=5). Scale bars indicate 50m. (F) RT-qPCR of Fxn levels 
in whole-lung from SU5416-treated obese ZSF1 (n=9) versus lean rats (n=10). (G and H) Fxn mRNA in CD31+ cells 
or whole lung from C57Bl6 mice exposed to chronic hypoxia (10% O2, 3 weeks) or normoxia (n=5). (I) FXN 
expression by RT-qPCR in PMVECs from patients with no PH compared to Group 1 PAH (n=3/group). (J) FXN 
levels co-localized with SMA+ cells in Group 1 PAH (n=8) or Group 3 PH (n=8) lungs compared to control (No 
PH) (n=6). Two-tailed Student’s t-test with error bars that reflect mean +/- SD. 
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Figure 21. Elevated markers of senescence in PH patient pulmonary vascular cells. 
(A) Representative brightfield images and quantification of senescence-associated (SA)--galactosidase positive 
PMVECs from a healthy versus a Group 1 PAH patient. (B) p16INK4 protein levels following forced overexpression 
of FXN and ISCU1/2 in Group 1 PAH PMVECs (n=3). (C) Immunofluorescent staining of p16INK4 (red), CD31 
(green), SMA (white), and DAPI (blue) and confocal microscopy of No PH (n=6), Group 1 PAH (n=8), or Group 3 
PH patient lungs (n=8). Scale bars indicate 50m. Two-tailed Student’s t-test with error bars that reflect mean +/- SD.   
 
B
No PH Group 1 PAH Group 3 PH 
p
1
6
/C
D
3
1
/a
-S
M
A
/D
A
P
I
p
1
6
/C
D
3
1
/D
A
P
I
A
C
S
A
-g
a
la
c
to
s
id
a
s
e
Healthy PAH
PMVECs
Human lung
p16
b-actin
16 kDa
42 kDa
L
V
-G
F
P
L
V
-F
X
N
L
V
-I
S
C
U
1
L
V
-I
S
C
U
2
L
V
-F
X
N
+
L
V
-I
S
C
U
1
L
V
-F
X
N
+
L
V
-I
S
C
U
2
PAH PMVECs
 89 
 
Figure 22. Epigenetic repression of FXN in response to acquired PH triggers. 
(A) Pulmonary artery endothelial cell (PAEC) FXN mRNA levels following siRNA transfection of targets associated 
with mutations in PH (ENG, CAV1, ACRVL1, EIF2AK4, BMPR2) compared to negative control (NC) (n=3). (B and 
C) RT-qPCR of relative HIF-1 and EPAS1 levels for PAEC transfection control of HIF-1, HIF-2, or combined 
isoform-specific siRNA. (D) RT-qPCR of CTCF transcript for PAEC transfection control of CTCF siRNA. (E) 
Immunoblot of CTCF protein in hypoxic PAECs (≥ 24 hours, <1% O2). (F) Immunoblot of CTCF protein in PAECs 
treated with CoCl2 (≥ 24 hours, 750M). (G) FXN mRNA levels in PAECs treated with I-BET151 (500nM) or vehicle 
control with or without IL-1 stimulation (>24 hours). (H and I) PAEC transfection control of BRD4 or BRD2 siRNA 
in normoxia and hypoxia conditions. (J) RT-qPCR of FXN levels in PAECs transfected with BRD2 siRNA and 
exposed to IL-1 or control. (K) Immunoblot of BRD2 and BRD4 expression in PAECs treated with CoCl2. (L) 
Representative immunoblot of FXN in PAECs transfected with BRD2, BRD4, and combined siRNAs compared to 
negative control and treated with CoCl2. Two-tailed Student’s t-test and two-way ANOVA (Tukey’s post hoc analysis) 
with error bars that reflect mean +/- SD. Experiments were performed at least three separate times in triplicate. 
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4.5 Discussion 
Expanding upon the relevance of FXN in pulmonary vascular disease beyond FRDA 
mutations, we observed decreased FXN and increased p16INK4 expression in the lungs of Group 1, 
2, and 3 PH animal models and patient tissues. Moreover, removal of apoptosis-resistant, senescent 
cells with the senolytic drug ABT-263 prevented PH development in Group 1 and 3 PH mouse 
models, supporting a causal role for FXN-dependent senescence across multiple PH subtypes. In 
addition, our data highlighted how triggers of PH, such as chronic hypoxia and inflammation, lead 
to HIF--mediated regulation of known (CTCF) and novel (BRD4) epigenetic modifiers of FXN 
transcription in PAECs. Notably, acquired FXN deficiency in pulmonary smooth muscle cells did 
not promote the genomic stress that precipitates senescence or PH development in vivo (Figure 
19), further distinguishing the importance of endothelial Fe-S cluster deficiency in pulmonary 
vascular disease. 
FXN joins a growing number of Fe-S assembly genes dynamically repressed by HIF- 
signaling in the endothelium (70-72). It is likely that these acquired HIF--driven deficiencies and 
their specific cell fates cumulatively contribute to the shifting pulmonary endothelial 
pathophenotypes throughout PH progression and across WSPH classifications. However, the 
contributions of this dynamic network of Fe-S biogenesis genes are only just emerging. Notably, 
this acquired reduction in FXN opposes prior studies which identified a HIF-dependent increase 
of FXN in non-vascular cells (282, 283). While the reasons for divergent gene regulation are not 
known in different hypoxic tissues, there may be cell-type specificity of the chromatin structure 
and its modulators, CTCF and BRD4, in exerting control of FXN. By expanding upon the 
comprehensive landscape of epigenetic factors involved in FXN regulation, our data endorse 
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epigenetic pharmacotherapies, specifically BRD4 inhibitors (149), that may work in multiple PH 
subtypes, at least in part, by increasing FXN levels in the pulmonary endothelium. Though not 
explored here, HDAC inhibition is an emerging therapeutic model in FRDA (187, 226, 227), and 
may apply to acquired FXN deficiency as well; conversely, given the importance of 
heterochromatic silencing in FXN mutations, BET-specific remodeling may be beneficial in the 
setting of FRDA. 
Our data support the relevance of endothelial senescence driven by FXN deficiency across 
multiple PH subtypes. Importantly, these observations offer an explanation for a predisposition to 
pre-capillary PH, especially in the context of combined pre- and post-capillary PH in Group 2 
patients. Further studies are warranted to elucidate the individual or additive effect of pulmonary 
endothelial FXN deficiency in the setting of left heart disease. Regardless, this shared FXN-
dependent mechanism holds therapeutic potential not only for patients with PAH but other PH 
groups with no currently available treatment options. Specifically, our findings endorse the use of 
emerging senotherapies (32, 297) in PH. Additional studies are required to explore the benefits of 
therapies that decelerate cellular progression toward senescence (e.g., rapamycin (298), resveratrol 
(231, 299)), senolytic therapies that remove senescent cells (300), and senomorphic therapies that 
suppress markers of senescence or their secretory phenotype without inducing apoptosis (297). 
Senomorphics represent an opportunity to prevent senescence-dependent pulmonary vascular 
remodeling while avoiding the potentially detrimental effects of drug-induced endothelial 
apoptosis. In fact, p38 kinase inhibitors were recently characterized as a potential senomorphic 
therapy in the setting of FRDA mutation-induced fibroblast senescence (301). Moreover, since the 
age of prevalent PH patients is increasing worldwide and older PH patients are more commonly 
afflicted by HFpEF (302), FXN-dependent endothelial senescence could also serve as a key 
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molecular driver for PH in the elderly. If so, determination of appropriate therapeutic timing of 
these drugs during PH development will be crucial as will determination of administration efficacy 
in young versus old patients.  
Altogether, we have defined a shared endothelial mechanism contingent on acquired FXN 
deficiency in Group 1, 2, and 3 PH (see working model below), thus providing a basis for therapies 
targeting senescence, particularly for PH patient groups with no treatment options. Whether FXN 
mutations result in similar metabolic dysfunction and PH is not yet defined. 
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5.0 FXN-dependent endothelial dysfunction in Friedreich’s ataxia patients 
            This work was adapted from a manuscript in revision: 
Culley MK, Zhao J, Tai YY, Tang Y, Perk D, Negi V, Yu Q, Handen A, Speyer G, Kim S, Lai Y-
C, Satoh T, Watson A, Al Aaraj Y, Sembrat J, Rojas M, Khan OF, Anderson DG, Dahlman JE, 
Norris KE, Gurkar A, Rabinovitch M, Gu M, Bertero T, Chan SY. Endothelial frataxin deficiency 
induces replication stress to promote senescence in pulmonary hypertension. In revision. 
 
Notably, Drs. Mingxia Gu and Marlene Rabinovitch provided differentiated inducible pluripotent 
stem cell-derived endothelial cells from patients with Friedreich’s ataxia compared to healthy age- 
and gender-matched controls (Figures 23 and 24). 
5.1 Introduction 
Trinucleotide repeat expansion mutations in the frataxin (FXN) gene cause Friedreich’s 
ataxia (FRDA) (183). This multisystem disease is defined by neurodegeneration and hypertrophic 
cardiomyopathy (and less often dilated cardiomyopathy) (194) with the latter driving mortality in 
roughly 60% of patients (197). Case reports have described pulmonary arteriolar vasculopathy in 
this population (200), consistent with the fact that up to 40% of patients with hypertrophic 
cardiomyopathy (HCM) in general suffer from Group 2 pulmonary hypertension (PH) (105, 199). 
Yet, PH and cardiopulmonary complications as a whole in FRDA have been surprisingly 
underreported (201, 202), in part due to the lack of hemodynamic outcomes and lung specimens 
available for study. Of the FRDA heart failure reports that are available, focus has been given to 
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the diastolic dysfunction and markedly elevated left ventricular filling pressures rather than the PH 
that, by definition, is present (202). 
Similarly, the molecular underpinnings of pulmonary vascular cells has not been 
investigated. Rather, studies have largely focused on cell types, such as cardiomyocytes and 
neurons, with high mitochondrial content and high metabolic rate as well as higher levels of 
baseline FXN than initially characterized in whole-lung tissues (303).  Common in multiple non-
vascular cell types, FRDA-dependent FXN deficiency led to mitochondrial dysfunction in the form 
of decreased mitochondrial respiration (203), reduced mitochondrial biogenesis (248), as well as 
oxidative stress and ensuing mtDNA and nuclear DNA damage (208, 209, 214, 215). While tissue 
damage in the form of slowed growth or apoptosis have been widely described in models of FRDA 
(220, 222, 223, 304), cellular senescence is an emerging characteristic of FXN deficiency in 
specific tissues (e.g., neurons, islet cells, fibroblasts) (224, 225) with specific data supporting 
irreversible growth arrest may be related to decreased mitochondrial respiration and aberrant Ca2+ 
signaling (224), mtDNA damage (305), telomere dysfunction (306, 307). FXN’s direct disruption 
of Fe-S-dependent DNA replication and repair machinery in FRDA has not been characterized; 
however, studies have directly linked mitochondrial Fe-S biogenesis and genomic instability (219). 
The complete mechanism by which FXN orchestrates these and other consequences of Fe-S 
deficiency to promotes senescence remains ill-defined. Moreover, how these examples of FXN-
driven dysfunction relate to endothelial cell function in patients with FRDA is not yet known. 
However, given that we have already demonstrated FXN-dependent senescence promotes PH 
pathogenesis and that this mechanism is pervasive in multiple PH subtypes, including Group 2 PH 
due to HFpEF, we hypothesized FXN mutations may promote similar endothelial phenotypes that 
could explain a potential predisposition for pulmonary vascular disease in the setting of HCM. 
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5.2 Materials & Methods 
            Shared methods were referenced in previous Materials & Methods sections (2.2, 3.2, 4.2) 
while new procedures have been described below. 
Cell culture  
Skin fibroblasts from a 36-year-old female (330 and 380 repeat expansions on each allele) 
and 30-year-old male (541 and 420 repeat expansions) with Friedreich’s ataxia were 
reprogrammed using retroviral by the Coriell Institute for Medical Research. These purchased 
inducible pluripotent stem cells (iPSCs) were differentiated into endothelial cells (iPSC-ECs) (308, 
309) by Mingxia Gu, Ph.D., who generously provided healthy, gender- and age-matched iPSC-
ECs for comparison. These cells were cultured on 0.2% gelatin in endothelial basal media 
supplemented with a growth media kit (PromoCell; Lonza) and 5% fetal bovine serum (FBS) 
without antibiotics or antifungals added. Experiments were performed between passages 2 to 6.  
 
Proximity ligation assay 
Endogenous interaction of the DNA Pol  protein subunits (POLD1 and 3) was assessed 
using a Duolink Proximity Ligation Assay kit (Sigma Aldrich) per the manufacturer’s instructions. 
Briefly, iPSC-ECs were plated in Lab-Tek II chamber slides (5000 cells/well), fixed with 4% 
paraformaldehyde for 15 minutes, permeabilized with 0.25% Triton X-100 for 15 minutes, and 
blocked for 30 minutes at 37 degrees C before incubation with mouse monoclonal antibody 
POLD1 (MA1-23200 Thermofisher Scientific) and rabbit monoclonal antibody POLD3 
(ab182564 Abcam) at 1:250 overnight at 4 degrees C. After washing, fixed cells were exposed to 
PLUS and MINUS PLA probes for 1 hour, ligated for 30 minutes, and amplified with polymerase 
for 1 hour and 40 minutes all at 37 degrees C. Cells were counterstained and mounted with DAPI 
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solution. Imaging was performed on a Nikon A1 microscope with 60x oil immersion objective at 
1.75x zoom; >10 images were taken per sample. Quantification was blinded and performed 
manually. 
5.3 Primary Data 
5.3.1 Genetic FXN deficiency mirrors the metabolic and genomic dysfunction that drives 
endothelial senescence 
To begin to causatively link genetic FXN deficiency to endothelial senescence, we 
employed inducible pluripotent stem cells from patients with FRDA mutations (310) that were 
differentiated into endothelial cells (iPSC-ECs), as previously described (311). Importantly, 
FRDA patient iPSC-ECs exhibited normal endothelial cell expression markers (Supplemental Data 
Figure 24A-B), function (Supplemental Data Figure 24C), and markedly reduced FXN levels 
(Supplemental Data Figure 24D-E). By comparing these genetically FXN-deficient cells to their 
gender- and age-matched controls, we sought to compare endothelial-specific alterations 
controlled by FRDA mutations in addition to acquired deficiencies. Using the mechanism 
delineated in FXN-deficient PAECs as a guide, similar pathophenotypes were assessed in our 
iPSC-EC model. First, both male (Figure 23A) and female (Supplemental Data Figure 24F) FRDA 
mutant endothelial cells exhibited definitively reduced BrdU incorporation. Simultaneously, 
genetic FXN deficiency resulted in decreased caspase-3/7 activity (Figure 23B, Supplemental Data 
Figure 24G) and elevated BCL2 protein expression (Figure 23C, Supplemental Data Figure 24H) 
compared to healthy control. Similar to transfected PAECs at day 8 (Figure 8A-B), loss of 
 97 
replicative potential alongside apoptosis resistance signaled FXN-dependent permanent growth 
arrest. Consequently, FXN-deficient iPSC-ECs displayed increased p16INK4 transcript (Figure 
23D, Supplemental Figure 24I) and protein expression (Figure 23E) and senescence-associated--
galactosidase (SA--gal) staining (Figure 23F). This senescent phenotype was accompanied by 
elevated IL-6 expression (Supplemental Figure 24J), indicative of the senescence-associated 
secretory phase (SASP), and a marked reduction in RRM2 transcript expression (Supplemental 
Data Figure 24K). Attempts to rescue this phenotype with FXN replacement did not alter BCL2 
or p16INK4 protein levels (BCL2, suggesting irreversibility of this endothelial phenotype. In 
addition, FRDA iPSC-ECs exhibited an imbalance in vasomotor tone effectors with increased 
EDN1 transcript and secreted protein levels (Figure 23G-H) and reduced NOS3 transcript levels 
(Figure 23I). 
To establish the molecular drivers of this pathogenic endothelial dysfunction with genetic 
FXN deficiency, we interrogated both genomic and metabolic modifiers. To start, immunoblot 
showed markedly increased ubiquitinated (Ub-H2AX) and phosphorylated H2AX (H2AX) in 
FRDA iPSC-ECs (Figure 23J), suggesting senescence is driven by persistent DDR and mirroring 
chronic FXN knockdown in PAECs. Given this FXN-dependent genotoxicity, we aimed to 
demonstrate that FXN deficiency directly impairs nuclear replication and repair. Using a proximity 
ligation assay, the Fe-S-dependent association of the DNA polymerase  catalytic subunit POLD1 
with its accessory subunits, in this case, POLD3 was measured (163). Confocal imaging showed 
iPSC-ECs with FRDA mutations exhibited decreased nuclear signal, denoting a FXN-driven 
reduction in the intact form of this high-fidelity polymerase (Figure 23K). Therefore, these 
findings delineate a FXN-driven mechanism in which direct attenuation of Fe-S-containing nuclear 
machinery may contribute to compromised DNA replication and repair. This FXN-driven 
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genotoxicity is accompanied by an increase in intracellular hydrogen peroxide in FRDA patient-
derived iPSC-ECs compared to healthy controls (Figure 23L). Cumulatively, these data identify 
shared endothelial pathophenotypes between both epigenetic and genetic FXN deficiency. 
Namely, chronic FXN deficiency attenuated mitochondrial and nuclear Fe-S-containing protein 
function which led to oxidative stress and compromised genomic integrity, and ultimately, 
dysfunctional endothelial cells characterized by increased vasomotor tone and senescence.  
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Figure 23. Genetic FXN deficiency coordinates senescence via metabolic and genomic stress. 
(A-L) Phenotypic experiments performed in male age-matched inducible pluripotent stem cell-derived endothelial 
cells (iPSC-ECs) from healthy versus patients. (A) Colorimetric BrdU incorporation assay. (B) Chemiluminescent 
caspase-3/7 activity.  (C) Immunoblot quantification of apoptosis resistance BCL2 protein.  (D) RT-qPCR of p16INKA 
transcript levels. (E) Relative p16INKA protein expression in male FRDA iPSC-ECs compared to healthy controls 
(n=3). (F) Representative light microscopic images of SA-galactosidase (blue) in male iPSC-ECs. Scale bar represents 
200m. (G and H) Transcript by RT-qPCR (n=6) and secreted protein by ELISA (n=3) of EDN1 in FXN-deficient 
iPSC-ECs. (I) RT-qPCR of NOS3 transcript in mutated versus healthy endothelial cells (n=6). (J) Immunoblot 
phosphorylated (H2AX) and ubiquitinated (Ub-H2AX) forms of H2AX in FRDA patient iPSC-ECs compared to 
control (n=3). (K) Proximity ligation assay followed by confocal microscopy showing quantification of associated 
POLD1 and POLD3 subunits of DNA Pol  in FRDA iPSC-ECs compared to healthy controls. Scale bars indicate 
10m. (L)  Amplex red colorimetric assay measuring intracellular hydrogen peroxide (H2O2) in FRDA mutant iPSC-
ECs compared to healthy controls (n=6). Two-tailed Student’s t-test with error bars that reflect mean +/- SD. 
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5.4 Supplemental Data 
 
Figure 24. Characterization of inducible pluripotent stem cell-derived endothelial cells from patients with 
Friedreich’s ataxia. 
(A) Representative immunofluorescent staining and confocal imaging of FRDA and healthy iPSC-ECs stained with 
endothelial marker VE-Cadherin (green) and counterstained with DAPI (blue). Scale bars indicate 10m. (B) 
Representative images of FRDA and healthy iPSC-ECs stained with vWF (green) and counterstained with DAPI 
(blue). Scale bars indicate 50m. (C) Representative images of FRDA or healthy iPSC-EC uptake of fluorescent ac-
LDL (red) and counterstained with DAPI (blue). Scale bars indicate 50m. (D and E) RT-qPCR and immunoblot of 
FXN levels in FRDA compared to healthy iPSC-ECs (n=3). (F-I) Phenotypic experiments performed in female age-
matched inducible pluripotent stem cell-derived endothelial cells (iPSC-ECs) from healthy versus patients. (F) 
Replication measured by colorimetric BrdU incorporation assay (n=2-4). (G) Chemiluminescent caspase-3/7 activity 
(n=3).  (H) BCL2 protein levels by immunoblot (n=3).  (I-K) p16INKA, IL-6, and RRM2 transcript levels by RT-qPCR 
in gender-matched iPSC-ECs (n=3). (L) Immunoblot of BCL2 and p16 protein expression in male FRDA iPSC-ECs 
with forced overexpression via lentivirus of FXN (LV-FXN) compared to control (LV-GFP) (n=3). 
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5.5 Discussion 
Little attention has been paid to the role of FXN mutations in vascular cell types, in 
particular endothelial cells. By utilizing unique iPS-derived endothelial cells from patients with 
FRDA, we were able to identify the same metabolic and genotoxic stress in the setting of not only 
epigenetic but genetic FXN deficiency. Specifically, similar to primary PAECs with extended 
FXN inhibition, FRDA iPSC-ECs exhibited irreversible senescence, driven by disruption of Fe-S-
dependent replication and repair machinery and persistent DDR. Simultaneously, FXN mutations 
resulted in an imbalance in vasomotor effectors which favored a pathological vasoconstrictive 
phenotype. This shift, specifically the increased ET-1, may be partially dependent upon oxidative 
stress, similar to results in PAECs. Therefore, these results provide a mechanism of endothelial 
cell senescence and, coupled with our data on how epigenetic FXN deficiency promotes 
senescence and PH, support the notion that FXN deficiency may drive pulmonary vascular disease 
in this population.  
Our data join upon a few recent publications that have illustrated cellular senescence in 
non-vascular tissues; in these studies, the focus has largely been on how FXN-driven 
mitochondrial dysfunction induces irreversible growth arrest (224, 225). While our data do not 
preclude the added effects of persistent oxidative stress on genomic stability, our findings provide 
mechanistic evidence for the direct effects of Fe-S deficiency in replication and repair machinery 
by highlighting a reduction in intact DNA Pol  (Figure 23K), which relies on Fe-S center 
integration for catalytic subunit assembly (163). Here we argue FXN-specific attenuation of Fe-S-
dependent nuclear protein function propels endothelial genomic instability and thus DDR and 
cellular senescence; this notion is reinforced by a recent study describing replicative stress, 
including altered fork dynamics and DNA damage in fibroblasts and PBMCs collected from 
 102 
patients with germline biallelic mutations in POLD1 and POLD2 subunit genes (162). However, 
reduction of in intact DNA Pol  represents only one of several nuclear proteins that rely on Fe-S 
centers for structural and functional integrity. There are alternative nuclear mechanisms by which 
the endothelium may reach irreversible growth arrest , including telomere damage (29). RTEL1 is 
an Fe-S-containing helicase that aids in the stability and elongation of telomeres (154), and its 
function may be disrupted by FXN deficiency. For example, in FRDA, telomere shortening has 
been observed in PBMCs (306) and linked to senescence in fibroblasts (307). Separately, 
telomerase activity has been linked to PH (312), supporting the value of future studies focused on 
defining putative telomere-dependent senescence in endothelial cells and PH. 
Further study in our unique endothelial model of genetic FXN deficiency may provide 
insight into mitochondria-specific changes (Ca2+ signaling (224), mtDNA damage (208, 209, 214, 
215, 305) as well as the interaction between Fe-S cluster deficiency in the mitochondria versus the 
nucleus. Moreover, the inclusion of additional patient samples with varying GAA expansion 
mutation lengths could provide valuable information about the relationship between extent of FXN 
reduction and the consequential endothelial phenotypes.  
To build upon this in vitro data, future experimentation should focus on characterizing 
FXN-dependent endothelial senescence and PH in vivo. Available animal models with GAA repeat 
expansions (KIKO, YG8R) exhibit consistent molecular changes with FRDA but very mild tissue 
dysfunction (313). Endothelial-specific changes as well as a PH phenotype have not been 
investigated in any of these mutated mice. Cell-specific knockout mice most effectively 
recapitulate FRDA-specific tissue dysfunction, including muscle creatinine kinase Cre 
recombinase mice which development cardiomyopathy (212). Evaluation of the cardiopulmonary 
pressures along with lung tissue histology could provide insight into HCM-induced PH. With this 
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in mind, endothelial- and cardiomyocyte-specific Fxn knockout mice alone and in combination 
may provide insight into the independent or additive consequences of endothelial FXN deficiency 
in the setting of HCM. 
The contribution of pulmonary vascular disease in FRDA relatively ignored, despite 
observations of pulmonary vascular remodeling in FRDA patient tissues (200) coupled with data 
on HCM patients suffering from pre-capillary PH (105, 199). Our findings support the notion that 
intrinsic FXN-driven endothelial senescence may serve as a primary predisposing mechanism for 
PH that could be exacerbated by worsening left heart hemodynamics in FRDA and/or Group 2 PH 
overall. While patient samples, particularly lung tissue, are rare, making the study of endothelial-
specific phenotypes difficult, initial pathology reports from two new FRDA patients describe 
pulmonary vascular changes consistent with those described by James and Fisch (200) and 
suggestive of PH. Future studies are warranted to confirm endothelial senescence and clinically 
characterize hemodynamic instability over time in this population (pre- versus post- versus 
combined pre- & post-capillary PH) (NCT02594917). 
Together, these data may ultimately provide a foundation for the genetic identification of 
a novel cohort of FXN-deficient patients at risk for PH. Our data also suggest patients with FRDA 
and PH might benefit from pre-existing vasodilatory treatments (117) or emerging epigenetic 
therapies (149). Second, endothelial senescence is an emerging characteristic of vascular diseases 
and may be prevented with targeted pharmacologic intervention (32). Bolstered by our data using 
a senolytic to prevent FXN-driven PH (Figure 9), additional studies may help determine whether 
senolytics (300) or therapies that decelerate cellular senescence (e.g., rapamycin (298), resveratrol 
(231, 299)) may be beneficial for FRDA-associated PH. In fact, resveratrol treatment has provided 
some clinical benefit to FRDA patients in preliminary clinical trial but its mechanism remains 
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incompletely defined; our data on the importance of FXN-driven senescence may support the 
molecular benefits of this therapy (231). If so, given that senescence is an irreversible phenotype, 
appropriate therapeutic timing of these drugs will be crucial during PH development as will 
determination of administration efficacy in young versus old patients. 
In summary, this study represents the first step in understanding endothelial FXN 
deficiency in FRDA, providing foundational evidence for pulmonary vascular dysfunction 
independent of or additive to the often fatal HCM in this patient population. 
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6.0 Significance 
There has been a long standing controversy surrounding the shifting phenotypes of 
endothelial cells in PH with a predominating theory of early apoptosis followed by 
hyperproliferation (21, 23, 274). While metabolic reprogramming (1) and DNA damage (82, 88, 
92, 93, 314) have been reported in PH, identification of a common master regulator of these 
processes as well as their coordinated contribution to the dynamic endothelial pathophenotypes in 
this disease have been elusive. In response, we established FXN as a lynchpin in both 
mitochondrial and nuclear function in the pulmonary endothelium. Specifically, FXN deficiency 
independently promoted both Fe-S-dependent metabolic reprogramming (Chapter 2) as well as 
replication stress and DNA damage (Chapter 3). These data define a unifying upstream driver for 
these previously disparate pathological processes in the endothelium and expand our 
understanding of the consequences of Fe-S cluster deficiency beyond the mitochondria in PH 
pathogenesis. 
Correspondingly, our findings delineate a FXN-specific mechanism by which reversible 
cell cycle arrest induced by metabolic and replication stress evolved toward  DDR-dependent 
senescence in vitro. We then causatively linked this new endothelial phenotype to pulmonary 
vascular disease, showing endothelial FXN deficiency and senescence in mice propelled PH 
development while treatment with a senolytic prevented it (Figures 9 and 10). Importantly, FXN 
knockdown in smooth muscle cells did not induce the genomic stress that predisposed to 
senescence in endothelial cells and thus did not induce PH development in vivo (Figure 19), 
illustrating the distinctive role of Fe-S cluster deficiency in the pulmonary endothelium. These 
results are among the first to describe endothelial senescence as a true pathological driver in PH 
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and offer an Fe-S-driven molecular explanation of the spatio-temporal nature of endothelial 
pathobiology in this disease.  
In Chapter 4, we established how triggers associated with different PH subtypes, such as 
chronic hypoxia (Group 3) (243) and inflammation (Group 1) (44), induced HIF--mediated 
regulation of FXN transcription via CTCF and BRD4 epigenetic modification in pulmonary 
endothelial cells (Figures 16-18). While in opposition to previous data supporting HIF--
dependent increases in FXN in hypoxic non-vascular cell types (282, 283), FXN joins other Fe-S 
biogenesis genes dynamically regulated by HIF- in the pulmonary endothelium (70-72). 
Bolstering this in vitro data, we illustrated reduction in FXN alongside elevated p16INKA expression 
in animal models and patient lung tissues across multiple WSPH groups (Figure 14 and 
Supplemental Data Figure 20), illustrating the relevance of acquired FXN deficiency and its 
coordination of endothelial senescence in Group 1, 2, and 3 PH. Moreover, using a senolytic, we 
defined the causative importance of endothelial senescence in disease development in different PH 
murine models (Figure 15). Notably, the identification of FXN-dependent mechanism in a model 
of Group 2 PH-HFpEF provides a novel molecular explanation for the development of PH in left 
heart disease that is not solely driven by vascular reactions to increased left heart afterload (105, 
113). These data may provide the basis for a mixed PH phenotype in which “Group 1-like” primary 
vascular dysfunction contributes to Group 2 PH (i.e., combined pre- and post-capillary 
hemodynamic alterations) (112). 
While mitochondrial dysfunction (203, 204), oxidative stress and DNA damage (208, 209, 
214-217), and more recently senescence (224, 225) have all been described in non-vascular tissues 
in the context of FRDA, the effects of FXN mutations in endothelial biology have not been 
characterized. Utilizing unique patients iPS-derived endothelial cells, we confirmed that genetic 
 107 
FXN deficiency and its metabolic and genotoxic consequences similarly converged on DDR-
associated senescence and endothelial dysfunction (Chapter 5). In particular, FXN mutations 
attenuated the Fe-S-dependent structural integrity of DNA Pol  and thus disrupted functional 
replication and repair processes (Figure 23). These results highlighted how genomic damage in 
FRDA may be driven not only by oxidative stress but also direct insufficiency of nuclear Fe-S-
containing proteins. More broadly, HCM cardiomyopathy drives mortality in most FRDA patients 
(197); yet, PH and cardiopulmonary complications as a whole in FRDA have been surprisingly 
underreported (201, 202). However, a single case report from over fifty years ago described 
pulmonary arteriolar vasculopathy in this population (200), consistent with the fact that up to 50% 
of patients with HCM in general suffer from Group 2 PH (105, 315). Therefore, these results offer 
a plausible explanation for a predisposition for PH, independent of or additive to left ventricular 
dysfunction, and ultimately may contribute to the identification of a group of FRDA patients with 
PH. 
By characterizing a shared mechanism across diverse WSPH groups, our FXN-driven 
model may provide several targets for diagnostic and therapeutic intervention. First, given that we 
expand upon the comprehensive landscape of epigenetic factors involved in FXN regulation, our 
data endorse epigenetic pharmacotherapies, including BRD4 inhibitors (149), that may work in 
multiple PH subtypes, at least in part, by increasing FXN levels in the pulmonary endothelium. 
Second, endothelial senescence is an emerging characteristic of vascular diseases and may be 
improved with targeted pharmacologic intervention (32). Bolstered by our data using a senolytic 
to prevent FXN-driven PH (Figures 9 and 15), additional studies may help determine whether 
senotherapies (297, 300) or therapies that decelerate cellular senescence (e.g., rapamycin (298), 
resveratrol (299)) may be beneficial in patients with Group 1 as well as Group 2 and 3 PH.  
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Moreover, these data may similarly provide  therapeutic insight for FRDA. First, our results 
on HIF--dependent epigenetic FXN reduction provide insight into the potential interaction 
between hypoxia and genetic FXN deficiency. While a recent study suggests sustained low oxygen 
tension improves Fe-S biogenesis in FXN-deficient models and proposes the symptomatic benefit 
of chronic hypoxic exposure in FRDA patients (245), our cumulative data oppose this notion. 
Instead, anaerobic conditions did not rescue pulmonary endothelial Fe-S cluster formation 
(Supplemental Data Figure 5A). Correspondingly, several PH manifestations (Supplemental Data 
Figure 5), including hemodynamic instability (Figure 9G-H), worsened with a ‘two-hit’ model of 
endothelial FXN knockdown and chronic hypoxia, cautioning against the systemic use of hypoxia 
treatment in FRDA which would not account for differences in cell-specific responses to hypoxia 
and instead could accelerate a patient’s predisposition to PH. Instead, by demonstrating endothelial 
vasomotor tone imbalance and senescence in the context of genetic FXN deficiency (Figure 23), 
we endorse the potential use of existing PAH-specific vasodilatory treatment (117) as well as 
senotherapies for cardiopulmonary disease in FRDA (301). 
In total, this work offers a pivotal endothelial-driven mechanism of across multiple PH 
etiologies, adding complexity to the spatio-temporal endothelial phenotypes in this vascular 
disease. Furthermore, our data solidify the regulatory actions of FXN in Fe-S biology, metabolism, 
and genomic integrity and offering compelling targets for more effective diagnostics and 
therapeutics in this deadly disease.  
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Figure 25. Working mechanism of FXN-dependent endothelial senescence in pulmonary hypertension. 
HIF- - hypoxia inducible factor alpha, CTCF - , BRD4 – bromodomain-containing protein 4, FXN – frataxin, Fe-S 
– iron-sulfur, OXPHOS – oxidative phosphorylation, ROS – reactive oxygen species, DDR – DNA damage response, 
SASP – senescence-associated secretory phenotype 
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7.0 Future Directions 
Short term experiments to address the limitations of the presented data have been described 
in their corresponding Discussion sections (2.5, 3.5, 4.5, 5.5). More broadly, our results inspire 
new questions relevant to endothelial Fe-S biology and the translational implications for our FXN-
dependent mechanism in FRDA and in PH generally. 
7.1 Mechanistic insight into Fe-S-dependent endothelial phenotypes 
7.1.1 Determine the interaction of FXN-dependent mitochondrial versus nuclear 
dysfunction 
Our data demonstrated deficiency of mitochondrial FXN independently coordinates the Fe-
S-dependent disruption of mitochondrial respiration and nuclear replication (Chapter 2, 3, and 5), 
supporting a specific role for FXN in nuclear Fe-S integrity. However, the relative contributions 
of attenuated organelle function to resultant endothelial senescence is not yet known. Experiments 
that determine the importance of metabolic reprogramming versus DNA damage in PH may 
provide insight into the value of metabolic versus genomic treatment intervention. To begin to 
understand this interaction, bi-directional cross-talk between the mitochondria and nucleus must 
be considered. Our preliminary data suggested that the FXN-dependent elevation in mitochondrial 
ROS does not acutely increase nuclear replication stress, DDR, and cell cycle arrest (Supplemental 
Data Figure 11C-D). However, mitochondria-driven oxidative stress may still contribute to 
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ongoing DNA damage in conditions of chronic FXN deficiency (316); and this idea is supported 
by the presence of oxidative damage of nuclear DNA in patients with FRDA (214-217).  
Beyond mitochondrial ROS, Fe-S-specific nuclear dysfunction may conversely attenuate 
mitochondrial metabolism and dynamics. For example, Sahin et al. have shown that telomere 
dysfunction decreased mitochondrial biogenesis via a p53-PGC1 axis (317). Decreased 
mitochondrial biogenesis has been observed in FRDA models and patient tissues (248). Therefore, 
it is possible that the mechanism described by Sahin and colleagues could be driven by the 
disruption of RTEL1, the Fe-S-containing helicase that aids in the stability and elongation of 
telomeres (154), in conditions of FXN deficiency. The implications for FXN-dependent telomere 
instability or attenuated mitochondrial biogenesis have not been explored in endothelial cells. 
Separately, Fang and colleagues describe a mechanism by which insufficient nucleotide excision 
repair (NER) by XPA decreased mitophagy via PARP1-SIRT1 axis. Notably, hierarchical 
clustering of XPA and other diseases associated with NER pathways (e.g., Cockayne syndrome 
and ataxia telangiectasia) was associated with phenotypically similar mitochondrial diseases 
including FRDA (318). Given that XPD, another NER protein, is reliant on Fe-S clusters for 
helicase function (319), FXN-dependent alterations in NER may contribute to defective 
mitophagy. Both of these studies highlight how nuclear damage shapes or even propagates 
mitochondrial dysfunction and suggest FXN-dependent genotoxicity may in turn disrupt 
mitochondrial integrity.   
Altogether, the complexities of bi-directional signaling between these organelles may 
suggest the need for combination therapies deficiency to simultaneously preserve mitochondrial 
and nuclear integrity in the setting of Fe-S cluster. Moreover, the potential reciprocal relationships 
between these organelles may favor targeting FXN directly and require the identification of new 
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drugs in addition to potentially emerging epigenetic therapies for FRDA (e.g., HDAC inhibitors 
(187, 226, 227)) and for PH (e.g., BRD4 inhibitors (149)).  
7.1.2 Interrogate the interaction between Fe-S biogenesis genes in the pulmonary 
endothelium 
Our laboratory has now definitively demonstrated that deficiencies of multiple Fe-S cluster 
assembly proteins independently drive the development of PH. In particular, HIF- dynamically 
controls acquired reduction of ISCU1/2, BOLA3, and now FXN in hypoxic conditions (70-72) 
(Figure 17). This in vitro regulation is reinforced by end-stage animal and patient lung tissues, 
particularly hypoxic Group 3 PH models, that exhibit decreased pulmonary endothelial expression 
of these genes simultaneously (70-72) (Figure 14 and Supplemental Data Figure 20). However, 
the interaction between these assembly proteins and their convergence on PH has not been 
characterized. 
To start, while certain metabolic phenotypes are conserved, certain Fe-S-dependent 
processes seem to differ between these biogenesis genes. Specifically, separate from synthetic role 
of ISCU1/2 and FXN in Fe-S biogenesis, BOLA3 acts a scaffolding protein that inserts previously 
synthesized Fe-S cofactors into a subset of mitochondrial proteins including lipoate synthase and 
ETC complexes (156, 176, 320). This process suggests that BOLA3-mediated Fe-S integration is 
dependent upon ISCU1/2, and this notion is reinforced by acquired and genetic deficiencies of 
each of these three genes resulting in attenuated mitochondrial respiration. However, disruption of 
the glycine cleavage system and ensuing hyperglycinemia driven by acquired and genetic BOLA3 
deficiency (72) is not a predominant phenotype in our data (Supplemental Data Figure 4F) or in 
patients with FRDA. Therefore, despite being positioned “downstream” of ISCU1/2 and FXN, 
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BOLA3 exerts specific and independent effects on metabolism, suggesting Fe-S biogenesis is a 
complex process rather than a linear one.  
Similarly, despite each coordinating a Warburg-like shift and oxidative stress, our results 
support that each protein can exert unique and predominate outcomes on endothelial phenotype 
(proliferation promoted by BOLA3 deficiency (72) vs. apoptosis by ISCU deficiency (70) vs. 
senescence by FXN deficiency). In addition to functional differences in the process of Fe-S cluster 
formation, several factors including timing, anatomic position, and disease etiology may explain 
these differences. First, a more thorough examination of each of these assembly proteins over the 
course of disease may provide insight into the time-dependent coordination of Fe-S gene 
biogenesis expression and corresponding endothelial outcomes. For example, it is possible that 
ISCU1/2 down-regulation precedes BOLA3 reduction partially explaining apoptotic injury in early 
disease hyperproliferation in late-stage lesions in PAH (21). Second, the employment of 
technologies (e.g., single-cell RNA sequencing) that interrogate diverse endothelial sub-
populations along the pulmonary vascular tree may reveal spatial differences in expression of these 
assembly genes and endothelial phenotype. Our data highlighted the shared contribution of binding 
partners, ISCU1/2 and FXN, to Fe-S-dependent processes outside of the mitochondria with rescue 
of replication stress and reversible growth arrest requiring forced expression of both proteins in 
hypoxic and inflammatory conditions when the endogenous protein levels are reduced 
(Supplemental Data Figure 12), demonstrating the interdependency of this network. Given that 
genotoxic stress can result in either apoptosis or senescence (87), it is conceivable that the 
divergence between apoptotic or senescent phenotypes in the pulmonary endothelium is partially 
dependent upon the relative spatio-temporal balance of these two Fe-S biogenesis genes. Lastly, 
these Fe-S-dependent endothelial phenotypes may change based upon PH etiology. Our study 
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expanded upon the importance of FXN and Fe-S cluster deficiency in multiple subtypes, including 
Group 2 PH; thus, comprehensive expression analysis across WSPH classifications will help 
answer whether FXN-dependent endothelial senescence plays a larger role in this lesser 
characterized, age-associated subtypes compared to other biogenesis genes. 
Altogether, spatio-temporal, etiological, and functional differences in ISCU1/2, BOLA3, 
and FXN-dependent endothelial dysfunction may partially explain the shifting phenotypes present 
in PH. This specific molecular signature may provide diagnostic and therapeutic insight with the 
advent of Fe-S-specific therapies. 
7.1.3 Explore the relationship between endothelial FXN deficiency and iron handling  
Mitochondrial iron handling includes not only Fe-S cluster formation but heme synthesis 
and iron storage (321). Despite FXN’s roles in Fe-S assembly (167), heme synthesis (182), and 
iron storage (180), iron imbalance as a result of FXN deficiency is controversial and incompletely 
defined. Mitochondrial iron overload was observed in tissues from FRDA patients and 
hypothesized as driving pathogenic oxidative stress via the Fenton reaction (205-207); in response, 
iron chelators have been explored as a potential therapeutic option but with variable results (240). 
Opposing studies suggest iron loading is merely an epiphenomenon (212) and even support that 
initial iron regulator protein 1 (IRP1)-mediated iron loading protects mitochondrial function in 
instances of FXN deficiency (322). Beyond cellular iron distribution, the heme synthesis enzyme 
ferrochelatase activity relies upon FXN and Fe-S biogenesis (182); however, FRDA patients do 
not have anemia despite the potential for FXN-dependent disruption of heme, possibly suggesting 
tissue-specific differences in iron handling (323). How FXN deficiency alters mitochondrial iron 
homeostasis and, in turn, how aberrant iron handling affects pulmonary endothelial phenotype, 
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particularly irreversible senescence, requires further study. There is some evidence that connects 
senescence with decreased heme oxygenase-1, the rate-limited enzyme involved in heme 
degradation (324, 325), which has already been linked to lung diseases including PH (326). 
However the complete connection between heme balance and senescence is not defined. 
Additional experiments exploring acute versus chronic heme homeostasis in FXN-deficient 
endothelial models may provide insight into another iron-dependent process that converges on 
irreversible cellular senescence. 
More broadly, whether FXN deficiency and iron imbalance in the pulmonary endothelium 
are relevant to PH is unclear. Data supports the association of iron deficiency and PAH (327, 328), 
and clinical trials for iron replacement in Group 1 PAH (64, 148) and Group 3 PH (329) are in 
progress. Given that our data reinforces endothelial Fe-S cluster deficiency as a driver of PH (70-
72), the broader relationship between FXN deficiency, endothelial iron handling, and disease 
should be explored. Specifically, it is not clear how systemic iron deficiency directly impacts FXN 
and Fe-S biogenesis or influences intracellular mitochondrial iron handling in the context of pre-
existing FXN deficiency. However, mice lacking the Fe-S cluster-dependent protein iron 
regulatory protein 1 (IRP1), Irp1-/-, develop PH in iron-deficient conditions (330), potentially 
indicating FXN-driven Fe-S deficiency and systemic iron deficiency would worsen disease. 
However, whether iron supplementation in FXN-dependent PH would an effective long-term 
treatment, given the potential for ineffective biogenesis and mitochondrial iron accumulation, is 
not yet understood. In fact, given that opposing data in sickle cell disease suggests iron overload 
may be a causative trigger in PH, our data may caution against excessive iron repletion (331). In 
total, our data on Fe-S integrity in this disease add to the complexity of intracellular and systemic 
iron balance in PH. 
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7.1.4 Define reversible versus irreversible FXN-driven endothelial phenotypes  
The reversibility of pulmonary vascular remodeling in PH across WSPH groups is largely 
undefined. Studies have demonstrated the reversal of PH in different animal models following 
hemodynamic unloading (332, 333). These studies mirror the reversible nature of specific PH 
groups such as congenital heart disease (CHD)-associated PAH following surgical correction (334) 
and Group 2 PH associated with congestive heart failure following placement of a left ventricular 
assist device (LVAD) (335). Conversely, certain patients experience persistent Group 2 PH due to 
valvular disease even after aortic valve replacement (336) or mitral balloon valvuloplasty (337). 
Similarly, a significant subset of corrected CHD patients experience PAH (338) and this 
irreversible phenotype has been linked to and anti-apoptotic endothelium (339). Beyond 
hemodynamic unloading, certain preclinical models driven by hypoxic and inflammatory triggers 
exhibit spontaneous reversal of smooth muscle remodeling over while models with significant 
neointimal proliferation do not, suggesting reversibility may be dependent upon shifting 
pulmonary endothelial phenotypes (340). The temporal molecular changes in the pulmonary 
endothelium that define reversible versus irreversible PH are not known.  
Our in vitro data illustrated a FXN-dependent transition from reversible growth arrest to 
irreversible endothelial senescence (Chapter 3). Specifically, experiments rescuing FXN 
(alongside its binding partner ISCU1/2) were able to reverse acute replication stress and cell cycle 
arrest (Supplemental Data Figure 12) but were ineffective when endothelial senescence was 
already present (Supplemental Data Figures 21B and 24L), suggesting a potential window in which 
FXN-driven phenotypes can be reversed. In this way, temporal insight into FXN-driven 
endothelial evolution may provide molecular insight into reversible versus irreversible endothelial 
phenotypes and thus stages of PH pathogenesis. Moreover, these data may highlight the 
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importance of therapeutic selection dependent upon the reversibility of endothelial phenotype. For 
our study specifically, additional in vivo experiments are required to confirm this evolution in our 
endothelial Fxn-/- mouse model and to compare the efficacy of FXN and ISCU1/2 replacement to 
senolytic treatment in preventing or reversing hemodynamic instability in different PH animal 
models (Figures 15). Future studies exploring how these separate treatments reverse pre-existing 
pulmonary vascular disease will be particularly important given that PH patients often have 
advanced disease at the time of therapy initiation (341).  
Clinically, characterization of this time-dependent mechanism will provide insight into the 
shifting pathophenotypes of the pulmonary endothelium and may ultimately inform treatment 
selection based upon endothelial disease stage. Confirming the relevance of this evolving 
endothelial mechanism in patients over the course of disease will be challenging. 
Immunofluorescent co-staining and single-cell RNA sequencing in post-mortem tissues coupled 
with expression analysis in blood outgrowth endothelial cells (342, 343) represent possible 
methods to approach this problem; however, feasible assessment of disease stage based upon 
endothelial phenotype to inform corresponding treatment choice will likely require the 
development of more sophisticated diagnostic tools.   
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7.2 Translational implications of FXN-dependent endothelial senescence 
7.2.1 Establish the senescence-associated secretory phenotype in endothelial FXN 
deficiency 
Diagnosis and therapeutic selection in PH are largely dependent upon invasive 
hemodynamic testing. Noninvasive measurements are currently limited to cardiac brain natriuretic 
peptide (BNP) and the N-terminal fragment of proBNP (NTproBNP) levels, which associate with 
exercise capacity (e.g. 6MWD), hemodynamic measurements (e.g., mPAP, PVR), functional class, 
and mortality for PAH (344, 345). The search for more definitive circulating biomarkers that could 
aid in the determination of diagnosis, prognosis, and therapeutic selection as well as response is 
ongoing (346, 347). Specifically, several inflammatory markers have been found to be elevated in 
the plasma of PAH patient; in particular, IL-6 levels predict patient mortality (44, 278-280).  
Separately, the senescence-associated secretory phenotype (SASP) includes an assemblage 
of pro-inflammatory molecules such as cytokines and metalloproteases that reflect and propagate 
the underlying tissue dysfunction; these markers may differ depending upon the stage of 
senescence, inciting stressors, and tissue type (281). Therefore, SASP profiles may hold potential 
as biomarkers for aging and age-related diseases with some level of specificity.  
Our limited data identified potential SASP markers by showing elevated levels of IL-6 and 
TNF driven by FXN deficiency (Figures 9F-G and Supplemental Data Figure 24J). As previously 
mentioned, further experimentation is required to define a complete FXN-dependent SASP profile 
as well as its subsequent control of immune cell recruitment and inflammatory signaling in PH. 
However, our genetic models of endothelial FXN deficiency provide an opportunity to screen for 
a cohort of secreted markers that could potentially be confirmed in the plasma of FRDA patients 
 119 
as well as PH patients from diverse WSPH groups. In this way, Circulating SASP markers could 
reflect the underlying pulmonary endothelial evolution toward senescence and therefore provide 
value information about reversible and irreversible stages of disease, and thus the potential 
effectiveness of therapies that increase FXN versus remove senescent cells. Correlative data 
between these secreted inflammatory markers and clinical parameters of PH (e.g., 6MWT, 
NYHA/WHO functional class) could improve prognostication as evidenced by the existing 
predictive value of IL-6 and other cytokines (44, 278-280). Overall, characterization of SASP 
panels support a move towards minimally noninvasive, precision medicine-based practices in the 
diagnostic and therapeutic management of PH.  
7.2.2 Establish whether endothelial FXN deficiency predisposes to pulmonary hypertension 
independent of left heart dysfunction 
Identification of a senescent phenotype coordinated by FXN mutations in iPSC-ECs 
(Chapter 5) provides a potential endothelial mechanism for pulmonary vascular disease in FRDA. 
Although underreported in FRDA, HCM is often accompanied by Group 2 PH with a certain subset 
of patients exhibiting combined pre- and post-capillary PH (105). Therefore, the relative 
contribution of endothelial versus myocardial FXN deficiency on PH development is unclear. 
Furthermore, whether genetic FXN deficiency in the pulmonary endothelium contributes to this 
mixed, Group 1-like hemodynamic phenotype in Group 2 PH is not yet known. To begin to address 
this question, I propose using tissue-specific conditional Fxn knockout mice: Fxn flox/flox mice 
(212) expressing VE-Cadherin (Cdh5(PAC)-CreERT2+) (261) and/or -myosin heavy chain Cre 
recombinase (MHC-MerCreMer+/+) (262). By evaluating the individual and combined 
endothelial and cardiomyocyte FXN knockout models compared to Fxn f/f controls, the 
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independent or synergistic effects of endothelial FXN deficiency on pulmonary vascular disease 
can be established. These animal experiments could supplement studies aiming to better 
characterize PH in the FRDA population (NCT02594917). 
Given that animal models of Group 2 PH due to HFpEF showed decreased FXN and 
increased p16INKA (Figure 14E-F and Supplemental Data Figure 20E-F), our findings support the 
notion that intrinsic FXN-driven endothelial senescence may predispose to PH in setting of left 
heart disease more generally. Assessing this mechanism in other acquired models of left 
ventricular dysfunction would confirm its application to a broader set of cardiovascular diseases. 
More work is also required to either confirm HIF--dependent epigenetic modulation or 
characterize new mechanistic control of FXN down-regulation in left heart disease. Additionally, 
the identification of new triggers associated with Group 2 PH (e.g., elevated left ventricular filling 
pressures) reduce FXN expression requires further studies. In summary, our data extend the 
importance of endothelial Fe-S biology to FRDA-induced HCM and more broadly Group 2 PH, 
providing new molecular targets in this lesser characterized but increasingly prevalent population. 
These findings may also provide an opportunity to clarify the molecular differences between pre-
, post-, and combined pre- and post-capillary PH. 
7.2.3 Determine if FXN-dependent senescence in the myocardial endothelium promotes 
ventricular dysfunction 
While our data have focused on the role of FXN-dependent senescence in the pulmonary 
endothelium, genetic FXN deficiency may promote similar pathology in extrapulmonary vascular 
beds. In particular, a few case reports have provided clinical and histologic evidence of some large 
artery stenosis (200, 348) as well as panvascular remodeling in the smaller myocardial vessels 
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(200) in the setting of FRDA. These findings are reinforced by decreased myocardial perfusion 
reserve index on cardiac MRI in patients with FRDA compared to healthy controls; interestingly, 
this reduction in myocardial perfusion was observed prior to development of HCM (349). 
However, cumulative data confirming potential coronary or microvascular disease in the FRDA 
population is lacking because diagnostic assessment and the majority of research in the field have 
been focused on the predominant HCM phenotype. Supporting these limited data in FRDA-
induced HCM, microvascular dysfunction is common, predates left ventricular dysfunction,  and 
predicts clinical deterioration and mortality in patients with HCM generally (350, 351). The 
diseased microvasculature is characterized by increased vessel wall thickness and fibrosis and 
decreased lumen diameter (350, 352). 
To this point, FXN deficiency may contribute to the underlying microvascular remodeling 
in cardiac tissue and, in turn, induce or worsen HCM development in FRDA.  While endothelial 
Fxn-/- mice do not exhibit gross alterations in left ventricular function (i.e., ejection fraction, 
fractional shortening) (Supplemental Data Figure 13D-F) , LV and RV pressure-volume loop 
analysis could provide a more detailed picture of subclinical left ventricular dysfunction that may 
predispose to HCM. Moreover, these measurements in mice treated with and without the senolytic 
may endorse the use of senotherapies to prevent microvascular dysfunction. More thorough 
histologic evaluation of RV and LV coronary vessels and the microvasculature from patients with 
FRDA would support these notions. It is also possible that FXN-dependent endothelial senescence 
promotes microvascular disease in other genetic and acquired forms of HCM, beyond FRDA. 
More broadly, cellular senescence represents an emerging mediator in peripheral vascular disease 
(31, 275); therefore, despite the potential endothelial heterogeneity, FXN-dependent senescence 
may also contribute to pathologies outside of the cardiopulmonary circuit.  
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7.2.4 FXN deficiency, sex differences, and pulmonary hypertension  
Studies to understand the PAH gender paradox of increased prevalence and also survival 
in female patients are ongoing with a focus on the importance of sex hormones in the context of 
pulmonary vascular and right ventricular function (96, 353). Very little preclinical or clinical data 
exists describing the effects of sex on Group 2-5 PH. Separately, relevant to Fe-S-dependent PH, 
Niihori et al. recently demonstrated that a rat model with the human MMDS1 mutations drove sex-
specific disease development (354); more work is required to determine if the PH phenotype in 
MMDS1 patients occurs more often in females versus males similar to this preclinical animal 
model (175). Together, these data lead to questions about whether FXN and Fe-S cluster deficiency 
contribute to sex differences in PH development.  
Speaking first to genetic FXN deficiency, our data in gender-matched iPS-derived 
endothelial cells from healthy versus FRDA patients illustrated comparable metabolic and 
genomic phenotypes (Chapter 5). These results suggest sex chromosome differences do not 
contribute to FXN-dependent endothelial senescence but do not preclude sex-driven differences 
due to sex hormones. More generally, age of onset and neurological disease severity in FRDA are 
largely driven by trinucleotide repeat mutation length (183, 195, 196); sex has not been identified 
as a major risk factor for the development of disease phenotypes. However, a few preclinical 
studies explore the benefits of the female sex hormone, estrogen, on mitochondrial function in 
conditions of FXN mutations (355, 356). Also, a recent study demonstrated female patients 
exhibited increased ejection fraction and slightly decreased left ventricular poster wall thickness 
at diastole (LVPWd) compared to male patients after adjusting for trinucleotide expansion length 
and age of onset (357), suggesting potential sex differences in HCM. As previously mentioned, 
PH in FRDA-induced HCM has not been adequately documented; however, if more attention were 
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given to characterizing clinical PH in this population, it is possible that gender-driven differences 
independent of or additive to HCM may affect morbidity and mortality. There is some evidence to 
support that females represent a greater proportion of patients with Group 2 PH (due to HFpEF 
(358)); however, additional studies are required to understand the sex-specific differences in 
acquired FXN deficiency and its coordination of endothelial senescence across diverse PH 
etiologies. 
7.2.5 Aging, FXN-dependent senescence, and pulmonary hypertension  
The age of patients diagnosed with PAH has steadily risen in recent decades (95, 359), and 
interest in age-associated alterations in pulmonary vascular function has grown (302, 360). 
Moreover, the increasing prevalence of Group 2 and 3 PH is partially driven by an increase of age-
associated diseases in the population (100). However, the molecular underpinnings of age-
dependent pulmonary vascular disease have not yet been defined. In general, cellular senescence 
contributes to aging and age-related diseases by imposing irreversible growth arrest that prevents 
tissue-repair capacity and producing a senescence-associated secretory phenotype (SASP) that 
promotes tissue inflammation (300, 361, 362). Notably, emerging evidence supports the efficacy 
of therapeutically targeting these pathogenic cells using senotherapies (32, 297).  
 
Several endogenous stressors, including metabolic and genotoxic stress, converge on 
irreversible senescence; both of these examples have already been associated with aging (30, 35-
37, 363) and separately linked to PH (1, 81). Our data highlight FXN as an upstream driver of 
these pathological processes related to senescence and aging; moreover, our results causatively 
link cellular senescence to multiple subtypes of PH. With this in mind, FXN-dependent endothelial 
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senescence could also serve as a key molecular mechanism for PH as patients age. Furthermore, 
while FRDA is not traditionally considered an age-related disease, our findings illustrated FXN-
dependent genotoxicity due to specific disruption of the Fe-S-containing nuclear protein, DNA Pol 
 (Figure 23K), strengthening the association between FRDA and several progeroid conditions 
caused by loss-of-functions mutations in these same Fe-S-containing nuclear proteins (159-162). 
Connecting genetic FXN deficiency to endothelial senescence, suggests FXN mutations may exert 
enough stress to mimic pathologic aging of the endothelium. Whether FXN deficiency and 
endothelial senescence promote age-related disease progression in PH or specifically in FRDA is 
not yet known. To begin to address these questions, models of PH, FRDA, or even models of 
physiologic or accelerated aging could be evaluated for an association between FXN-dependent 
senescence in the pulmonary endothelium and worsening pulmonary vascular dysfunction with 
increasing age.  
Investigating PH perturbations through the lens of aging may provide valuable 
opportunities to adapt PH management in an increasingly older population. With the continued 
development of senotherapies (32, 297), our data place pulmonary vascular disease on the list of 
conditions that respond to these drugs. Thus, these finding may provide a novel therapeutic 
strategies for those patients with no existing therapeutic options, particularly patients with Group 
2 and 3 PH and FRDA patients with potential cardiopulmonary involvement. 
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Appendix A  
Table 1. Taqman primers 
Targets Species Assay ID 
ACTB 
Human Hs99999903_m1 
Rat Rn00667869_m1 
Mouse Mm02619580_g1 
BRD2 Human Hs01121986_m1 
BRD4 Human Hs04188087_m1 
CDH5 Human Hs00901465_m1 
CDKN2A 
Human Hs00923894_m1 
Rat Rn00580664_m1 
Mouse Mm00494449_m1 
CTCF Human Hs00902016_m1 
EDN1 Human Hs01574659_m1 
EPAS1 Human Hs01026149_m1 
FXN 
Human Hs00175940_m1 
Rat  Rn01501403_m1 
Mouse Mm00784016_m1 
HIF1A Human Hs00153153_m1 
IL1B Human Hs01555410_m1 
IL6 Human Hs00174131_m1 
ISCU Human Hs00384510_m1 
NOS3 Human Hs01574659_m1 
PECAM1 Human Hs01065279_m1 
SIN3A 
Human Hs00411592_m1 
Rat  Rn01417686_m1 
Mouse Mm00488255_m1 
TNFA Mouse Mm00443258_m1 
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Table 2. Antibodies 
Target Company Cat. No. Species Concentration 
Immunoblot 
ATM Cell Signaling Technologies 2873T Rabbit 1 / 1000 
p-ATM (Ser1981) Abcam ab81292 Rabbit 1 / 1000 
ATR Cell Signaling Technologies 2790S Rabbit 1 / 1000 
p-ATR (Ser428) Cell Signaling Technologies 2853T Rabbit 1 / 1000 
β-actin Santa Cruz Biotechnologies sc47778 Mouse 1 / 1000  
BRD2 Abcam ab139690 Rabbit 1 / 1000 
BRD4 Abcam ab128874 Rabbit 1 / 1000 
CHK1 Cell Signaling Technologies 2360S Mouse 1 / 1000 
p-CHK1 (Ser345) Cell Signaling Technologies 2341T Rabbit 1 / 1000 
CHK2 Cell Signaling Technologies 2662T Rabbit 1 / 1000 
p-CHK2 (Thr68) Cell Signaling Technologies 2661T Rabbit 1 / 1000 
CTCF Abcam ab70303 Rabbit 1 / 1000 
FXN Abcam ab110328 Mouse 1 / 200 
γH2AX (Ser139) Abcam ab11174 Rabbit 1 / 500 
MCM2 Cell Signaling Technologies 3619T Rabbit 1 / 1000 
NOS3 Santa Cruz Biotechnologies sc376751 Mouse 1 / 1000 
CDKN2A/p16INKA Abcam ab108349 Rabbit 1 / 1000 
p21Cip1 Abcam ab188224 Rabbit 1 / 1000 
p53 Cell Signaling Technologies 9282T Rabbit 1 / 500 
RPA32 Cell Signaling Technologies 2208T Rat 1 / 1000 
p-RPA32 (Ser4/Ser8) Bethyl Laboratories A300-245A-M Rabbit 1 / 500 
RPA70/RPA1 Cell Signaling Technologies 2267S Rabbit 1 / 1000 
Immunofluorescent staining 
CD31 Santa Cruz sc376764 Mouse 1 / 100 
CD144 Abcam ab33168 Rabbit 1 / 100 
BrdU BD Biosciences 347580 Mouse 1 / 50 
BrdU Abcam ab6326 Rat 1 / 75 
FXN Abcam ab113691 Mouse 1 / 100 
CDKN2A/p16INKA Abcam ab108349 Rabbit 1 / 100 
αSMA Abcam ab21027 Goat 1 / 350 
vWF Abcam ab8822 Goat 1 / 50 
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Table 3. Differential gene expression from long RNA sequencing 
GeneID baseMean log2FC lfcSE stat pvalue padj 
RIBC2 23.117334 3.569134422 0.40084769 8.90396658 5.39E-19 2.37E-17 
SUV39H1 51.181708 3.226929067 0.68461537 4.71349198 2.44E-06 2.52E-05 
RRM2 2133.2882 2.93278685 0.13532202 21.67265 3.72E-104 3.85E-101 
PLK1 555.19806 2.875692761 0.24310308 11.8291089 2.76E-32 3.05E-30 
MCM2 1033.9317 2.803988837 0.23731556 11.8154444 3.25E-32 3.57E-30 
MND1 56.974405 2.748418509 0.2565398 10.7134196 8.80E-27 6.90E-25 
MCM10 371.18842 2.743411594 0.13004953 21.0951293 8.82E-99 6.73E-96 
PBK 658.13171 2.705440546 0.1627312 16.6252114 4.58E-62 1.44E-59 
HIST1H2AI 3318.1463 2.69730566 0.21432872 12.5849005 2.56E-36 3.34E-34 
FAM111B 359.46324 2.68469146 0.30452109 8.81611018 1.19E-18 4.97E-17 
KIF14 447.10367 2.674996165 0.19380813 13.8022911 2.47E-43 4.02E-41 
CCNA1 1079.2252 2.655432007 0.15922976 16.6767314 1.94E-62 6.23E-60 
PKMYT1 174.80079 2.634660924 0.27584973 9.55107296 1.28E-21 7.00E-20 
CLSPN 460.63331 2.621023469 0.12221305 21.4463471 4.94E-102 4.21E-99 
AURKB 441.27513 2.6049598 0.14511667 17.9507959 4.73E-72 2.14E-69 
HMMR 725.1965 2.575849472 0.2423893 10.6269108 2.23E-26 1.70E-24 
EXO1 216.6497 2.570756578 0.30475354 8.43552651 3.30E-17 1.25E-15 
E2F2 71.314683 2.559136062 0.2884234 8.8728448 7.13E-19 3.08E-17 
AC112777.1 44.199984 2.557590933 0.2776906 9.21021785 3.25E-20 1.60E-18 
DEPDC1B 252.40774 2.549993068 0.22654773 11.2558758 2.17E-29 2.00E-27 
AC112198.2 26.976993 2.549583269 0.41371374 6.16267493 7.15E-10 1.29E-08 
ZNF367 210.45391 2.548969437 0.25452612 10.0145691 1.32E-23 8.25E-22 
CDC6 664.70275 2.537647741 0.16269008 15.5980489 7.51E-55 1.75E-52 
E2F8 110.39371 2.514100594 0.22948874 10.955224 6.27E-28 5.35E-26 
HIST1H3J 1859.1948 2.512567742 0.21516153 11.6775881 1.66E-31 1.74E-29 
HIST1H1A 193.75132 2.507398563 0.1875544 13.3689136 9.19E-41 1.40E-38 
CDC20P1 63.554892 2.491629084 0.26057261 9.56212973 1.15E-21 6.31E-20 
HIST1H1B 5651.246 2.478934387 0.20385236 12.1604399 5.05E-34 6.10E-32 
MKI67 1668.0947 2.45326694 0.17296232 14.1838229 1.15E-45 2.04E-43 
ZWINT 879.97087 2.435619918 0.1412515 17.2431441 1.26E-66 4.94E-64 
UBE2C 603.41074 2.430239053 0.12257958 19.8258072 1.78E-87 1.03E-84 
SHCBP1 936.84993 2.428479982 0.0898679 27.022775 7.98E-161 3.86E-157 
CDC20 1102.4648 2.422717273 0.14975042 16.1783668 7.17E-59 2.00E-56 
LMNB1 1301.7786 2.419973442 0.17025555 14.2137713 7.53E-46 1.38E-43 
E2F1 263.13655 2.411863468 0.29677528 8.12690154 4.40E-16 1.52E-14 
BUB1B 786.39282 2.404951519 0.1187358 20.254646 3.23E-91 2.13E-88 
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Table 3 continued 
HIST1H2BL 949.04334 2.384675789 0.21436308 11.1244706 9.54E-29 8.48E-27 
CDC25C 199.68914 2.379738654 0.16395652 14.5144493 9.81E-48 1.92E-45 
SPC25 239.56428 2.373687699 0.15306607 15.5076023 3.08E-54 6.87E-52 
CENPF 2135.9149 2.372068558 0.19591321 12.1077518 9.61E-34 1.14E-31 
HIST2H3D 639.49303 2.36909182 0.22318751 10.6148049 2.54E-26 1.93E-24 
HIST1H1D 1247.9422 2.367605192 0.20999998 11.2743115 1.76E-29 1.63E-27 
LOC100505658 11.071309 2.354041222 0.79816867 2.94930297 0.0031849 0.01469969 
ESPL1 329.83775 2.333527851 0.18544492 12.5834014 2.61E-36 3.37E-34 
HIST2H3A 906.11625 2.326928898 0.19096621 12.1850295 3.74E-34 4.55E-32 
HIST2H3C 906.11625 2.326928898 0.19096621 12.1850295 3.74E-34 4.55E-32 
CDC45 468.82521 2.30452412 0.11140239 20.6864866 4.58E-95 3.32E-92 
CDCA2 558.48322 2.300918068 0.09648038 23.8485601 1.05E-125 1.52E-122 
ORC1 197.87128 2.295665737 0.14601077 15.7225785 1.06E-55 2.60E-53 
FBXO43 25.692352 2.287580956 0.32196659 7.10502587 1.20E-12 3.07E-11 
ASPM 1913.051 2.28456541 0.168372 13.5685588 6.15E-42 9.80E-40 
GAPDHP55 17.15148 2.282182233 0.79216611 2.88093901 0.0039649 0.01770856 
NEK2 290.41379 2.279906597 0.19495737 11.6943853 1.36E-31 1.44E-29 
NCAPG 1221.166 2.253717777 0.18947267 11.8946853 1.26E-32 1.41E-30 
ESCO2 419.77004 2.252081432 0.28761578 7.83017348 4.87E-15 1.55E-13 
PIMREG 351.90192 2.24965097 0.13017961 17.2811312 6.53E-67 2.63E-64 
KIF15 338.12363 2.249587063 0.18804309 11.9631464 5.54E-33 6.23E-31 
CENPE 957.94646 2.244570255 0.27161739 8.26372078 1.41E-16 5.09E-15 
MFSD2A 43.486035 2.232941161 0.30366346 7.35334171 1.93E-13 5.28E-12 
NCAPG2 777.3632 2.232745025 0.07644273 29.2080738 1.53E-187 2.22E-183 
HIST1H2AG 2757.9971 2.217633033 0.21553675 10.2888858 7.91E-25 5.33E-23 
CENPM 198.80897 2.217543584 0.16096854 13.7762547 3.54E-43 5.70E-41 
ERCC6L 203.89231 2.214179955 0.39134647 5.65785087 1.53E-08 2.29E-07 
FST 194.44762 2.197534288 0.18309086 12.0024247 3.45E-33 3.94E-31 
CEP55 1376.2562 2.197443918 0.22926376 9.58478522 9.27E-22 5.19E-20 
HIST1H3D 2423.1019 2.192605613 0.22832591 9.60296455 7.77E-22 4.36E-20 
SPAG5 755.71633 2.189401636 0.0873912 25.0528846 1.62E-138 2.94E-135 
SNORD3B-2 1063.0217 2.188683118 0.34071207 6.42384972 1.33E-10 2.62E-09 
TOP2A 3592.7566 2.185275396 0.20868936 10.4714272 1.17E-25 8.64E-24 
PSMC3IP 93.269868 2.180037755 0.19602555 11.121192 9.89E-29 8.75E-27 
NUF2 397.02345 2.175473196 0.2234938 9.73393102 2.16E-22 1.29E-20 
HJURP 631.5794 2.172582131 0.10762561 20.1864796 1.29E-90 8.11E-88 
GTSE1 369.70861 2.171515245 0.19101179 11.3684878 6.00E-30 5.69E-28 
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Table 3 continued 
CCND1 11354.4 2.167255495 0.17129233 12.6523791 1.09E-36 1.46E-34 
CDCA8 428.17365 2.166042451 0.13583607 15.9460036 3.04E-57 7.72E-55 
POLQ 364.56533 2.165160413 0.15240582 14.2065467 8.34E-46 1.51E-43 
CCSAP 198.53413 2.147179649 0.14306312 15.0086179 6.45E-51 1.42E-48 
AC016394.1 54.058352 2.146829451 0.2578957 8.32440952 8.48E-17 3.13E-15 
CCNA2 1394.4858 2.144868339 0.07924809 27.0652364 2.53E-161 1.83E-157 
DLGAP5 1483.4594 2.144091356 0.24318919 8.81655694 1.18E-18 4.96E-17 
TTK 617.01186 2.141556617 0.27189285 7.87647262 3.37E-15 1.09E-13 
TROAP 215.23853 2.134561195 0.14252768 14.9764673 1.05E-50 2.26E-48 
SAPCD2 219.61279 2.125469841 0.46528573 4.56809596 4.92E-06 4.76E-05 
KIF18B 183.90643 2.125282521 0.24445254 8.69404982 3.50E-18 1.41E-16 
NCAPH 372.90994 2.124126711 0.21318988 9.96354393 2.20E-23 1.37E-21 
TRBC2 79.710599 2.121370833 0.17520061 12.1082386 9.55E-34 1.14E-31 
RAD51AP1 339.74136 2.10566617 0.20867813 10.0904974 6.09E-24 3.90E-22 
KIF2C 803.65626 2.101283936 0.09960801 21.0955325 8.74E-99 6.73E-96 
MCM4 1866.4084 2.098748743 0.16045329 13.080123 4.28E-39 6.20E-37 
CDK1 1330.4448 2.097086049 0.21627325 9.69646518 3.12E-22 1.82E-20 
SPC24 821.7186 2.070427734 0.18146983 11.4092118 3.76E-30 3.64E-28 
KIF4A 763.92282 2.070127899 0.11295472 18.3270603 5.03E-75 2.61E-72 
CENPU 402.85578 2.065807556 0.30987322 6.66662186 2.62E-11 5.63E-10 
TICRR 184.44546 2.060711046 0.18176948 11.3369477 8.61E-30 8.10E-28 
SLC26A2 1269.7059 2.052786087 0.09389449 21.8626906 5.89E-106 7.11E-103 
MYBL2 597.2461 2.0430817 0.22281904 9.1692422 4.76E-20 2.31E-18 
SH2D5 30.825609 2.040567437 0.33013671 6.18097705 6.37E-10 1.15E-08 
TK1 1119.1573 2.037600989 0.18801916 10.8371988 2.29E-27 1.88E-25 
PRC1 2081.3417 2.037180554 0.08908885 22.8668417 9.94E-116 1.31E-112 
VCL 5919.3093 2.032048674 0.19971337 10.1748252 2.57E-24 1.71E-22 
APOBEC3B 163.45022 2.031809067 0.20074963 10.1211101 4.45E-24 2.90E-22 
FANCB 118.13057 2.03025104 0.21890633 9.27451957 1.78E-20 8.95E-19 
BUB1 1201.9966 2.027684504 0.12349027 16.4197921 1.38E-60 4.00E-58 
SKA1 216.10806 2.022150418 0.1117698 18.0920997 3.68E-73 1.78E-70 
CENPA 244.43194 2.018394381 0.11761203 17.1614625 5.16E-66 1.97E-63 
ZNF695 28.306929 2.007080077 0.27924381 7.1875544 6.60E-13 1.73E-11 
BLM 277.27749 2.005132525 0.25726949 7.79389952 6.50E-15 2.05E-13 
ATAD5 283.07492 1.997823769 0.1202672 16.6115425 5.75E-62 1.77E-59 
HIST2H4A 3404.3519 1.995383418 0.18856604 10.5818809 3.62E-26 2.72E-24 
HIST2H4B 3404.3519 1.995383418 0.18856604 10.5818809 3.62E-26 2.72E-24 
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Table 3 continued 
BIRC5 1172.9219 1.9832642 0.09190578 21.5793189 2.81E-103 2.72E-100 
CDCA5 372.12853 1.983178292 0.15705716 12.6271119 1.50E-36 1.99E-34 
TPX2 1846.267 1.975850844 0.12376283 15.9648163 2.25E-57 5.82E-55 
TYMS 760.51926 1.972073853 0.11189341 17.6245757 1.60E-69 6.80E-67 
RAD54L 85.648872 1.971130072 0.29070234 6.78057867 1.20E-11 2.67E-10 
ARHGAP11A 802.34191 1.967961615 0.15219773 12.9302951 3.04E-38 4.27E-36 
TCF19 306.30475 1.96769542 0.15814141 12.4426324 1.53E-35 1.95E-33 
HIST2H2AA4 5357.1638 1.96521137 0.20789943 9.45270189 3.30E-21 1.73E-19 
KNL1 1155.6739 1.962987281 0.19048447 10.3052352 6.67E-25 4.54E-23 
HIST1H2BJ 3586.2545 1.961684374 0.18896645 10.381125 3.02E-25 2.16E-23 
ANLN 2484.7996 1.96122788 0.19548341 10.0327075 1.09E-23 6.96E-22 
CKAP2L 318.82222 1.952740864 0.22278079 8.76530197 1.86E-18 7.72E-17 
NDUFS1 3107.7453 1.941843152 0.07223054 26.8839634 3.38E-159 1.23E-155 
KIF11 1051.0482 1.935206946 0.13801018 14.0222042 1.14E-44 1.97E-42 
AC009533.1 25.906451 1.931136329 0.29700163 6.50210688 7.92E-11 1.61E-09 
GINS2 385.0208 1.929025238 0.09870457 19.5434245 4.69E-85 2.52E-82 
U1 4835.3306 1.924579639 0.28544449 6.74239554 1.56E-11 3.43E-10 
DHFRP1 83.40605 1.916018058 0.1754542 10.9203319 9.22E-28 7.72E-26 
ATAD2 1125.4919 1.910718204 0.19878264 9.61209778 7.11E-22 4.01E-20 
AURKA 836.81632 1.910217944 0.07809639 24.4597464 3.96E-132 6.38E-129 
KIF18A 313.15119 1.906901454 0.33477428 5.69608106 1.23E-08 1.86E-07 
CCNB1 2469.5881 1.896521268 0.1124428 16.8665429 7.93E-64 2.67E-61 
DMC1 22.2276 1.893908916 0.31707873 5.9729927 2.33E-09 3.94E-08 
CDCA3 106.0391 1.893725992 0.15725271 12.0425649 2.12E-33 2.46E-31 
DEPDC1 626.76901 1.893061776 0.22360531 8.46608595 2.54E-17 9.68E-16 
GINS1 626.28783 1.891110811 0.07182429 26.3296851 8.77E-153 2.54E-149 
CENPW 571.14488 1.891032662 0.1814102 10.4240702 1.93E-25 1.40E-23 
HMOX1 9691.9738 1.88979321 0.19073062 9.90817932 3.84E-23 2.37E-21 
PTTG1 1175.0803 1.885430478 0.162134 11.6288406 2.94E-31 3.05E-29 
RTKN2 34.062609 1.877431788 0.24755164 7.58400065 3.35E-14 1.01E-12 
HIST2H2BF 1208.0429 1.873433958 0.11823272 15.845309 1.51E-56 3.79E-54 
HIST2H2BB 137.73334 1.872271499 0.25323567 7.39339561 1.43E-13 3.95E-12 
FEN1 1124.0882 1.869096579 0.08552383 21.8546863 7.02E-106 7.82E-103 
CCNB2 646.64882 1.86781101 0.11360708 16.440974 9.73E-61 2.88E-58 
MCM7 2060.0388 1.862612514 0.16230068 11.4763072 1.74E-30 1.72E-28 
NUSAP1 1190.3152 1.857066384 0.23098008 8.03994188 8.99E-16 3.03E-14 
CKS1B 899.95306 1.84910032 0.20171066 9.16709285 4.86E-20 2.34E-18 
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Table 3 continued 
NDC80 691.63119 1.845181819 0.19408883 9.50689359 1.96E-21 1.05E-19 
ASF1B 320.88132 1.841096821 0.19428109 9.47645938 2.63E-21 1.40E-19 
SKA3 182.55414 1.831288296 0.27320183 6.70306025 2.04E-11 4.42E-10 
RN7SL411P 51.279588 1.825204802 0.62557496 2.91764363 0.0035269 0.01603294 
PCLAF 538.76221 1.818238668 0.1884228 9.64978069 4.93E-22 2.82E-20 
SGO1 136.36186 1.815518439 0.15523739 11.6951102 1.35E-31 1.44E-29 
POLE2 191.241 1.809180142 0.2182282 8.29031344 1.13E-16 4.10E-15 
KIF20B 772.92577 1.804635151 0.22035611 8.18963052 2.62E-16 9.18E-15 
CPA3 323.40374 1.803660824 0.22039324 8.18383023 2.75E-16 9.58E-15 
KSR2 223.70979 1.791187903 0.33768881 5.30425608 1.13E-07 1.47E-06 
PLK4 396.5061 1.788755834 0.25544433 7.00252705 2.51E-12 6.16E-11 
IQGAP3 611.28639 1.780899961 0.2760468 6.45144226 1.11E-10 2.20E-09 
AUNIP 78.423145 1.772130172 0.20082512 8.82424561 1.10E-18 4.66E-17 
SCN10A 11.979003 1.76903547 0.33435735 5.29085262 1.22E-07 1.57E-06 
MTFR2 100.35275 1.766605077 0.15455364 11.4303684 2.95E-30 2.87E-28 
RNU2-63P 54.342688 1.765862412 0.37050817 4.7660553 1.88E-06 1.99E-05 
CIP2A 581.8738 1.765408631 0.17080136 10.3360337 4.84E-25 3.37E-23 
TRAIP 115.66301 1.763669423 0.18711151 9.42576641 4.27E-21 2.21E-19 
KIF20A 1675.3065 1.758355786 0.1035358 16.9830702 1.10E-64 3.97E-62 
MAD2L1 1004.4273 1.753616184 0.29816866 5.8812895 4.07E-09 6.59E-08 
FBXO5 345.89994 1.753416649 0.17587975 9.96940583 2.07E-23 1.30E-21 
ORC6 496.26601 1.750242541 0.15921553 10.9929136 4.13E-28 3.57E-26 
OIP5 144.29159 1.746750427 0.19356266 9.02421165 1.81E-19 8.25E-18 
HIST1H4H 2328.891 1.746332521 0.24526864 7.12008086 1.08E-12 2.77E-11 
FANCD2 559.37199 1.739478041 0.09961083 17.4627398 2.75E-68 1.14E-65 
BRCA1 635.89418 1.727748408 0.2461515 7.0190447 2.23E-12 5.51E-11 
DIAPH3 678.12383 1.719223135 0.06590147 26.0877828 5.02E-150 1.21E-146 
HPDL 18.070531 1.716726485 0.41835119 4.10355345 4.07E-05 0.00032195 
HELLS 753.19571 1.714486027 0.18495439 9.26977724 1.87E-20 9.32E-19 
MEX3A 217.97298 1.699883818 0.24070428 7.06212548 1.64E-12 4.14E-11 
KIF23 824.04743 1.697711737 0.15153902 11.2031327 3.94E-29 3.57E-27 
CDKN3 392.25386 1.694736443 0.23839276 7.10900983 1.17E-12 2.99E-11 
DDX12P 37.166453 1.690357233 0.24640194 6.860162 6.88E-12 1.58E-10 
KIF22 871.61658 1.686732846 0.17037063 9.90037345 4.15E-23 2.55E-21 
RACGAP1 1134.706 1.686475252 0.09391937 17.9566285 4.26E-72 1.99E-69 
UBE2T 527.19773 1.669031519 0.22271007 7.49418968 6.67E-14 1.94E-12 
PSKH1 496.667 1.66610044 0.25631925 6.50009867 8.03E-11 1.63E-09 
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Table 3 continued 
BRIP1 473.77015 1.663633058 0.19072779 8.72255174 2.72E-18 1.11E-16 
FOXM1 515.17246 1.657876762 0.18655773 8.88666899 6.30E-19 2.75E-17 
RFC3 334.42454 1.656086929 0.22679367 7.3021743 2.83E-13 7.62E-12 
CENPN 653.65795 1.653951254 0.14374712 11.5059786 1.23E-30 1.24E-28 
HIST1H1C 7969.1127 1.653230961 0.14087128 11.7357562 8.36E-32 8.97E-30 
ERBB4 16.032415 1.64879566 0.36137769 4.56252753 5.05E-06 4.88E-05 
AMMECR1 207.7059 1.64750642 0.11766157 14.0020776 1.51E-44 2.58E-42 
HIST1H2AD 2082.4186 1.629814817 0.24893513 6.54714665 5.86E-11 1.21E-09 
CDT1 216.72694 1.624616336 0.27177726 5.97774924 2.26E-09 3.83E-08 
ELOA 1427.9888 1.619931888 0.09603037 16.8689541 7.61E-64 2.63E-61 
SGO2 536.70956 1.618376613 0.26447353 6.11923863 9.40E-10 1.65E-08 
FANCI 949.00572 1.611617021 0.17036556 9.45975835 3.09E-21 1.63E-19 
KIF24 191.8654 1.611142944 0.15503142 10.3923637 2.69E-25 1.93E-23 
MCM5 1411.3884 1.610272601 0.22444778 7.17437522 7.26E-13 1.89E-11 
MELK 869.37716 1.599830917 0.09991731 16.0115487 1.06E-57 2.80E-55 
ESM1 9899.4797 1.598155711 0.12190473 13.1098741 2.89E-39 4.23E-37 
HIST2H2AB 425.28317 1.593343061 0.22247799 7.16180073 7.96E-13 2.07E-11 
HMGB3 498.52991 1.593084779 0.13760763 11.5770091 5.39E-31 5.50E-29 
CENPI 424.04432 1.592636565 0.17609886 9.04399137 1.51E-19 6.97E-18 
AC025186.1 27.996867 1.589836916 0.58660983 2.71021186 0.006724 0.0276064 
EZH2 412.05357 1.587865025 0.10735051 14.791407 1.66E-49 3.45E-47 
PSRC1 176.29214 1.568642191 0.14637334 10.716721 8.50E-27 6.69E-25 
HMGB2 2292.604 1.568040553 0.1559332 10.0558477 8.66E-24 5.53E-22 
TRIP13 614.84366 1.565748672 0.09338421 16.7667394 4.27E-63 1.41E-60 
ZGRF1 322.83503 1.560556364 0.31250432 4.99371131 5.92E-07 6.83E-06 
EME1 85.803992 1.545264262 0.19478388 7.93322461 2.14E-15 7.04E-14 
CDCA7 200.6527 1.544947061 0.16155121 9.56320326 1.14E-21 6.29E-20 
DNAJC9 1592.8551 1.54045667 0.14461746 10.6519412 1.71E-26 1.32E-24 
BRI3BP 378.99044 1.539131333 0.12822362 12.0034927 3.41E-33 3.92E-31 
CDC25A 502.48238 1.528392527 0.20436295 7.47881401 7.50E-14 2.16E-12 
NCR3LG1 342.75209 1.526528918 0.14811436 10.306421 6.59E-25 4.51E-23 
AC099850.3 55.063654 1.526193909 0.20695005 7.37469682 1.65E-13 4.51E-12 
PCNA 2464.1064 1.526114909 0.12738515 11.9803204 4.51E-33 5.10E-31 
POC1A 335.70946 1.523358479 0.15573835 9.78152466 1.35E-22 8.23E-21 
H2AFX 928.5996 1.518253001 0.21647455 7.01354055 2.32E-12 5.70E-11 
PMCH 46.670173 1.514486083 0.31331529 4.83374463 1.34E-06 1.45E-05 
XRCC2 227.97307 1.512620554 0.18455117 8.19621239 2.48E-16 8.71E-15 
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Table 3 continued 
PRC1-AS1 30.406321 1.511133029 0.29491081 5.124034 2.99E-07 3.63E-06 
PRR11 517.51051 1.511015786 0.15551776 9.71603392 2.58E-22 1.52E-20 
CHAF1A 436.34831 1.509722452 0.20293421 7.43946762 1.01E-13 2.85E-12 
MT1L 244.61351 1.508905864 0.17653856 8.54717452 1.26E-17 4.89E-16 
DSCC1 115.55902 1.504964796 0.20130435 7.47606696 7.66E-14 2.19E-12 
CENPH 250.50041 1.499182622 0.19387576 7.73269752 1.05E-14 3.26E-13 
HIST1H4C 2872.3958 1.496480525 0.26621009 5.62142686 1.89E-08 2.77E-07 
ITPRIPL1 15.913448 1.495747648 0.41715724 3.58557276 0.0003363 0.00211006 
WDR76 400.57419 1.492004765 0.18006539 8.28590547 1.17E-16 4.25E-15 
RECQL4 214.0686 1.481551566 0.39916842 3.71159514 0.000206 0.00137087 
ATXN7L3B 1790.6603 1.478658665 0.07360439 20.0892738 9.16E-90 5.53E-87 
PRIM1 230.5377 1.476483709 0.23386558 6.31338608 2.73E-10 5.21E-09 
FRMD3 309.82484 1.474895613 0.14540763 10.1431791 3.55E-24 2.34E-22 
TMPPE 151.17379 1.463599399 0.1788081 8.18530804 2.72E-16 9.49E-15 
LOC101928000 58.851503 1.463464179 0.36173637 4.04566504 5.22E-05 0.00040084 
DHFR 826.74501 1.455652558 0.15577119 9.34481231 9.21E-21 4.70E-19 
WDR62 164.99055 1.45562888 0.14418215 10.0957633 5.77E-24 3.72E-22 
MTBP 227.81888 1.450294584 0.22987411 6.30908184 2.81E-10 5.35E-09 
MCM6 1093.2605 1.448839803 0.11016625 13.1513949 1.67E-39 2.47E-37 
GINS3 395.83036 1.448665964 0.09231665 15.6923586 1.71E-55 4.12E-53 
RNU5A-8P 448.00294 1.441365996 0.55443936 2.59968193 0.009331 0.0361496 
AC124798.1 49.553494 1.43547415 0.28892029 4.96840886 6.75E-07 7.72E-06 
AC025257.1 28.261761 1.435323873 0.42306591 3.39267202 0.0006921 0.00395196 
NEIL3 148.53789 1.42613477 0.17180474 8.3009046 1.03E-16 3.78E-15 
CORO1A 41.272285 1.422687989 0.32233682 4.4136689 1.02E-05 9.17E-05 
C17orf53 107.8356 1.417045651 0.20658554 6.85936511 6.92E-12 1.58E-10 
RRM1 2324.373 1.415645322 0.12924335 10.953332 6.40E-28 5.43E-26 
HIST1H2BK 2770.5042 1.414069006 0.13589213 10.4058198 2.33E-25 1.68E-23 
DKC1 613.1487 1.412619666 0.08562058 16.4985988 3.76E-61 1.13E-58 
DNA2 317.00432 1.411034139 0.25021615 5.63926093 1.71E-08 2.53E-07 
H2AFZ 7415.6934 1.410132108 0.16124548 8.74525068 2.23E-18 9.14E-17 
POLR3G 242.36435 1.408553799 0.26868684 5.24236236 1.59E-07 2.01E-06 
STIL 557.46654 1.408315062 0.18861484 7.46661866 8.23E-14 2.34E-12 
CIT 524.8398 1.402590634 0.14820621 9.46377795 2.97E-21 1.57E-19 
ANKRD18B 87.122203 1.401137311 0.20301662 6.90158921 5.14E-12 1.20E-10 
LMNB2 3076.3963 1.400383081 0.2580708 5.42635239 5.75E-08 7.79E-07 
CAAP1 470.16262 1.398951442 0.11087844 12.6169836 1.70E-36 2.24E-34 
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DTL 441.36332 1.392999398 0.13440562 10.3641455 3.61E-25 2.53E-23 
CEP128 160.82571 1.392216033 0.15645781 8.8983477 5.67E-19 2.49E-17 
AC129102.1 63.299976 1.388891685 0.22425367 6.19339546 5.89E-10 1.07E-08 
SASS6 141.82151 1.388453037 0.25187815 5.5123998 3.54E-08 4.98E-07 
CCDC190 174.68451 1.378607546 0.33248392 4.14638859 3.38E-05 0.00027279 
TEDC2 96.554256 1.375736918 0.27869982 4.93626771 7.96E-07 9.00E-06 
RMI2 111.75327 1.369175441 0.1665085 8.22285591 1.99E-16 7.04E-15 
RNU5D-1 1014.4104 1.367146431 0.45962806 2.97446251 0.002935 0.01372992 
CENPK 657.8913 1.366143922 0.2155155 6.33895911 2.31E-10 4.44E-09 
CDKN2C 231.44259 1.363052746 0.25201054 5.40871331 6.35E-08 8.54E-07 
CCDC150 94.613768 1.359950427 0.17618617 7.71882617 1.17E-14 3.61E-13 
MMS22L 528.12247 1.35992528 0.24120761 5.63798674 1.72E-08 2.54E-07 
RAD51 303.43119 1.358335984 0.14195506 9.56877435 1.08E-21 6.01E-20 
MYBL1 86.056227 1.350848346 0.19585593 6.89715308 5.31E-12 1.23E-10 
SKINT1L 151.94016 1.349785709 0.47444464 2.84498043 0.0044414 0.01950536 
MAT2B 2430.1136 1.348570166 0.12109971 11.1360313 8.38E-29 7.50E-27 
AC012073.1 21.399341 1.348303005 0.27202601 4.95652245 7.18E-07 8.19E-06 
TACC3 1019.3557 1.344151684 0.24267276 5.53894757 3.04E-08 4.33E-07 
SMC2 1186.346 1.33804234 0.23534636 5.68541756 1.30E-08 1.97E-07 
EPS15 1365.6275 1.336006531 0.15148377 8.81946971 1.15E-18 4.85E-17 
SNRPD1 1251.9534 1.332255115 0.15439352 8.62895758 6.19E-18 2.46E-16 
HASPIN 188.49686 1.331510418 0.2771571 4.80417206 1.55E-06 1.67E-05 
PARPBP 398.80953 1.330128058 0.26556572 5.00865879 5.48E-07 6.37E-06 
NCAPD3 807.35733 1.328894028 0.14919952 8.9068249 5.25E-19 2.32E-17 
FAM217B 213.98647 1.323541842 0.19603573 6.75153362 1.46E-11 3.24E-10 
NPIPB13 36.932537 1.322955488 0.47883262 2.76287669 0.0057294 0.02413824 
AC093724.1 98.493058 1.321790257 0.19924135 6.63411616 3.26E-11 6.96E-10 
INCENP 422.71843 1.320502427 0.29495413 4.47697555 7.57E-06 7.02E-05 
HDAC9 464.40399 1.318398361 0.18689678 7.0541525 1.74E-12 4.37E-11 
DPF1 36.215744 1.31004718 0.22105813 5.92625643 3.10E-09 5.11E-08 
UBE2L2 11.24113 1.307386758 0.49619484 2.63482538 0.0084181 0.03331602 
MCM8 329.99701 1.306006611 0.18760037 6.96164191 3.36E-12 8.10E-11 
COPZ1 2846.0648 1.304481998 0.11875968 10.9842162 4.55E-28 3.90E-26 
KIF21A 367.73939 1.301018403 0.18787941 6.92475236 4.37E-12 1.04E-10 
ARHGAP11B 203.74858 1.296531029 0.22919474 5.65689707 1.54E-08 2.30E-07 
LOC100288637 203.74858 1.296531029 0.22919474 5.65689707 1.54E-08 2.30E-07 
HK2 341.53522 1.293134263 0.3190438 4.05315585 5.05E-05 0.00038924 
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HIST1H2BD 2986.6156 1.292667751 0.17472561 7.39827286 1.38E-13 3.82E-12 
CCNE2 281.0081 1.290631503 0.25381687 5.08489259 3.68E-07 4.40E-06 
BRCA2 639.10801 1.287333456 0.25720159 5.00515356 5.58E-07 6.47E-06 
SNAPIN 632.58885 1.28388851 0.1390747 9.23164686 2.67E-20 1.32E-18 
KNSTRN 815.49035 1.283829918 0.15206914 8.44240906 3.11E-17 1.18E-15 
PANK3 3485.3471 1.283706085 0.12438467 10.3204527 5.70E-25 3.93E-23 
C1orf112 347.88823 1.277229114 0.2086281 6.12203766 9.24E-10 1.63E-08 
AC007952.4 387.62091 1.27694874 0.17378916 7.34768906 2.02E-13 5.50E-12 
HIST2H2BE 1185.9087 1.276167311 0.11107175 11.4895762 1.49E-30 1.49E-28 
SPINT1 14.439956 1.275970425 0.41064633 3.10722472 0.0018885 0.00944069 
NUP43 1139.7512 1.273228155 0.08765341 14.525712 8.33E-48 1.65E-45 
CCNF 1037.6789 1.266696247 0.22580938 5.60958218 2.03E-08 2.96E-07 
RNVU1-15 111.82175 1.264210997 0.35892605 3.52220462 0.000428 0.00260467 
FANCA 328.64935 1.260435183 0.14176809 8.89082436 6.07E-19 2.66E-17 
WDHD1 646.4879 1.259835604 0.20241265 6.22409519 4.84E-10 8.91E-09 
AC092718.4 61.548606 1.258282344 0.17209119 7.31171871 2.64E-13 7.12E-12 
EMC8 734.44259 1.251031503 0.12813652 9.76327051 1.62E-22 9.82E-21 
AC004837.3 106.5479 1.247782254 0.19218869 6.49248525 8.44E-11 1.71E-09 
GINS4 180.23854 1.242146216 0.25651152 4.84245789 1.28E-06 1.40E-05 
PDE4A 69.797885 1.239440025 0.22756656 5.44649452 5.14E-08 7.00E-07 
HIST1H1E 5468.6793 1.235739421 0.13600611 9.0859113 1.03E-19 4.81E-18 
PAQR4 244.27634 1.235049262 0.34890282 3.53980873 0.0004004 0.00245864 
CCDC34 138.43867 1.234596999 0.19685491 6.27160875 3.57E-10 6.75E-09 
AP005901.5 17.452557 1.227887421 0.47877078 2.5646666 0.0103275 0.03930631 
HIST1H2BN 788.76664 1.226429625 0.13643512 8.98910522 2.49E-19 1.12E-17 
RFC4 353.70216 1.22200686 0.16466739 7.42106179 1.16E-13 3.25E-12 
CEP72 58.200039 1.215965959 0.27761433 4.3800548 1.19E-05 0.00010571 
AC016205.1 16.448007 1.21231496 0.39976685 3.03255498 0.0024249 0.01164818 
CENPL 361.35842 1.210675566 0.15902836 7.61295392 2.68E-14 8.07E-13 
INHBA 746.78687 1.207369506 0.13167166 9.16954731 4.75E-20 2.31E-18 
AL359955.1 656.36579 1.207003409 0.37238622 3.24126767 0.00119 0.00629611 
TGFBR2 17498.128 -1.201063689 0.13583514 -8.8420689 9.40E-19 3.99E-17 
BAALC 58.127567 -1.204504116 0.24066304 -5.0049402 5.59E-07 6.48E-06 
PDGFRA 42.767575 -1.204727365 0.25821248 -4.6656435 3.08E-06 3.12E-05 
ZNF366 99.52198 -1.206200258 0.15367372 -7.8490989 4.19E-15 1.34E-13 
GADD45A 945.0534 -1.207406483 0.13480245 -8.9568588 3.34E-19 1.49E-17 
UST 27.766104 -1.210405836 0.35446632 -3.4147274 0.0006385 0.00367875 
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AC046143.1 50.848978 -1.210724048 0.22991655 -5.2659281 1.39E-07 1.79E-06 
FAM129A 396.37557 -1.217603711 0.19192417 -6.3441918 2.24E-10 4.30E-09 
NOTCH4 413.53144 -1.219238441 0.39052028 -3.1220874 0.0017957 0.00901725 
KAT2B 582.45842 -1.225794323 0.14938567 -8.2055684 2.30E-16 8.10E-15 
CLU 10468.9 -1.226028833 0.27933796 -4.389052 1.14E-05 0.00010186 
COL1A2 364.78877 -1.233110106 0.24978001 -4.9367846 7.94E-07 8.99E-06 
P4HA3 664.30837 -1.233504589 0.12706612 -9.7075807 2.80E-22 1.64E-20 
TCTEX1D1 61.359636 -1.234669381 0.15640635 -7.8939849 2.93E-15 9.51E-14 
ADIRF 878.10435 -1.235885215 0.11346566 -10.892152 1.26E-27 1.03E-25 
LYNX1 103.76244 -1.237324861 0.43556852 -2.8407123 0.0045013 0.01973842 
AL162591.2 128.81737 -1.239596279 0.18610089 -6.6608832 2.72E-11 5.85E-10 
SCG5 22.525507 -1.240790136 0.347984 -3.5656528 0.000363 0.00225148 
LIMCH1 1280.1678 -1.241228008 0.07713306 -16.092036 2.90E-58 7.94E-56 
PCDHB14 20.839867 -1.246577463 0.28439491 -4.3832622 1.17E-05 0.00010424 
RAET1E 21.635233 -1.250679218 0.27400525 -4.5644352 5.01E-06 4.84E-05 
LAYN 54.80174 -1.251019562 0.24303208 -5.1475492 2.64E-07 3.23E-06 
C5orf24 1870.644 -1.251849991 0.1009674 -12.398557 2.66E-35 3.35E-33 
LRRC17 135.91509 -1.256482265 0.24476972 -5.1333239 2.85E-07 3.46E-06 
A2M 718.56177 -1.264572276 0.23854371 -5.3012183 1.15E-07 1.49E-06 
ARRDC2 565.25509 -1.267367564 0.23353216 -5.426951 5.73E-08 7.77E-07 
HTR1D 44.20154 -1.274253533 0.27722038 -4.5965363 4.30E-06 4.21E-05 
GPR153 79.396324 -1.274446617 0.41049347 -3.1046696 0.0019049 0.00951277 
ECM1 41.636062 -1.27838442 0.32946009 -3.8802406 0.0001044 0.00074012 
ERV3-1-
ZNF117 
1230.7988 -1.283426189 0.25395321 -5.05379 4.33E-07 5.10E-06 
ZNF117 1230.7988 -1.283426189 0.25395321 -5.05379 4.33E-07 5.10E-06 
ST6GALNAC3 1254.0912 -1.285673243 0.20883554 -6.1563911 7.44E-10 1.34E-08 
TFPI 11563.945 -1.286311191 0.18582101 -6.9223131 4.44E-12 1.05E-10 
COMMD8 601.58342 -1.290753736 0.19964332 -6.465299 1.01E-10 2.03E-09 
SULT1A4 212.98652 -1.291052888 0.47099947 -2.741092 0.0061235 0.02550945 
RAET1G 35.621521 -1.292043371 0.37273833 -3.466355 0.0005276 0.00312296 
CTNNBIP1 671.32944 -1.292256361 0.17829776 -7.247743 4.24E-13 1.13E-11 
LRRC4 41.32126 -1.292639173 0.3278491 -3.942787 8.05E-05 0.00059029 
ERMAP 185.05008 -1.297277846 0.10530606 -12.319119 7.15E-35 8.93E-33 
DKK3 9125.1752 -1.300223282 0.17715016 -7.3396675 2.14E-13 5.80E-12 
C16orf45 382.18734 -1.303789826 0.09672878 -13.478821 2.08E-41 3.25E-39 
AL359075.2 30.578831 -1.308667027 0.24694457 -5.2994364 1.16E-07 1.51E-06 
FABP5P7 1809.8448 -1.317383831 0.19904471 -6.6185323 3.63E-11 7.68E-10 
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Table 3 continued 
LZTS3 118.95805 -1.319350695 0.43868144 -3.0075371 0.0026337 0.01249798 
MRC2 1406.136 -1.32361 0.30966229 -4.2743661 1.92E-05 0.00016336 
VWCE 69.39641 -1.327737587 0.23453306 -5.6611959 1.50E-08 2.26E-07 
TGFBI 2043.78 -1.33110736 0.23136557 -5.7532648 8.75E-09 1.36E-07 
CACNA2D4 15.757074 -1.33212132 0.28917169 -4.6066796 4.09E-06 4.03E-05 
SLFN5 2036.4851 -1.333378369 0.10117199 -13.179323 1.15E-39 1.73E-37 
DPP4 381.77811 -1.336267281 0.0832259 -16.055906 5.20E-58 1.40E-55 
CLDN10 49.411962 -1.339695961 0.28642659 -4.6772751 2.91E-06 2.96E-05 
CD302 206.64002 -1.34165915 0.15761415 -8.5123014 1.71E-17 6.56E-16 
UNC5A 20.21472 -1.342312134 0.3138887 -4.2763953 1.90E-05 0.00016198 
TNFRSF10C 628.86495 -1.343264628 0.1913228 -7.0209332 2.20E-12 5.45E-11 
OLFML3 133.08632 -1.344992827 0.14915613 -9.0173484 1.93E-19 8.76E-18 
NIPAL2 352.99401 -1.348545197 0.21734338 -6.2046757 5.48E-10 1.00E-08 
MAN2A1 3193.2091 -1.349793534 0.10382015 -13.001267 1.20E-38 1.73E-36 
TNFRSF4 36.34785 -1.353258871 0.36659772 -3.6914001 0.000223 0.00147096 
GALNT15 774.75198 -1.360911938 0.10075937 -13.506555 1.43E-41 2.25E-39 
ANGPTL4 2293.4956 -1.3631653 0.29389014 -4.6383499 3.51E-06 3.50E-05 
VSIR 251.98626 -1.364493736 0.32928785 -4.1437719 3.42E-05 0.00027577 
VAV3 82.893286 -1.367763011 0.20845175 -6.561533 5.33E-11 1.10E-09 
CTSO 210.17955 -1.370401505 0.12391916 -11.058835 1.99E-28 1.73E-26 
CREG2 60.642394 -1.373646934 0.16318822 -8.417562 3.84E-17 1.45E-15 
TMEM273 99.362736 -1.38454 0.21591871 -6.4123208 1.43E-10 2.82E-09 
HDHD2 240.71987 -1.391232217 0.14439287 -9.6350481 5.69E-22 3.23E-20 
DDR1 177.51728 -1.395929448 0.47341534 -2.9486359 0.0031918 0.01471487 
SEPTIN4 46.787194 -1.399458563 0.23480816 -5.9600083 2.52E-09 4.23E-08 
FABP5 3342.2236 -1.408454587 0.10945736 -12.86761 6.85E-38 9.37E-36 
PCDH12 2076.812 -1.40937066 0.2300461 -6.1264706 8.98E-10 1.59E-08 
PKHD1L1 185.82948 -1.416110326 0.25073323 -5.6478766 1.62E-08 2.41E-07 
WASF3 410.16945 -1.424469548 0.16338001 -8.7187507 2.81E-18 1.14E-16 
C3AR1 21.67256 -1.42450288 0.31492485 -4.5233105 6.09E-06 5.78E-05 
NR1H3 195.38941 -1.437999209 0.1373323 -10.470947 1.17E-25 8.64E-24 
MRAP2 113.18589 -1.447566236 0.15328803 -9.4434392 3.61E-21 1.89E-19 
ITGA1 139.43635 -1.449989601 0.19417018 -7.4676225 8.17E-14 2.33E-12 
ANGPTL2 688.69628 -1.453009958 0.24504229 -5.9296293 3.04E-09 5.02E-08 
TSPAN7 99.357979 -1.461962488 0.25932825 -5.637498 1.73E-08 2.54E-07 
GBP1P1 22.91641 -1.46198008 0.3361011 -4.3498224 1.36E-05 0.00011906 
PDE1A 13.016007 -1.464651647 0.50082939 -2.9244523 0.0034506 0.01573075 
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LINC01676 45.585381 -1.472476651 0.49166342 -2.9948876 0.0027455 0.01295182 
ANK2 27.210849 -1.472971609 0.27332792 -5.3890273 7.08E-08 9.47E-07 
GJA4 82.955669 -1.479241009 0.21187292 -6.9817369 2.92E-12 7.09E-11 
CCDC85A 329.84583 -1.485488714 0.24204687 -6.1371944 8.40E-10 1.49E-08 
NT5E 12672.711 -1.487471422 0.08779254 -16.943028 2.17E-64 7.66E-62 
RCSD1 40.694565 -1.494365563 0.21427317 -6.9741141 3.08E-12 7.46E-11 
C7orf61 63.48895 -1.494857446 0.16713655 -8.9439288 3.76E-19 1.67E-17 
PPP1R3C 131.65505 -1.500423247 0.22312511 -6.7245826 1.76E-11 3.86E-10 
CASP12 52.876803 -1.502340871 0.22849552 -6.5749249 4.87E-11 1.02E-09 
NPR1 538.83256 -1.513189899 0.20824066 -7.2665439 3.69E-13 9.86E-12 
STK38L 1284.7612 -1.521639063 0.21095545 -7.2130823 5.47E-13 1.44E-11 
KLF3-AS1 38.40152 -1.531333521 0.22152124 -6.9128067 4.75E-12 1.12E-10 
FKBP9 3350.2897 -1.540300878 0.24547188 -6.2748568 3.50E-10 6.63E-09 
CASP7 2248.9129 -1.555491842 0.10957606 -14.195544 9.76E-46 1.75E-43 
SCN9A 68.465392 -1.566055956 0.21539668 -7.2705667 3.58E-13 9.59E-12 
SELE 594.27571 -1.569000578 0.14695114 -10.677022 1.30E-26 1.02E-24 
GIMAP5 320.29696 -1.571824555 0.08807523 -17.846386 3.08E-71 1.35E-68 
STAT4 12.328683 -1.581922948 0.39830987 -3.9715886 7.14E-05 0.00052861 
NOD2 18.672904 -1.59323019 0.42836653 -3.7193153 0.0001998 0.00133332 
DIRAS3 94.993933 -1.595976249 0.16439344 -9.708272 2.78E-22 1.64E-20 
FLT4 259.78441 -1.596372751 0.24589262 -6.492154 8.46E-11 1.71E-09 
AFAP1L2 64.634125 -1.598931167 0.16543282 -9.665139 4.24E-22 2.44E-20 
CRACR2B 85.69024 -1.60070439 0.20887683 -7.6633889 1.81E-14 5.52E-13 
GPER1 45.900124 -1.601020752 0.3306841 -4.8415413 1.29E-06 1.40E-05 
ENPP2 15.395559 -1.601802395 0.35708251 -4.4858047 7.26E-06 6.76E-05 
CAPN11 44.670411 -1.606357347 0.34410282 -4.6682482 3.04E-06 3.08E-05 
TSPAN11 30.207552 -1.613577268 0.2580819 -6.2521908 4.05E-10 7.59E-09 
ADAM19 1218.4925 -1.615213679 0.21117747 -7.6486079 2.03E-14 6.16E-13 
APOL3 2613.8586 -1.629875908 0.08953184 -18.204428 4.76E-74 2.38E-71 
STS 410.37233 -1.639048235 0.12668918 -12.937555 2.76E-38 3.93E-36 
MAMDC2 570.01204 -1.642942096 0.41803565 -3.9301483 8.49E-05 0.00061751 
CROT 494.65672 -1.664783399 0.14609709 -11.395048 4.43E-30 4.25E-28 
IL17D 567.08646 -1.66600686 0.28077056 -5.9336949 2.96E-09 4.91E-08 
C11orf96 122.74701 -1.666152227 0.24803567 -6.7173895 1.85E-11 4.04E-10 
GPR143 94.378224 -1.668640683 0.20657015 -8.0778404 6.59E-16 2.24E-14 
SLC46A3 205.2689 -1.670558374 0.1202486 -13.892539 7.03E-44 1.19E-41 
DLL4 927.46527 -1.672419411 0.16801058 -9.9542504 2.42E-23 1.50E-21 
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PRDM8 24.313391 -1.676699531 0.32905314 -5.0955281 3.48E-07 4.17E-06 
SELP 28.850907 -1.677875242 0.43475381 -3.8593687 0.0001137 0.00079846 
PDE6G 15.30847 -1.677884802 0.40648409 -4.1277994 3.66E-05 0.00029351 
ACOX2 31.844044 -1.684081238 0.26915083 -6.2570166 3.92E-10 7.37E-09 
PIK3IP1 695.62969 -1.687564552 0.13077209 -12.904623 4.24E-38 5.85E-36 
AC073957.2 144.3911 -1.689300448 0.16284788 -10.373487 3.27E-25 2.31E-23 
AXL 3963.1907 -1.690147602 0.2408561 -7.0172506 2.26E-12 5.57E-11 
GPR146 87.304749 -1.692432063 0.45754436 -3.6989464 0.0002165 0.00143378 
UBE2V2 825.44376 -1.69897173 0.19877018 -8.5474178 1.26E-17 4.89E-16 
FER1L6 56.291428 -1.703367572 0.19243015 -8.8518747 8.61E-19 3.67E-17 
LOC643733 334.50835 -1.707144071 0.11523939 -14.813893 1.19E-49 2.54E-47 
AC011462.1 63.131586 -1.733490512 0.39577988 -4.3799359 1.19E-05 0.00010571 
SLCO2A1 44.566787 -1.74164529 0.47712497 -3.6502917 0.0002619 0.00169224 
CSF3 183.37549 -1.758957931 0.35044791 -5.0191708 5.19E-07 6.04E-06 
SLC16A6 51.645752 -1.805787395 0.21681435 -8.3287264 8.17E-17 3.03E-15 
MAN2B2 1025.1129 -1.824615948 0.28286585 -6.4504639 1.12E-10 2.21E-09 
FLVCR2 143.19376 -1.826378202 0.20629595 -8.8531946 8.50E-19 3.64E-17 
CXCL11 1722.5106 -1.837373834 0.12550171 -14.64023 1.56E-48 3.13E-46 
RARRES1 62.023695 -1.851800234 0.19436637 -9.5273693 1.61E-21 8.73E-20 
CADM3 360.84828 -1.87950193 0.37104409 -5.065441 4.07E-07 4.83E-06 
CETP 49.883219 -1.886917403 0.21533765 -8.7625989 1.91E-18 7.88E-17 
CDA 47.662579 -1.895993165 0.28969317 -6.5448322 5.96E-11 1.22E-09 
EFCC1 15.575221 -1.916545005 0.30249242 -6.3358447 2.36E-10 4.53E-09 
COL3A1 40.400174 -1.922798034 0.40076982 -4.7977615 1.60E-06 1.72E-05 
PDE2A 869.24503 -1.923922854 0.20927135 -9.1934366 3.80E-20 1.87E-18 
HTRA3 379.95067 -1.936347208 0.29980628 -6.4586612 1.06E-10 2.10E-09 
AC104211.1 13.171417 -1.937970507 0.34061324 -5.6896512 1.27E-08 1.92E-07 
ABCG2 375.38901 -1.944187952 0.1249885 -15.554934 1.47E-54 3.39E-52 
DPH6-AS1 21.470913 -1.951397289 0.37109627 -5.2584664 1.45E-07 1.85E-06 
C6orf120 959.69983 -1.986479752 0.09786296 -20.298587 1.32E-91 9.14E-89 
CYBRD1 1923.1816 -1.990120579 0.09277984 -21.449925 4.57E-102 4.14E-99 
B3GNT9 149.8303 -1.990880579 0.3286008 -6.0586601 1.37E-09 2.38E-08 
CX3CL1 131.14226 -2.001551956 0.27568449 -7.2602995 3.86E-13 1.03E-11 
AC007744.1 124.5417 -2.046991166 0.36502761 -5.6077707 2.05E-08 2.98E-07 
ATE1-AS1 16.284309 -2.054612175 0.3515136 -5.8450432 5.06E-09 8.12E-08 
RHOU 22.118653 -2.055930413 0.42150817 -4.8775577 1.07E-06 1.19E-05 
TXLNB 48.198802 -2.123405715 0.27466031 -7.7310251 1.07E-14 3.30E-13 
 
 140 
Table 3 continued 
HCRTR1 21.5268 -2.13529697 0.30281633 -7.0514592 1.77E-12 4.45E-11 
PDK4 525.95048 -2.233637083 0.08723376 -25.605192 1.34E-144 2.77E-141 
CLEC10A 13.640022 -2.247771733 0.38441087 -5.8473157 5.00E-09 8.02E-08 
SERPINB2 42.227974 -2.264074712 0.85179122 -2.658016 0.0078602 0.03143228 
INHBB 90.948833 -2.285054054 0.14081579 -16.227258 3.24E-59 9.20E-57 
TMOD1 22.331191 -2.303103918 0.33327003 -6.9106241 4.83E-12 1.13E-10 
IFIT2 1948.7785 -2.333650107 0.1825531 -12.783404 2.03E-37 2.75E-35 
FXN 174.63685 -2.344964395 0.15031999 -15.599817 7.30E-55 1.73E-52 
MMP28 36.726355 -2.502987493 0.5600543 -4.4691872 7.85E-06 7.23E-05 
GALNT1 13427.198 -2.519354332 0.17835095 -14.125825 2.63E-45 4.60E-43 
ABCA1 715.05659 -2.570443708 0.16541236 -15.539611 1.87E-54 4.24E-52 
IDO1 87.981361 -2.652000567 0.18492875 -14.340662 1.22E-46 2.27E-44 
IL33 390.49746 -2.761173874 0.25297676 -10.914733 9.80E-28 8.17E-26 
AQP1 228.76836 -2.787729624 0.24684464 -11.293458 1.41E-29 1.32E-27 
CXCL10 325.97754 -2.913522824 0.25181125 -11.570265 5.83E-31 5.91E-29 
AL731556.1 21.20983 -3.440277005 0.99422203 -3.4602704 0.0005396 0.00317882 
INTS6P1 14.203793 -4.236036704 1.46793486 -2.8857116 0.0039053 0.01751163 
UBD 55.751544 -5.303267085 1.34407913 -3.9456509 7.96E-05 0.00058387 
 
Table 4. Hemodynamic data for AKR/J mouse model of Group 2 PH-HFpEF  
Treatment *RVSP (mmHg) Relative Vessel Remodeling 
Regular diet 27 1.09 
Regular diet 30 0.80 
Regular diet 29 1.14 
Regular diet 27 0.97 
Regular diet 25 1.00 
High-fat diet 38 1.64 
High-fat diet 47 2.74 
High-fat diet 34 2.68 
High-fat diet 32 2.26 
High-fat diet 38 3.14 
* RVSP – right ventricular systolic pressure 
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Table 5. Hemodynamic data for ZSF1 rat model of Group 2 PH-HFpEF  
Treatment *RVSP (mmHg)  
Lean 28 
Lean 23 
Lean 15 
Lean 17 
Lean 30 
Lean 28 
Lean 29 
Lean 33 
Lean 28 
Ob-Su 43 
Ob-Su 43 
Ob-Su 37 
Ob-Su 36 
Ob-Su 42 
Ob-Su 40 
Ob-Su 36 
Ob-Su 31 
Ob-Su 39 
* RVSP – right ventricular systolic pressure 
 
Table 6. Clinical information for Group 1 PAH patients  
Age Gender *mPAP (mmHg) Diagnosis Clinical description 
34 Female 50 Idiopathic Cardiopulmonary arrest (autopsy) 
64 Female 55 Idiopathic Cardiopulmonary arrest (autopsy) 
68 Female 44 Scleroderma Bilateral lung transplant 
1 Male 50 Trisomy 21 Lung resection 
12 Male 53 BMPR2 Mutation Bilateral lung transplant 
16 Male 62 Idiopathic Bilateral lung transplant 
19 Male 48 Idiopathic Lung resection 
42 Male 57 Scleroderma Bilateral lung transplant 
* mPAP – mean pulmonary arterial pressure 
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Table 7. Clinical information for Group 3 IPF-PH PH patients 
Age Gender *mPAP (mmHg) Diagnosis Clinical description 
69 Female 29 IPF and PH Bilateral lung transplant 
50 Male 30 IPF and PH Bilateral lung transplant 
58 Male 28 IPF and PH Bilateral lung transplant 
61 Male 37 IPF and PH Bilateral lung transplant 
62 Male 28 IPF and PH Bilateral lung transplant 
63 Male 27 IPF and PH Bilateral lung transplant 
66 Male  34 IPF and PH Bilateral lung transplant 
72 Male 46 IPF and PH Rapid autopsy 
* mPAP – mean pulmonary arterial pressure 
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